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Introduction 
 
 
 
Pigmentation is one of the features in biology that presents a tremendous variety 
in terms of colors, shades, patterns and locations. It is seen by animals with eyes and 
depends on light. In fact, in places were light is absent, multi-cellular organisms generally 
lose their vision along with their pigmentation even though the loss of these two traits is 
not necessarily molecularly connected. Pigmentation functions are extremely diverse, 
protecting against ultra violet-radiation (UV), providing camouflage, male/female 
distinction, intra and inter-species communication and signaling (Figure 1).  Easy 
visibility is likely a prime reason why pigmentation has been one of the first animal traits 
studied in modern biology. In addition, in vertebrates, pigment-bearing cells called 
melanocytes have been implicated in the normal development of several sensory organs, 
including the inner ear, where melanocytes play a critical role in the formation and the 
maintenance of the homeostasis of the endolymph and are necessary for hearing 
(Tachibana, 1999), and the eye, where retinal pigmented epithelium (RPE) cells play a 
supportive role for the retina and serve as a light screen (Bharti et al., 2006).  
In humans, besides protection against UV induced DNA damage of the outer layers of the 
skin, pigmentation carries a cultural weight that seems to fluctuate with time and 
customs. For Middle-Age occidental and Asian societies, pale skin was very often 
associated with beauty or high societal rank. Nowadays, however, the pursuit of skin 
tanning has become a trend, which unfortunately has dramatic health consequences. 
Figure 1 : The various functions of pigmentation
Fig.1A : Protection against 
UV damage
Fig.1B : Protection against 
predators, camouflage
Fig.1B : Male/Female 
distinction
Fig.1C : Intra-species 
communication
Fig.1D : Inter-species 
communication/signaling
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Melanocyte-derived tumors, known as melanomas, have become one of the major public 
health issues in countries where the environment as well as individual genetic 
susceptibilities play key roles in the development of such pathologies. A good example 
for the interaction between genetic susceptibilities and the environment is the comparison 
of lifetime risk of cutaneous melanoma between the UK and Australian populations. With 
essentially the same genetic background, Australians have on average a 4 times higher 
risk to get melanoma than their relatives from the UK (Giblin and Thomas, 2007). 
Among the few high penetrance factors greatly correlated with the appearance of 
melanomas, we find inactivation of several key proteins involved in cell cycle regulation 
such as CDKN2A (encoding p16INK4a and p14ARF), cell and DNA integrity maintenance 
such as P53 or survival signaling pathways inhibition such as the Phosphatase and Tensin 
homolog (PTEN) (Meyle and Guldberg, 2009). 
Although the vast majority of melanoma susceptibility gene mutations have a much lower 
penetrance, they can have a great importance in tumor formation, though not alone, but in 
combinations with other susceptibility genes. In fact, the purpose of this thesis is not to 
investigate what are the bold and dramatic effects of the lack of a protein on pigment 
cells, but rather to understand how minute genetic changes, either in the germ line or 
induced somatically, can have significant effects on a cell type or an entire living 
organism. Hence, the study of such a sensitive process like pigmentation offers the 
opportunity to understand molecular changes at the macroscopic, phenotypic level. 
 
The study of coat pigmentation presents three critical advantages to biological 
experimentation: Pigmentation phenotypes are easily noticeable without any alteration to 
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the animal, the pigmentation process involves many of the major cellular parameters such 
as cell proliferation, differentiation, migration, maintenance, survival and death. 
Nevertheless pigmentation defects do not affect the development of a viable and fertile 
adult animal.  
This thus motivated our group to study the development and functions of melanocytes. 
To do so, we chose the mouse model, which provides for powerful genetic manipulations. 
The mouse also has a relatively short generation time and shares with humans a similar 
number of conserved genes in a genome of similar size, enabling us to assess biological 
relevance within the time constrains of a thesis project. 
 
1) The developmental origin of pigment cells: 
 
In mammals, pigment cells, located throughout the dermis and the epidermis in 
the adult, originate from a very unique embryonic structure called the Neural Crest (NC) 
(Sommer, 2011). This transient structure forms at the margin of the developing neural 
tube from ectodermal tissue. The Neural Crest is capable of generating a great variety of 
cells. Among them, we find neurons, glia, chondrocytes, osteoblasts, smooth muscle 
cells, and melanocytes (Calloni et al., 2009; Le Douarin et al., 2008). After an epithelial 
to mesenchymal transition, NC derived cells can start migrating and differentiating into 
various cell types. The position of the progenitor cells along the axial level seems to pre-
determine their fate during later differentiation steps. While some cell types such as 
sensory neurons, glial cells or pigment cells originate from the entire neuraxis, the source 
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of skeletal muscle precursor cells, for instance, is limited to the cranial neural crest (Le 
Douarin et al., 2008).  
NC cells are originally pluripotent but lose this feature during their developmental 
specification. Melanocyte progenitor cells called melanoblasts are defined by the co-
expression of early differentiation markers. Among them is KIT, the receptor for KIT 
Ligand, which plays a vital role in the survival and migration of progenitor cells. 
Alterations of the KIT signaling pathway lead to significant pigmentation defects in the 
mouse (Hou et al., 2000; Seldin et al., 1990). However, in vitro, KIT null NC cells can 
give rise to melanoblasts expressing a number of markers also found in melanocytes, with 
the exception of the pigmentation gene Tyrosinase (Tyr) (Hou et al., 2000). Another 
marker is MITF, a basic-helix-loop-helix leucine-zipper transcription factor, whose 
expression is turned on strongly during the specification of the pigment cell lineage, 
starting as early as E9.5 and staying high throughout life in mature melanocytes. A third 
one is EDNRB, the receptor for Endothelin 3, which promotes melanocyte proliferation. 
In fact, full differentiation of mature melanocytes can be obtained in vitro from E9.5 NC 
explants cultured in the presence of Endothelin 3 and KIT-ligand (Hou et al., 2000). A 
fourth one is Dopachrome Tautomerase (Dct), whose expression product is involved in 
pigment synthesis. The timing of in vitro differentiation follows the pattern observed in 
vivo, where Dct expression is seen at day 1 corresponding to E10.5 in vivo, followed by 
the expression of the pigmentation gene Tyrosinase related protein 1 (Tyrp1) seen at day 
5 (E14.5 in vivo), and by the expression of Tyr at day 6 (E16.5 in vivo). Pigmentation 
then occurs around day 10 (Figure 2). In contrast to differentiated melanocytes, 
melanocyte stem cells (MelSC) are immature melanoblasts, which do not produce 
9.5 10.5 11.5 12.5 13.5 14.5 15.5 16.5 17.5 18.5
0 1 2 3 4 5 6 7 8 9
E
Day
MSA Dermis Epidermis Hair Follicle
MITF
KIT
DCT
TYRP1
TYR
In vivo
In vitro
Melanoblast
Precursor
Early
Melanoblast
Late
Melanoblast
Mature
Melanocyte
Figure 2: Differentiation of Melanocytes from precurssor cells. 
Schematic timeline representation of the transcriptional activation 
of several key differentiation markers in Neural crest cultures.
      (From Hou et al. 2000)
MSA: Migration Staging Area, DCT: Dopachrome Tautomerase
TYR: Tyrosinase, TYRP1: Tyrosinase Related Protein 1
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melanin. They are maintained in a MITF/KIT-independent manner but retain high levels 
of DCT expression (Nishimura, 2011; Nishimura et al., 2002; Sommer, 2011). To this 
day, however, no marker or set of markers distinguishing MelSC from differentiated 
melanocytes have been identified. The branching out of MelSC from the melanocyte 
differentiation pathway occurs during the initial melanoblast migration to the hair follicle. 
Melanoblasts migrate to a specific stem cell niche in the upper part of the hair follicle, 
called the bulge, where they become MelSC, whereas cells migrating to the lower part of 
the hair follicle, called the bulb, terminally differentiate. During each hair cycle, MelSC 
located in the bulge area migrate to the hair bulb and mature to become pigmented 
melanocytes, while MelSC remaining in the bulge would settle in a quiescent/self 
renewal pathway. The switch between differentiation and “stemcellness” seems to be 
dictated by one or more extrinsic factors within the local environment surrounding the 
cell, but such factors are no longer required once the fate switch has been achieved. In 
fact, “stemcellness” of melanoblasts can be preserved in culture under simple conditions. 
One of the likely targets of these fate-switching factors might be the differential 
expression regulation of a specific set of genes. 
 
2) Genes involved in melanocyte development: 
 
So far, 378 loci have been identified to have an impact of melanocyte biology, of 
which only 171 genes have been cloned to this date in the mouse 
(http://www.espcr.org/micemut). Among them, we find genes implicated commonly in 
developmental signaling pathways, such as Wnt and Notch signaling, genes specifically 
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involved in the pigmentation pathway, such as the Melano-Cortin Receptor 1 (MC1R), or 
genes that are ubiquitously expressed and present, when mutated, a pigmentation 
phenotype, such as the B-cell lymphoma 2 gene (Bcl2) implicated in the inhibition of 
apoptosis. Out of this extensive list, the Microphthalmia-Associated Transcription Factor 
(MITF) has been demonstrated to be the melanocyte master regulator (Levy et al., 2006a; 
Vance and Goding, 2004), because it controls all the major cellular processes of the 
melanocyte cell lineage, such as differentiation, proliferation, and survival. Therefore, we 
focused our interest on how MITF is regulated and what consequences result from the 
modification of some of its activities. 
Among the main regulatory mechanisms linking extracellular signaling pathways to 
MITF function, we find phosphorylation, which can adjust MITF target gene activation 
and its biological availability through the modulation of MITF stability. MITF Serine 73 
phosphorylation is one of the critical sites that has been linked to modulations of MITF 
activity (Hemesath et al., 1998). It has so far been extensively studied, but for most of it, 
only in vitro. 
In order to study the function of MITF phosphorylation in vivo, or the consequences 
resulting from its lack, we generated MITF S73 phosphorylation mutant animals. In this 
thesis we focused on the role of this particular MITF posttranslational modification, using 
both MITF transgenic animals and MITF knock-in mutant mice, on pigment cell biology 
in vivo. 
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3) History of Mitf: 
 
The microphthalmia locus has first been described in 1942 by a German 
geneticist, Paula Hertwig (Hertwig, 1942). Intriguingly, the feature that led to the name 
of this particular locus was not the lack of pigmentation, but rather the resulting eye 
phenotype that mutant locus provoked. Only in 1993, the corresponding gene, Mitf, was 
cloned through the result of an insertional null allele, known now as Mitfmi-vga9 
(Hodgkinson et al., 1993). When homozygous, this allele presented the same phenotypic 
characteristic as the original Mitfmi allele and intercrosses between the original Mitfmi 
allele and a Mitfmi-vga9 showed no complementation. MITF was found not only to be 
expressed in NC-derived pigment cells but also at high levels in the RPE where it has 
been shown to play a key role in the regulation of normal eye development (Hodgkinson 
et al., 1993; Nakayama et al., 1998). Mitf is also expressed in mast cells, which are cells 
of the adaptive immune system, and osteoclasts and at low levels in many other cell 
types. While Mitf expression in heart is low per cell, the fact that every cell expresses it 
leads to high signals in tissue extracts. Nonetheless, apart from the pigment cells, mast 
cells and osteoclasts, none of the other cell types seems to be severely affected by the 
impairment of MITF expression.  
 
Since Mitf was cloned, more than 30 different spontaneous or chemically or radiation-
induced Mitf alleles have been described in the mouse alone. The identification of this 
relatively high number of alleles can be explained by the ease with which coat color 
mutants can be seen in mouse colonies and highlights the sensitivity of pigmentation to 
Introduction 
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change in MITF activity. As described in more details later, the list of Mitf alleles 
represent many types of genetic mutations: single amino acid changes, single amino acid 
deletion, protein truncations, exon skipping mutations, promoter deletions, repeat element 
insertions and frame shift mutations (Hallsson et al., 2000; Steingrimsson et al., 1994) 
(Figure 3). Some of these alleles have been extensively analyzed and their associated 
phenotypes explained, but for others, such as Mitfmi-bws, the amount of information is still 
insufficient to establish a direct genotype/phenotype correlation (Hallsson et al., 2000; 
Wen et al., 2010). 
 
Mitf is at the “epicenter” of melanocyte biology:  
In mammals, birds and fish, Mitf has been shown to promote differentiation functions, by 
direct activation of genes involved in pigmentation including, Tyr, Dct, Tyrp1, Pmel17, 
Silver among others (Hemesath et al., 1994). It has also been shown to control the cell 
cycle through the regulation of p21 and p27 via diaphanous-1 (Carreira et al., 2006). 
Furthermore it may control cell survival with the positive activation of Bcl2 (McGill et 
al., 2002). However, there is little evidence that MITF is pro-proliferative. Bismuth et al. 
published a set of experiments with MITF transfected HEK293 cells, showing that MITF 
lacking exon 6A had a higher rate of BrdU incorporation than EGFP-transfected cells 
(Bismuth et al., 2005). In the total absence of MITF, however, melanoblasts are absent. 
Whether they die or whether their development is diverted to other lineages, such as 
Schwann cells, is not yet clear, however, Dupin et al. argue that cultured avian Schwann 
cells can transdifferentiate into melanoblasts, and melanoblasts into Schwann cells 
(Dupin et al., 2003). Therefore, it is conceivable that the number of Schwann cells 
1A 1J 1C 1Mc 1E 1H 1D 1B 1M 2A/B 3 4 5 6A/B 7 8 9
ATG ATG ATG ATG
78.8 10.1 32.4 1.8 2.5 37.7 12.3 1.2 1.0 1.9 7.4 2.1 4.2 3.2 4.0
mde
▲
●
●
●
Mitfmi-vga-9
Mitfmi-enu22
Mitfmi-bws
Mitfmi-S73A
▲
Mitfmi-bw
Mitfmi-enu198
MitfMi-enu5/Mi-bcc2/Mi-H
MitfMi-wh
MitfMi-or
Mitfmi
Mitfmi-vit
Mitfmi-enu122
Mitfmi-b
Mitfmi-di/mi-ce
Mitfmi-rorp
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●
●
●
●
●
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●
▲
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Allele specifically mentioned in this report
Mitfmi-S-S73A
Mitfmi-S-S73D
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Mitfmi-∆D
Figure 3: Schematic distribution of the major mouse Mitf alleles 
and the positions of their respective genetic mutations on the gene
Introduction 
 11 
increases in Mitf null mutants, but direct evidence for this is not available. In zebrafish, 
activation of Wnt signaling has been demonstrated to increase pigment cell numbers at 
the expense of sensory neuron and glial cell populations (Dorsky et al., 1998). The loss of 
Wnt signaling has the opposite effect of increasing sensory neurons and glial cell 
numbers at the expense of melanoblasts. In contrast, a gain of Wnt signaling results in an 
increase of the number of sensory neurons but not melanocytes, at the expense of other 
neural crest derivatives. The lack of Wnt signaling in NC-derived cells leads to the loss of  
the pigmentary cell population with a gain in the number of glial cells (Hari et al., 2002). 
 
4) Genetic and biochemical characteristics of MITF: 
 
MITF is a nuclear protein and contains a nuclear localization signal (IERRRR) 
located in its basic domain (Takebayashi et al., 1996). It is a member of the large family 
of basic Helix-Loop-Helix Leucine-Zipper transcription factors (bHLH-LZ), like MAD 
and MAX, and binds DNA on E-box derived sequence motifs, CACGTG or CATGTG, 
called M-boxes (Aksan and Goding, 1998; Hemesath et al., 1994; Strub et al., 2011). 
Specifically, it belongs to a subfamily called MiT transcription factors (Mitf-Tcfe) 
consisting of Tcfe3, Tcfeb and Tcfec, with which Mitf has been shown to directly interact 
to form heterodimers in vitro. However, it is not quite clear if these heterodimers have 
any functional relevance in vivo, as melanoblasts are not affected by Tcfe gene mutations 
(Steingrimsson et al., 2002). Nevertheless, genetic interaction has been shown between 
dominant negative Mitfmi and a null allele of Tcfe3 in osteoclasts (Hershey and Fisher, 
2004). Such interactions are not seen with the Mitf null allele Mitfmi-vga9. Mitf is highly 
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conserved throughout the animal kingdom. It is found in C. elegans, D. melanogaster, 
fish, reptiles, birds, and mammals with high similarity scores (Figure 4). 74% of its basic 
DNA binding domain are fully conserved amino acids or conservative substitutions. It 
reaches 100% of conservation if only amino acids making contacts to DNA are taken in 
to account (Hallsson et al., 2007). Mutations in the Mitf gene have also been found in 
many species, including zebra fish, quail and many mammals (rat, guinea pig, dog, 
human, pig) (Hodgkinson et al., 1998; Opdecamp et al., 1998; Tachibana, 2000). 
 
5) Clinical significance: 
 
In humans, MITF-mutations can lead to depigmentation of the skin, light hair 
color, and in some cases deafness and developmental defects of the eye (Tassabehji et al., 
1994), a syndrome called Waardenburg syndrome type 2A and/or Tietz syndrome. In 
some cases, Mitf mutations previously characterized in mice are also found in patients. 
For instance, the deletion of an arginine in the basic domain of the Mitfmi allele is 
equivalent to the deletion reported in 2 families with Tietz syndrome (Izumi et al., 2008). 
In contrast to mice heterozygous for Mitfmi, heterozygous humans display strong 
pigmentary deficiencies not only in the skin but also in the eye, and they are hearing-
impaired. No homozygous patient has been recorded so far, perhaps because the loss of 
MITF function in human is lethal during the development of the fetus. 
 
 
Fig. 4A: Protein sequence alignement of MITF against MiT family 
members and protein homologs from other animal species.
Critical mutants are annotated with their corresponding effect on the protein.  
Fig. 4B: Structural representation of the basic and Helix 1 
domain and localisation of the mutations of several Mitf alleles
Figure 4: Sequence conservation of MiT family members 
and their homologs across animal species.
      (From Hallsson et al. 2007)
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6) Mitf gene structure and expression profile: 
 
The Mitf gene, spread over 214 kb in the mouse, is relatively complex with 
currently 9 known alternative promoters: A, J, C, Mc, E, H, D, B and M. A tenth 
promoter, CM, has been described in human MITF (Shiohara et al., 2009). For some, the 
first exon is non-coding, for others it is coding, leading to MITF protein isoforms 
differing at the amino-terminus (Figure 5). These alternative promoters bear very specific 
activation profiles among the different cell types of the organism. For instance, isoforms 
A, B, H and J are expressed ubiquitously in the mouse (Amae et al., 1998). H-Mitf is 
present at high levels in heart, D-Mitf is exclusively found in the RPE (Bharti et al., 
2008), and M-Mitf is exclusively expressed in the melanocyte cell lineage (Amae et al., 
1998; Fuse et al., 1999; Yasumoto et al., 1998). The body of the gene carries 8 exons, 
common to all isoforms (2-9). Of the later, one, exon 2, contains a 5’ alternative splice 
site, and another, exon 6, contains a 3’ alternative splice site. Indeed, alternative splicing 
leads to exclusion of exon 2B and exon 6A in 5 to 10% and 50% respectively of Mitf 
transcripts (Bismuth et al., 2008; Hallsson et al., 2000). The DNA binding and 
dimerization domains are covering a sequence from exon 6B to exon 8. Mitf contains 
both symmetric and asymmetric exons. Symmetric exons consist of multiples of 3 base 
pairs, resulting in the conservation of the reading frame if they are skipped in the mature 
mRNA. Asymmetric exons, in contrast, are not multiples of 3 base pairs. Therefore, 
asymmetric exon skipping results in a shift of the reading frame and likely protein 
truncation due to premature stop codons and/or non-sense mediated decay (NMD) of the 
mRNA when a premature translation termination codon appears in internal exons. 
1A 1J 1C 1Mc 1E 1H 1D 1B 1M 2A/B 3 4 5 6A/B 7 8 9
ATG ATG ATG ATG
78.8 10.1 32.4 1.8 2.5 37.7 12.3 1.2 1.0 1.9 7.4 2.1 4.2 3.2 4.0
▲
▲
▲ ▲ ▲ ▲ ▲ ▲ ▲
Bac Mi2 (228.2 kb)
Bac Mi1 (243.6 kb)76 kb
14.2 kb
93.9 kb
47.5 kb
Mitf gene (214 kb)
104 101 128 56 279/250 33 60/168 84 96 118 18/57 76 148 399
2A/b 3 4 9876A/B5
2A 2B 6A 6B
1A (526 aa)
1B
1J/E/D (474 aa)
1C (502 aa)
1MC (534 aa)
1H (510 aa)
1M (419 aa)
1B (501 aa)
Alternatively spliced exonsAlternative aminotermini
1M
regular splicing alternative splicingbHLH-Zip domain▲ promoters
2.1 (intron length, kbp)
118 (number of basepairs/exon)
exon, codingexon, non-coding
ATG ATG
Figure 5: Representation of Mitf alternative promoter use
and subsequent alternative splicing of exons 2B and 6A.
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Intriguingly, while exons 2 to 5 can be excluded individually or all together with 
conservation of the open reading frame, the exons coding for the DNA binding and 
dimerization domains are all asymmetrical. cDNA cloning experiments performed by 
Steingrimsson’s group, showed a glimpse of Mitf mRNA diversity, some of which 
lacking several exons. The possibility for these truncated transcripts to have any 
functional significance or to be just failed spliced materials, is yet to be determined 
(Hallsson et al., 2000). 
 
All Mitf transcripts A, C, D, E, H, J, and Mc initiated from either one of the promoters 
lying upstream of B are spliced into exon 1B and subsequently into exon 2A, 3 etc. M-
Mitf derived isoforms are the only transcripts that do not contain exon 1B. Although 
shown for only a few isoforms, it is conceivable that each of them may or may not 
contain the alternativly spliced exons 2B or 6A. Exon 6A alternative splicing and its 
consequences have been well documented with respect to the M-MITF isoform and 
biology of melanocytes. The presence of exon 6A in M-MITF leads to an increase in 
transcriptional activity on its target genes and an increased inhibition of cell cycle 
progression (Bismuth et al., 2005). Although evidence exists with respect to the 
alternative splicing of exon 6A in other isoforms, such as A-Mitf or H-Mitf, little is 
known about its biological relevance in cell types other than melanocytes. Exon 6A is 
included in 50 to 60% of the M-Mitf transcripts. Galibert’s group has shown, however, 
that the splicing of exon 6A was highly variable in melanoma cells, with a much higher 
ratio for exon 6A exclusion compared to normal melanocytes (Primot et al., 2010). The 
same group has shown evidence linking the MAPK pathway with exon 6A splicing. The 
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inhibition of ERK leads to an increase of exon 6A exclusion in melanoma cells. Although 
MITF 6A+ protein has been shown to inhibit DNA synthesis more strongly than MITF 
6A(-), it is not clear if the MAPK regulation of exon 6A splicing is part of a feedback 
loop in order to maintain the cell cycle progression, or if it is a way to further decrease 
Mitf-mediated cell survival.  
In contrast, exon 2B alternative splicing has been more recently discovered and bears 
more complex mechanisms of activity regulation of MITF. Exon 2B inclusion seems to 
occur in the vast majority of Mitf transcripts, of which normally no more than 10% lack 
exon 2B . Bismuth et al. showed that MITF 2B+ has a higher ability to block cell cycle 
progression than MITF lacking the amino-terminus including exon 2B, suggesting that 
MITF 2B- proteins might have a reduced transcriptional activity, similar to the activity 
reduction seen in the MITF 6A- (Bismuth et al., 2005). In addition, this decreased 
inhibition was only observed with MITF containing exon 6A. Interestingly, somatic 
mutations resulting in exon 2B exclusion have recently been identified in melanoma 
samples, suggesting exon 2B is biologically relevant in melanoma proliferation (Cronin 
et al., 2009). However, so far, little is known about the regulation of exon 2B splicing and 
its consequences on melanocytes under normal conditions.  
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7) Mitf transcriptional regulation: 
 
M-Mitf expression is regulated during melanoblast development by a set of 
transcription factors and signaling pathways. 
Among them, four transcription factors, SOX10, PAX3, CREB and LEC/TCF, as well as 
two signaling pathways, Wnt/β-catenin and cAMP, play major roles in the transcription 
activation and maintenance of Mitf expression (Figure 6). 
 
A) M-Mitf regulation through SOX10 transcription factor:  
Sox10 (Sry-like HMG box containing gene) belongs to the SRY (sex determining region 
Y) transcription factor family, contains a High Mobility Group DNA binding domain, 
and binds (A/T)(A/T)CAA(A/T)G consensus motifs (Kuhlbrodt et al., 1998).  Mutations 
of SOX10 in humans are associated with Waardenburg-Shah syndrome type 4 (WS4), 
resulting in a combination of Waardenburg syndrome and Hirschprung disease (Pingault 
et al., 1998), that is various degrees of hearing loss, pigmentation defects, and distal 
motility defects in the large intestines due to the absence of myenteric plexus neurons. In 
the mouse, the dominant allele Sox10DOM can lead to a depigmented belly spot – as seen 
in numerous Mitf mutants – and a megacolon (Mollaaghababa and Pavan, 2003). 
Sox10DOM/+; Mitfmi/+ double mutant mice show aggravated coat depigmentation 
compared to single mutants. Several groups showed direct activation of the M-Mitf 
promoter by SOX10, consistent with the observed genetic interaction (Lee et al., 2000; 
Mollaaghababa and Pavan, 2003; Verastegui et al., 2000). In addition, it has been found 
that SOX10 and MITF can act in synergy on different promoters, such as the Dct and Tyr 
MC1R
cAMP
Figure 6: Regulation of transcriptional activation of the M-Mitf isoform
         (From Steingrimsson et al. 2004)
Introduction 
 17 
promoters, without direct physical interaction. Complementary studies realized by 
Fisher’s group have shown that SOX10 binding on the M-Mitf promoter allowed the 
binding and the activation of Mitf transcription by CREB and reciprocally, CREB binding 
on the M-Mitf promoter increased SOX10-mediated transcriptional activation of Mitf 
(Huber et al., 2003). This process is thought to increase M-Mitf expression specificity to 
melanocytes only. 
 
B) M-Mitf regulation through Pax3 transcription factor:  
Pax3 belongs to the Paired-Box (PAX) transcription factor family. Members of the PAX 
family typically contain a paired box domain and a paired-type homeodomain and play 
significant roles in the developing embryo. In humans, mutations in PAX3 are associated 
with Waardenburg syndrome type 1 and 3 manifested by cranio-facial abnormalities, skin 
and hair pigmentation defects, and inner ear and eye development defects. Like SOX10, 
PAX3 promotes Mitf transcription activation (Watanabe et al., 1998), but can also 
collaborate with MITF to activate the Tyrp1 promoter (Galibert et al., 1999). 
 
C) M-Mitf regulation through cAMP signaling pathway:  
Ballotti R.’s group showed in B16 melanoma cells that an increased concentration of 
cAMP by Forskolin treatment led to an increase of MITF protein expression (Bertolotto 
et al., 1998). In melanocytes, intracellular cAMP levels can be regulated by the α-
MSH/MC1R pathway. Keratinocyte-secreted α-melanocyte stimulating hormone (α-
MSH) binds to melanocortin receptor 1 (MC1R), a G-protein coupled receptor expressed 
by melanocytic cells, and leads to an increase of the cAMP concentration (Price et al., 
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1998). Protein Kinase A is then subsequently activated which promotes the 
phosphorylation of cyclic-AMP response element binding protein (CREB). CREB then 
homodimerizes and can bind its DNA target sequences, one of which is located on the M-
Mitf promoter. 
 
D) M-Mitf regulation through the canonical Wnt/β-catenin signaling pathway:  
Frizzled receptor bound WNT protein leads to a dissociation of the Axin/APC/GSK3/β-
catenin complex (Hart et al., 1998). β-Catenin is no longer phosphorylated and stabilized 
and is then translocated to the nucleus and cooperates with LEF/TCF to bind on one or 
more of the 3 sites present on the M-Mitf promoter and activate its transcription (Takeda 
et al., 2000b). In several animal models, canonical WNT signaling has been shown to 
play an important role in the generation of pigment cells. Dorsky et al. showed that WNT 
is required for the development of melanophores in zebra fish and several groups showed 
that WNT1 and WNT3 were able to influence the number of melanoblasts in the 
developing mouse embryo (Dorsky et al., 1998; Dunn et al., 2005; Dunn et al., 2000). In 
addition, an increase of the β-catenin pathway in B16 melanoma cells leads to an increase 
in MITF protein expression (Saito et al., 2003; Takeda et al., 2000b). 
 
8) Mitf and melanoma: 
 
Melanoma, the melanocyte-derived cancer, ranks among the highest in cancer-
related death in humans. Its high resistance to chemo and radiation-therapy leaves only 
little flexibility other than the surgical removal of the primary tumor before it 
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metastasizes and spreads to other organs. Given Mitf’s major role in melanocyte biology, 
it’s not surprising that Mitf is also a major regulator of melanoma formation and 
metastasis (Vance and Goding, 2004). Interestingly, metastatic tissues have been 
demonstrated to be associated with very disparate Mitf levels. Although Comparative 
Genomic Hybridization assays from metastatic melanoma samples suggest that 
microphthalmia locus can be amplified multiple times in some cases (Garraway et al., 
2005; Gast et al., 2010; Jonsson et al., 2007), Mitf mRNA and protein levels do not 
necessarily correlate with microphthalmia locus copy numbers. In addition, Samuels’ 
group was able to identify the occurrence of various MITF mutations that arose 
specifically in tumor and metastasis samples from melanoma patients (Cronin et al., 
2009). All of these mutations were tested in vitro and lead to a decrease of MITF 
transcriptional activation on two target gene promoters. This heterogeneity in MITF 
activity levels is also reflected by the heterogeneous nature of melanoma itself, where 
even within a tumor, great heterogeneity can arise and reveal an underlying genomic or 
epigenetic instability of these malignant cells.  
Hence, the variations not only of MITF levels but more importantly its biological activity 
may reveal the underlying pathways that are differentially activated in one tumor versus 
another. It also seems that MITF levels fluctuate between different tumor growth stages, 
allowing cancer cells to oscillate between differentiated, proliferative and invasive 
phenotypes, a phenomenon called “phenotype-switching” (Hoek and Goding, 2010). 
Among the principle signaling pathways involved in melanocyte proliferation control, the 
MAPK pathway is one most often genetically altered. B-RAF and N-RAS mutations are 
found, respectively, in 60% and 30% of melanoma cases and are mutually exclusive 
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(Meyle and Guldberg, 2009). In both genes, the large majority of the mutations 
corresponds to an increase of the kinase activity of the protein. The MAPK pathway is 
altered in a quantitative or qualitative manner in 100% of the melanoma cases. Under 
normal conditions, constitutive activation of MAPK results in the induction of senescence 
related cell cycle arrest (Dhomen et al., 2009). To overcome this barrier that normally 
prevents further progression, additional alterations affecting cell cycle regulators such as 
Cdkn2a, Cdk4 or p53 are required (Bennett, 2008; Dahl and Guldberg, 2007; de Snoo and 
Hayward, 2005). Very specific growth characteristics are associated with the 
accumulation of mutations in these genes, from radial to vertical growth and, ultimately, 
migration to other organs. 
Although MITF doesn’t directly regulate the MAPK activity, the MAPK pathway is 
directly linked to post-translational modifications of MITF and is able to regulate MITF 
activity and stability (Hemesath et al., 1998; Wu et al., 2000). In this particular case, the 
MAPK pathway plays a dual role by increasing MITF target gene activation and 
decreasing MITF levels by subsequent poly-ubiquitination and proteasome-mediated 
degradation. 
Besides proliferation, another critical parameter for an increase in cell number is survival. 
In melanocytes, Bcl2 and Melanoma-inhibitor of apoptosis protein (ML-IAP or Livin or 
Birc7) have been shown to be key factors to prevent cells from entering apoptosis 
prematurely. Bcl2 is one of the many critical target genes regulated by Mitf and Bcl2 
deficient mice display premature graying, which is greatly amplified with a reduction in 
MITF activity (McGill et al., 2002). In melanoma cell lines, down regulation of Mitf by 
RNAi has been shown to decrease Bcl2 expression leading to a decrease in cell numbers 
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(McGill et al., 2002). In contrast, Mitf overexpression in melanoma cell lines leads to cell 
cycle arrest (Carreira et al., 2006). The above evidence emphasizes the ambivalent role 
that Mitf play by affecting cell proliferation, differentiation and survival. Small changes 
in MITF activity can therefore have drastic consequences with respect to melanocyte 
biology. The use of the genetic mouse model allows us to molecularly dissect MITF 
functions and provides a very well buffered biological system that prevents the 
interference of experimental artifacts that one often encounters in vitro.  
 
9) Mitf alleles in mice:  
 
Among the 36 different mutant alleles that have been described in the mice, most 
affect the bHLH domain of MITF protein through various ways such as single amino acid 
deletion (Mitfmi: deletion of one of the 4 arginines in the basic domain), single amino acid 
changes (MitfMi-wh: I212N, Mitfmi-or: R216K), and splice defects resulting in a missing 
exon (Mitfmi-ew: ∆Exon 6A/6B). A special case is presented by Mitfmi-S73A where the 
primary mutation is a point mutation in Serine-73 that also leads to preferential 
elimination of the corresponding exon from mature mRNA (Bauer et al., 2009; Bismuth 
et al., 2008; Steingrimsson et al., 1994) (Figure 7). In addition to these 36 alleles, 6 novel 
alleles are described in this thesis: Mitfmi-S-S73ANeo, Mitfmi-S-S73A∆Neo, Mitfmi-S-S73DNeo, Mitfmi-S-
S73D∆Neo, Mitfmi-S-S73SNeo and Mitfmi-S-S73S∆Neo.  
 
Fig.7A : C57BL6/J
        Wild type allele
Fig.7B : Mitf
mi-vga9
/Mitf
mi-vga9
 Functionnally null
Fig.7C : Mitf
Mi-wh
/Mitf
+
         Dominant Negative
Fig.7D : Mitf
mi-sp
/Mitf
mi-sp
    Hypomorphic splice mutant
Fig.7E : Mitf
mi-sp
/Mitf
mi-vga9
Fig.7F : Mitf
mi-bws
/Mitf
mi-bws
   Splice mutant
Fig.7G : Mitf
mi-rw
/Mitf
mi-rw
        Isoform specific mutant
Fig.7H : Mitf
mi-bw
/Mitf
mi-bw
             Insertional mutant
Fig.7I : Mitf
mi-∆D
/Mitf
mi-∆D
        Isoform specific mutant
Figure 7 : Illustration of the diversity of Mitf 
alleles and their corresponding phenotypes
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A) Historical and principal mutants: 
 All bHLH-domain mutants present similar phenotypes as the null Mitfmi-vga9 allele when 
homozygous, with absence of neural-crest derived melanocyte, small eyes 
(microphthalmia) and a loss of hearing. However, subtle biologically relevant differences 
exist and help reveal differences in the underlying molecular mechanisms. For instance, 
most Mitf mutations have, in the mouse, very small effects or none at all at the 
heterozygous state. For instance, a small white belly spot can be present in Mitfmi-or or 
Mitfmi mice and hearing may be normal. More severe pigmentation defects are only 
observed when the gene dose or MITF activity is reduced to 50% or less of wild type, 
depending on the allele. In humans, however, alteration of only one of the two MITF 
alleles is often sufficient to display phenotypic defects including hearing deficiencies 
(Nobukuni et al., 1996; Pingault et al., 2010). 
The Mitfmi-vga9 null allele, the historically important allele that led to the cloning of the 
Mitf gene (Hodgkinson et al., 1993), is the result of insertions of tandem repeats of a 
vasopressin-β galactosidase transgene construct, 800 bp upstream of the exon 1M. The 
consequence of this insertion consists in the disruption of any Mitf transcript produced by 
the 8 upstream promoters as well as the deregulation of the downstream M promoter. 
In fact, the Mitfmi-vga9 allele produces no Mitf RNA and protein in most tissues including 
heart and skin. In RPE, however, in situ hybridization using a full length cDNA probe 
have shown a reduced Mitf signal but this signal can potentially be attributed to aberrant 
transcripts initiated from the transgene or to a cross reactivity with the closely related 
Tcfec transcript, which has recently been shown to be upregulated in the developing RPE 
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in the absence of Mitf expression (Rowan et al., 2004). In any event, even the RPE shows 
no MITF protein accumulation (Nakayama et al., 1998). 
The Mitfmi-or and Mitfmi alleles display similar phenotypic characteristics as both of these 
alleles affect one of four arginines clustered in exon 7. These mutations interfere with 
DNA binding of the resulting proteins (Steingrimsson et al., 1994). In addition, the Mitfmi 
mutation affects MITF’s nuclear localization signal, such that the mutated protein is no 
longer strictly nuclear. Mitfmi is associated with the most severe phenotype in the 
homozygous conditions resulting in death after weaning as a result of severe osteoporosis 
and starvation linked to the lack of tooth eruption. These extra phenotypic features 
associated with the Mitfmi allele can be attributed to the inability of MITFmi heterodimers 
to bind DNA as well as the sequestration of other MIT family members, leading to a 
further decrease of their respective availability to bind DNA. 
The MitfMi-wh allele presents a unique feature among all Mitf alleles as it displays a strong 
coat color dilution along with a loss of hearing at the heterozygous state (Takebayashi et 
al., 1996). This apparent dominant-negative activity is paired with a homozygous 
phenotype similar to, but less severe than in Mitfmi or Mitfmi-vga9 null mutant homozygous 
animals. In fact, although the lack of NC-derived melanocytes is complete, the severity of 
the microphthalmia of MitfMi-wh/MitfMi-wh mice is reduced compared to that of Mitfmi-
vga9/Mitfmi-vga9 mice. MitfMi-wh is also one of the few alleles known to display allelic 
complementation, meaning that compound heterozygotes such asMitfMi-wh/Mitfmi or 
MitfMi-wh/Mitfmi-vga9 show eyes of normal size unlike their microphthalmic homozygous 
parents. Recent unpublished biochemical work performed by Steingrimmsson’s group on 
the crystal structure and binding capacity of the MITFMi-wh protein shows that the protein 
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is capable of binding M-boxes, but is also capable of binding other E-box-like motifs 
with a higher affinity than wild-type MITF. These results suggest that MITFMi-wh could 
shift the transcription activation from melanocyte-specific genes to normally non-MITF-
specific target genes and thereby interfere with, or alter the normal melanocyte 
differentiation and maturation pathway (Steingrimsson E unpublished).  
B) Splice mutants:  
Among the mutant Mitf alleles that carry splice defects, Mitfmi-sp (mi-spotted) and Mitfmi-
bws (mi-black and white spots) present complex mechanisms that bring only partial 
answers to explain their phenotypes. The Mitfmi-sp allele is the result of an insertion of an 
extra Cytidine in the alternatively spliced exon 6A between the F190 codon and the P191 
codon. This insertion results in a shift in the open reading frame and the generation of a 
stop codon shortly after the beginning of exon 6B in mRNAs that have exon 6A included. 
As mentioned above, exon 6A is generally included in about 50% of the M-Mitf 
transcripts; hence half of the mRNAs should carry a premature STOP codon in exon 6B, 
within 60 bases of the exon-exon junction and therefore triggering NMD of the Mitf 6A+ 
mRNA. Alternatively, it is possible that the extra Cytidine disrupts the polypyrimidine 
tract that regulates splicing. Despite this genetic alteration, Mitfmi-sp/Mitfmi-sp mice are 
fully pigmented with normal-sized eyes (Boissy and Lamoreux, 1995). Nevertheless, they 
display Mitf RNA levels close to 80%, rather than the expected 50%, hence showing that 
there is a compensatory upregulation of transcription or a reduction in production of the 
6A+ isoform, reducing the amount of Mitf message subject to NMD. Mitfmi-sp is a 
hypomorphic allele that displays its phenotype only in the presence of another null or 
dominant-negative Mitf allele. Regardless of its reduced transcript level, in vitro results 
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with Mitf cDNA over-expression have shown that MITF 6A- has a lower activity on 
differentiation genes, and a lower DNA binding affinity compared to the MITF 6A+ 
isoform (Murakami et al., 2007). In addition, MITF cell cycle arrest related activities are 
significantly decreased in the presence of MITF 6A- compared to MITF 6A+ (Bismuth et 
al., 2005).  
The Mitfmi-bws allele was historically the first Mitf mutant that was demonstrated to affect 
exon 2B with Mitf transcripts lacking exon 2B (Mitf 2B-) representing ~50% rather than 
the normally observed ~10% (Hallsson JH 2000). The molecular analysis revealed a G>A 
mutation 12 base pairs upstream of exon 2A. Mitfmi-bws / Mitfmi-bws homozygous mice 
display large white areas with black spots which tend to gray with aging. Therefore, loss 
of exon 2B was thought to be associated with a great loss of MITF activity. However, 
new evidence presented in this thesis suggest that this allele is associated with a 
substantial reduction of Mitf RNA levels, reflecting additional alterations yet to be 
identified.  
 
C) Isoform specific mutants:  
A few alleles are known to affect specifically a set of isoforms and have therefore been 
useful to study the particular role of some of these isoforms during development. For 
instance, the Mitfmi-rw (mi-red eye white) allele is characterized by a deletion spanning the 
H, D and B promoters and corresponding exons (Bharti et al., 2008; Hallsson et al., 
2000). This genomic deletion leads to the absence of H-Mitf, D-Mitf and B-Mitf 
transcripts. It also results in an upregulation of the upstream A, J and E isoforms. Both J 
and E isoforms normally use the start codon located in exon 1B as translation initiation 
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site (Bharti et al., 2008). But in the case of Mitfmi-rw, exon 1B is missing, hence the next 
available start site is located in exon 2B, resulting in a M-MITF-like isoform truncated at 
its N-terminal end. The Mitfmi-rw/Mitfmi-rw is very particular and reflects the complexities 
resulting from the expression of aberrant isoforms at abnormal levels. The homozygous 
mice are mostly white with a variably-sized black spot on the head and occasionally on 
the belly. The eye size is much reduced but there is considerable variability.  
The Mitfmi-bw allele (mi-black-eye white) is characterized by the insertion of a 7 kb L1 
SINE element in intron 3 resulting in the specific down regulation of the expression of 
the M-Mitf isoform (Yajima et al., 1999). Mitfmi-bw / Mitfmi-bw homozygous mice display a 
white coat with the complete lack of NC-derived melanocytes, due to the lack of the 
melanocyte specific Mitf isoform. Eye size and pigmentation remain, however, 
unaffected as the maintenance of significant Mitf expression in the RPE of the A-Mitf 
and H-Mitf isoform may be sufficient to support normal development of this tissue.  
More recently, Mitf-isoform targeted knockouts have been generated in our group in 
order to understand the role of some of the major MITF isoforms, such as A-MITF and 
D-MITF. Although these specific mutants do not display strong phenotypes on their own, 
a striking phenotype can be revealed, for instance, in Mitfmi-∆D/Mitfmi-∆D mice in 
combinations with gene dose changes in the eye transcription factor Pax6.  
While the lack of availability of isoform-specific antibodies has restricted the analysis of 
isoform distribution mainly to mRNA expression by real-time PCR, the sensitivity of this 
technique has allowed precise measurements of the level of specific isoform per cell, 
even when only small amounts of tissue are available. Nonetheless, it remains an open 
question whether all the full-length and some of the truncated mRNA isoforms are 
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translated into protein. Furthermore, even if they were all translated, it remains unclear 
whether all protein isoforms would be biologically relevant. In that regard, mechanisms 
such as RNA interference and micro RNA regulations are efficient ways to modify the 
ability of a specific RNA to lead to a specific protein. In the case of Mitf, several binding 
sites of miRNA, though mostly confined to the 3’ untranslated region, have been 
identified using bioinformatic tools several years ago, but it is not until recently that 
breakthrough discoveries in the miRNA world were linked to Mitf regulation. In fact, 
Mitf regulates and is regulated by RNAi and the miRNA machinery. The mouse M-Mitf 
message is over 4.5 kb long with more than half of the sequence being non coding. 
Recent work done by Haflidadottir et al. has demonstrated the effect of two miRNA, 
miR-148 and miR-137 binding to the 3’ untranslated region, on the expression of MITF 
protein in melanocytes and melanoma cells (Haflidadottir et al., 2010). More strikingly, 
Mitf has been associated with the regulation of a key enzyme in the miRNA-processing 
machinery: DICER (Levy et al., 2010). DICER plays a critical role in the maintenance 
and function of a large number of cell types. Hence, one of the ubiquitous roles of Mitf 
could be associated with the maintenance and survival of differentiated cells through the 
expression of a vital enzyme such as DICER. In melanocytes, both in vitro and in vivo 
DICER expressions are required for survival even in the presence of functional Mitf. 
The above-mentioned elements on Mitf post-transcriptional regulations are further 
evidence supporting the inadequacy of the in vitro model to integrate the diversity of Mitf 
regulation, and further motivated us to pursue the study of Mitf activity regulation in 
vivo. 
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10) The roles of post-translational modifications for modulating activity: 
 
As it has been described earlier, MITF is able to control proliferation, 
differentiation, migration, death, and other melanocyte specific processes. These 
processes, like cell death and proliferation, are sometimes biologically synergistic and 
make sense when one single transcription factor, by acting positively on target genes, can 
promote cell division and inhibit cell death at the same time. However, the positive 
regulation of two fundamentally opposed biological processes, such as differentiation and 
proliferation, by one single transcription factor may not be easy to understand. In the case 
of Mitf, proliferating, migrating or differentiating melanocytes must be able to modulate 
specific sets of target genes by molecular modifications of MITF to allow the cells to 
choose between these distinct biological behaviors. Hence MITF transcriptional 
activation is unlikely to be linear on each of its target genes and may be dependent on a 
particular set of post-transcriptional modifications. One possibility is that different 
isoforms have different specific activities and the outcome of the regulation of the 
combination of these isoforms ultimately results in the fine-tuning of target gene 
expression. Thus, it would only be correct to refer to MITF “activities” and not generalize 
MITF activity as a single term. In addition to this transcription regulation, post-
translational modifications are usually important regulators of protein activity. They can 
act on various levels by changing protein stability and target-binding affinity, cellular 
localization, or interaction with partners or co-factors. Like with a large majority of 
eukaryotic proteins, MITF protein is subject to various post-translational modifications, 
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including serine/threonine phosphorylation, lysine mono and poly-ubiquitination, 
acetylation, and SUMOylation (Figure 8).  
 
A) M-MITF SUMOylation in melanocytes:  
SUMOylation stands for the enzymatic reaction catalyzing the conjugation of Small 
Ubiquitin-related Modifiers on an amino acid sequence, through three individual steps 
involving different proteins: activation, involving the E1 enzyme (SAE1/SAE2), 
conjugation, involving the E2 enzyme (UBC9) and transfer on the protein substrate 
involving the cooperation of E2 and E3 protein ligase (Miller et al., 2005; Murakami and 
Arnheiter, 2005). The fixation of SUMO occurs on Lysines belonging to the Ψ-K-x-D/E 
consensus site, where Ψ is stands for a hydrophobic amino acid. Three types of SUMO 
proteins are known so far: SUMO-1, SUMO-2 and SUMO-3. Although mixed chains of 
these proteins can be formed, SUMO-1 protein itself lacks a SUMOylation site and 
therefore prevents the further branching of additional SUMO proteins. MITF contains at 
least two SUMOylation sites on K182 and K316. SUMOylation on either or both sites 
has been shown to decrease the transcriptional activity of multiple M-box containing 
promoters but not on single M-box containing promoters in vitro (Miller et al., 2005; 
Murakami and Arnheiter, 2005). This alone shows that post-translational modifications 
can affect MITF activities in a target gene specific manner in vitro, even if signaling 
pathways resulting in MITF SUMOylation have yet to be identified. In addition, recent 
epidemiological data have identified a SUMOylation mutant in the European population. 
This variant is a p>E318K germline mutation and is associated with a higher risk of both 
sporadic and familial melanoma (Bertolotto et al., 2011a; Yokoyama et al., 2011). 
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Figure 8: Representation of the major types and positions of MITF 
post-translational modifications and their respective signaling pathways.
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B) M-MITF Acetylation in melanocytes:  
MITF contains two known aceylation sites on K206 and K243. However, the effect of 
MITF acetylation seems to depend on the location of these modifications. Unpublished 
work performed by Schepsky et al. suggest that, on the one hand, K206 acetylation leads 
to an increased transcriptional activity of MITF. On the other hand, K243 seems to be 
constitutively acetylated in vitro, and the prevention of acetylation at this position leads 
to a significant increase in activity (Schepsky A, Steingrimsson E Unpublished). Like for 
SUMOylation however, no clear signaling pathway leading to a change in MITF 
acetylation has been identified so far. 
 
C) M-MITF phosphorylation in melanocytes:  
Phosphorylation of M-MITF protein has been demonstrated on several sites along its 
amino acid sequence as a result of the activation of two principle signaling pathways in 
melanocytes.  
KIT-ligand signaling: The serine at position 73 in the M-MITF 2B+ 6A+ isoform, 
is subject to phosphorylation by ERK subsequent to KIT-ligand signaling in melanocytes, 
which activates the Mitotic-Activated Protein Kinase (MAPK) pathway (Hemesath et al., 
1998). Ser73-Phosphorylated MITF was shown to have an increased transcriptional 
activity on a tyrosinase reporter gene. In addition, activation of the MAPK pathway 
through KIT-ligand binding is thought to lead to the phosphorylation of another serine at 
position 409 in the M-MITF 2B+ 6A+ isoform through RSK1 (Wu et al., 2000). The role 
of this Ser409 phosphorylation remains, however, controversial. The original publication 
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stated that a protein non-phosphorylatable at both S73 and Ser409 was not able to bind 
DNA, and had a much smaller apparent molecular weight than the single mutated 
proteins (Wu et al., 2000). More recent publications demonstrated that S73/409A double 
mutant proteins do not show this apparent smaller molecular weight and were able to 
activate a reporter gene (Phung et al., 2011). Therefore this raises the possibility the 
protein presented in the original paper had additional alterations besides the serine 
substitutions.  
 
Nevertheless, S73/409 doubly phosphorylated MITF was shown to be subject to 
ubiquitination on K201 and subsequent proteasome-mediated degradation. USP13, a de-
ubiquitinase, has recently been involved in the regulation of the ubiquitination rate of 
MITF (Zhao et al., 2011). Modulations of USP13 expression drastically modify the level 
of MITF protein in vitro. 
Hence phosphorylation of S73 shows a dual effect: on the one hand, it increases the 
binding activity of MITF protein, and on the other, it decreases the amount of available 
protein by targeting MITF protein for degradation. 
 
WNT signaling: Mitf also bears additional phosphorylation sites, such as S298 
activated by GSK-3β, and S307 activated by p38 MAPK (Takeda et al., 2000a). The 
biological relevance of these sites in melanocytes still needs to be explored in detail.  
 
In a first attempt to assess the question of the role of phosphorylation, a mouse with a 
mutation at MITF serine-73 Mitfmi-S73A was generated by Bismuth et al. and analyzed for 
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both pigmentation phenotypes and proliferation rates of E9.5 derived Neural Crest 
Cultures (NCC). RT-PCR measurement of Mitf isoform distribution in three mutant mice 
revealed, however, that the mutation affected the proper inclusion of exon 2B in Mitf 
mRNA, resulting in the apparent exclusion of exon 2B in >90% of Mitf transcripts in 
both heart and skin (Bismuth et al., 2008). Nevertheless, the lack of Mitf 2B+ expression 
did not show any visible pigmentation phenotype in the homozygous adult mouse. Mitfmi-
S73A melanocytes proliferate more readily compared to wild type melanocytes. Moreover, 
heterologous cells transfected with Mitf 2B- expression plasmids proliferate normally 
while those transfected with Mitf 2B+ expression plasmids were inhibited (Bismuth, 
unpublished observation). Hence, this sensitization of exon 2B exclusion seems to have 
drastic consequences on melanocyte behavior depending on whether the melanocytes are 
in their natural in vivo environment or in vitro. This differential behavior suggests that 
extracellular signals, as well as the direct microenvironment surrounding the melanocyte, 
play key roles in switching between proliferation and differentiation states.  
 
The complexity of Mitf isoform distribution, the unexpected alteration in the alternative 
splicing profile of Mitf messages, and its consequences on melanocyte biology motivated 
us to develop quantitative methods, such as Real-Time PCR, to measure the amount of 
transcripts initiated from specific promoters as well as the amount of specific alternative 
splice variants in the total transcript pool. 
 
Using these techniques, we carried out a first study aimed at identifying the molecular 
mechanisms that are involved in the genetic interaction of the Kitw-LacZ allele with only 
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very specific Mitf alleles. Among them, the Mitfmi-bws allele is associated with an 
unexpectedly severe pigmentation defect when crossed with Kitw-LacZ. We, therefore, 
attempted to explain how this Mitf allele, originally characterized as an Mitf exon 2B 
splice mutant, was leading to such a dramatic phenotype in combination with a reduction 
of the MAPK signaling pathway. 
 
Despite the failure of the Mitfmi-S73A genetic model to dissociate two very distinct and 
perhaps independent mechanisms, MITF S73 Phosphorylation and Mitf exon 2B 
alternative splicing, this sensitized Mitf allele can be used to study the molecular 
mechanisms linking exon 2B alternative splicing regulation with the S73 codon. 
However, in order to understand the full extent of the influence of both mechanisms on 
melanocyte biology, it is crucial to be able to dissociate them from one another. Hence, 
we first collaborated with the Steingrimsson group who used a BAC-rescue transgenic 
approach in order to answer several critical questions assessing the link between 
phosphorylation, splicing and MITF activity. 
 
We then addressed the need for a genetic model, which allows the dissociation of S73 
codon mutation from exon 2B alternative splicing regulation, and used the presence of 
the floxed Neo cassette as a way to exacerbate the phenotypes of mice bearing single 
amino acid differences at residue-73. By extensive intercrosses with various Mitf alleles 
as well as molecular quantification of message and protein levels, we characterized the 
role of S73 phosphorylation in vivo.  
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Ultimately, we analyzed a particular allele found through the analysis of a ENU 
mutagenesis screen aiming to identify modifiers of the Mitf gene network. Such modifiers 
would enhance or suppress the pigmentation defects associated with the sensitized 
genetic background. 
 
The results of these studies presented in the next section of this thesis attempt to answer 
several critical questions about Mitf regulations: 
 
- What are the molecular bases of the genetic interactions observed in Mitfmi-bws/+; 
Kitw-LacZ double mutant mice? 
 
- Is an S73A/S409A double mutant MITF protein truly functionally dead in vivo? 
 
- How is exon 2B alternative splicing regulated by a single amino acid change at 
the S73 position? 
 
- What are the in vivo consequences of a forced incorporation of a non-
phosphorylatable alanine on MITF activity? 
 
 
 
 
 
 
 
 
 
 
 
Résultats  
 
 
 
 
 
 
 
 
Résultats 
 35 
Résultats 
 
1 – Méthodes de biologie moléculaire pour l’analyse de l’épissage alternatif et 
de l’initiation de la transcription du facteur de transcription bHLH-LZ Mitf. 
 
L’activité de facteurs de transcription est souvent régulée par des modifications 
post traductionnelles. Une des conditions requise pour ce type de modifications 
correspond à la présence, dans l’ARNm correspondant, des exons qui sont directement 
sujets à ces modifications, ou codent pour des domaines protéiques qui influencent ces 
modifications de façon indirecte. L’incorporation ou l’exclusion de ces exons sont 
régulées principalement par épissage alternatif, mais peuvent également dépendre de la 
sélection du site d’initiation de la transcription et/ou de poly-adénylation. Ainsi, la 
collecte d’informations sur ces évènements d’inclusion et d’exclusion d’exons, à la fois 
quantitatives et qualitatives, présente un grand intérêt pour des projets expérimentaux 
visant à muter de façon endogène certains codons, car dans certains cas, ces mutations 
peuvent entrainer des défauts d’épissage. C’est pour cette raison qu’ici, nous avons choisi 
l’exemple du facteur de transcription Mitf pour décrire des méthodes de quantification 
d’épissage alternatif et de sélection de promoteur chez la souris. 
Ces méthodes de quantification ainsi que les protocoles utilisés pour l’extraction des 
échantillons biologiques nécessaires aux expériences sont décrites dans l’Article 1. 
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The following results present a set of methods to determine, with quantitative and 
qualitative data, the expression profile of a complex gene, such as Mitf that uses 
differential promoter initiation as well as alternative splicing. The publication answers the 
critical need of quantifying specific RNA isoforms in cases where the absence of 
isoform-specific antibodies restricts the analysis to the RNA level. 
The strategy and the protocol used to obtain the biological materials necessary for the 
measurement of gene product variants are described in the following Article 1 
 
 
 
 
 
 
 
 
 
Article 1 
The basic-helix-loop-helix-leucine zipper gene Mitf: 
analysis of alternative promoter choice and splicing.  
Methods Mol Biol. 2010;647:237-50  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Chapter 14
The Basic-Helix-Loop-Helix-Leucine Zipper Gene  
Mitf : Analysis of Alternative Promoter Choice and Splicing
Kapil Bharti, Julien Debbache, Xin Wang, and Heinz Arnheiter 
Abstract
The activity of transcription factors is often regulated by Post-translational modifications. A precondition 
for such modifications is the presence, in the corresponding mRNAs, of the exons that either directly 
encode the modifiable residues in question, or encode protein domains that influence their modification 
indirectly. The inclusion or exclusion of coding exons is regulated predominantly by alternative splicing 
but can also depend on promoter choice and polyadenylation site selection. Information about exon 
inclusion and exclusion, both qualitatively and quantitatively, is particularly important for experiments 
designed to mutate endogenous codons because such mutations can alter splicing patterns. Therefore, 
we here describe methods employed to quantitate exon inclusion and exclusion, using as example a 
mouse transcription factor gene, Mitf.
Key words: Reverse transcriptase polymerase chain reaction, Real-time PCR, Serine phosphoryla-
tion, Knock-in allele
A prerequisite for Post-translational modifications is the incorpora-
tion of the specific exons coding for the modifiable residues. It is 
particularly important to determine the relative efficiency of exon 
inclusion or exclusion in cases where endogenous genes are mutated 
in codons that affect modifiable residues as such mutations can lead 
to the absence rather than the (intended) presence of the modifi-
able residue. It is for this reason that we here describe methods that 
can be employed to analyze and quantitate promoter and splice 
choices that determine the presence or absence of specific exons.
Our description focuses on a model gene, Mitf. This gene 
encodes a basic helix-loop-helix–leucine zipper transcription 
factor whose major role in vertebrates is the regulation of the 
1. Introduction
Paul J. Higgins (ed.), Transcription Factors: Methods and Protocols, Methods in Molecular Biology, vol. 647,
DOI 10.1007/978-1-60761-738-9_14, © Springer Science+Business Media, LLC 2010
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development and function of melanin-bearing pigment cells (that 
is, melanocytes and retinal pigment epithelium or RPE cells) (1). 
Mutations in Mitf can lead to severe deficiencies in neural crest-
derived melanocytes which in mammals are not only associated 
with loss of coat pigmentation but also with deafness (2). In man, 
for instance, about 20% of congenital hearing deficiencies of 
the type “Waardenburg syndrome II” are associated with 
heterozygosity for mutations in MITF (3). In birds and rodents, 
homozygosity for Mitf mutations can also be associated with the 
“transdifferentiation” of retinal pigment epithelium cells into a 
retina-like tissue, a developmental aberration associated with 
small eyes (called microphthalmia, hence the name, Mitf = 
microphthalmia-associated transcription factor) (4). Nevertheless, 
although Mitf is expressed in many more cell types besides pig-
ment cells, most of them do not display overt phenotypes when 
Mitf is mutated. Among those that are affected are mast cells, B 
cells, and osteoclasts. The latter cells show severe impairments 
when Mitf is mutated in such a way that the mutant protein, 
which forms obligatory homo- and heterodimers, acts in a domi-
nant-negative manner. Mice with such mutations can have an 
osteopetrosis leading to premature death at weaning (5).
Although encoded by a single gene, MITF is not a single 
protein but represents a family of isoforms generated by alterna-
tive promoter choice, alternative splicing, and a series of function-
ally relevant post-translational modifications (reviewed in ref. 
(2)). In fact, the 214,000 bp gene (mouse, human) has at least 
nine different promoters, at least six of which associated with 
Fig. 1. Partial gene structure of Mitf, focusing on alternative promoters D and H and showing noncoding/coding parts of 
5¢ exons, splice patterns and primer selection for quantitative determination of promoter choices. Note that isoform H 
utilizes an translational start codon in exon H, and isoform D a start codon in the 3¢ part of exon 1B, called exon 1B1b. 
For results obtained using these primers, see ref. (6).
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unique amino-terminal protein sequences. Some of these 
promoters show a precise tissue-specific and developmental regu-
lation (ref. (6), see also Fig. 1). Moreover, modifications of 
splicing patterns have been associated with specific pigmentary 
phenotypes in mice (7). Lastly, serine phosphorylation, sumoyla-
tion, and acetylation have all been shown to affect MITF activity 
in vitro. For instance, sumoylation at lysine-182 and lysine-316 
decreases MITF activity in a promoter-specific way that depends 
on the number of cognate promoter motifs (E-boxes) capable of 
interacting with MITF (8, 9). Moreover, it has been reported 
that MAPK-mediated phosphorylation at serine-73 increases the 
protein’s capacity to stimulate the promoter of tyrosinase, a mel-
anocyte differentiation gene, and that double phosphorylation at 
serine-73 and serine-409 leads to increased MITF protein degra-
dation (10, 11). Serine-73 is present in exon 2B (see Fig. 2), an 
Fig. 2. Partial gene structure of mouse Mitf, focusing on exon 2A/2B and showing alternative splice products and primer 
choices for quantitative determination of exon inclusion. The top shows a partial gene structure for the region spanning 
exon 1B and 3. Note that two alternative promoters linked to either exon 1B or 1M and the common splice acceptor in 
exon 2A. Exon 2 is bipartite, with exon 2B either included (Mitf 2B+) or excluded (Mitf 2B−) from the mRNA. Primers 
overlapping the 2A/2B junction or the 2A/3 junction are shown, with reverse primers placed such that similar size prod-
ucts result for the two exon 2B splice versions. The schematic also shows the relative position of a serine-73-to-alanine 
codon mutation (S73A). This mutation favors exon 2B exclusion.
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exon that is normally absent in only 5–10% of Mitf mRNAs, but 
is absent in over 95% of mRNAs transcribed from a mutant Mitf 
allele characterized by a serine-73-to-alanine codon change 
(12). These observations suggest that the serine-73 codon is 
part of an exonic splice enhancer sequence that binds specific 
arginine/serine-rich proteins which are known to regulate mRNA 
splicing (for a recent review, see ref. (13)). This example high-
lights the importance of exonic sequences in determining splice 
choices and hence, ultimately, whether the protein can be Post-
translationally modified or not (see Fig. 3).
Fig. 3. Real-time PCR to quantify exon inclusion/exclusion. (a) Establishment of standard curves. Graded amounts of 
mouse Mitf standard cDNA were mixed with heterospecific cDNA, and real-time PCR was performed as indicated in the 
text. 2B+ primers correspond to primer pair a–c from Fig. 2, and 2B− primers correspond to primer pair b–d from Fig. 2. 
(b) Quantitation of exon 2B exclusion in RNA prepared from HEK293 cells transfected with the minigene as described in 
text and Fig. 2. Regular PCR followed by product identification by gel electrophoresis was done with a forward primer in 
exon 1M and a reverse primer in exon 3. This yields a product of 312 bp when exon 2B is included, and of 144 bp product 
when exon 2B is excluded. S73A corresponds to a minigene with a two base-pair change in codon 73 (AGC-to-GCC). 
Results are given as mean with bars indicating standard deviation from three measurements. (c) Similar quantitative 
assay performed with cDNA obtained from hearts of wild type mice or mice with the S73A codon change as indicated for 
(b). Note that the difference between wild type and mutant is more pronounced in vivo compared to minigene-transfected 
cells. wt wild type.
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 1. Pregnant mouse females, for instance C57BL/6J (Jackson 
Labs, Bar Harbor, ME).
 2. RNaseZap (Ambion, Austin, TX), RNase inhibitor solution 
for cleaning surgical instruments. Store at room 
temperature.
 3. Straight surgical scissors (27 mm for mouse dissection and 
15 mm for removing embryos from the uterus, ROBOZ 
Scientific, Gaithersburg, MD).
 4. Two pairs of microdissection tweezers (tips 0.05 × 0.01 mm) 
(ROBOZ Scientific, Gaithersburg, MD).
 5. 10 cm and 3.5 cm Petri dishes (Becton Dickinson and 
Company, Franklin Lakes, NJ).
 6. DEPC-treated Molecular Biology grade water (Quality 
Biologicals, Inc., Gaithersburg, MD). Store at room 
temperature.
 7. 10× PBS (Quality Biologicals, Inc., Gaithersburg, MD). Mix 
100 ml of 10× PBS with 900 ml of DEPC-treated water to 
make 1× PBS. Store at 4°C.
 8. 1.5 ml microcentrifuge tubes (Denville Scientific, Metuchen, 
NJ).
 9. Plastic tissue grinders (Bel-art Products, Pequannock, NJ).
 1. Dulbecco’s Modified Eagle’s Medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS) and 1% Penicillin/
Streptomycin (Gibco/BRL, Carlsbad, CA). Store all reagents 
at 4°C.
 2. Solution of 0.05% trypsin and ethylenediamine tetraacetic 
acid (EDTA) (Gibco/BRL, Carlsbad, CA). Store at 4°C.
 3. 10 and 6 cm tissue culture grade dishes (Becton Dickinson 
and Company, Franklin Lakes, NJ).
 4. Tris/EDTA (TE): 10 mM Tris-Hcl, 1 mM EDTA, pH 7.4 
(Quality Biologicals, Inc., Gaithersburg, MD). Store at room 
temperature.
 5. Effectene Transfection Kit (Qiagen, Valencia, CA). Store 
at 4°C.
 6. 15 ml centrifuge tubes (Denville Scientific, Metuchen, NJ).
 1. RNeasy Mini RNA Extraction Kit (Qiagen, Valencia, CA). 
Store at room temperature.
2. Materials
2.1. Embryo 
Harvesting and Tissue 
Grinding
2.2. Cell Culture  
and Transfection
2.3. RNA Extraction 
and cDNA Preparation
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 2. Ethanol 200 proof (The Warner-Graham Company, 
Cockeysville, MD). Mix 70 ml of 200 proof ethanol with 
30 ml of DEPC-treated water to make 70% ethanol.
 3. RNase-free-DNase (3,000 Kunitz units/ml, Qiagen, Valencia, 
CA).
 4. Nanodrop Spectrophotometer (Nanodrop Technologies, 
Wilmington, DE).
 5. SuperScript First-Strand Synthesis System for RT-PCR 
(Invitrogen, Carlsbad, CA). Store at −20°C.
 1. Taq 2000 Polymerase (5 units/µl) (Stratagene, La Jolla, CA). 
Store at −20°C.
 2. 2 mM dNTPs (MBI Fermentas, Glen Burnie, MD). Store at 
−20°C.
 3. Primers, final concentration 10 pmole/µl (Genelink, 
Hawthorne, NY). Store at −20°C.
 4. PCR tubes 0.2 ml (Denville Scientific, Metuchen, NJ).
 5. Molecular biology grade water (Quality Biologicals, Inc., 
Gaithersburg, MD). Store at room temperature.
 6. Dyad DNA Engine Themocycler (MJ mini, now Bio-Rad, 
Hercules, CA).
 7. 5× DNA loading dye (Teknova, Hollister, CA).
 1. Ultra pure agarose (Invitrogen, Carlsbad, CA). Store at room 
temperature.
 2. 50× TAE (Quality Biologicals, Inc., Gaithersburg, MD). 50× 
TAE is diluted to 1× by mixing 20 ml of 50× TAE in 980 ml 
of deionized water.
 3. Ethidium bromide 10 mg/ml (Sigma, St. Louis, MO).
 4. Sub-Cell GT agarose gel electrophoresis unit (Bio-Rad, 
Hercules, CA).
 5. Pharmacia EPS 250/200 power supply (GE Healthcare, 
Pharmacia, Uppsala, Sweden).
 6. Molecular weight marker, DNA ladder mix (MBI Fermentas, 
Glen Burnie, MD). Store at −20°C.
 1. Power SYBR Green Mix (2×) (Applied Biosystems, Foster 
City, CA). Store at 4°C.
 2. 96-well optical reaction plate (Applied Biosystems, Foster 
City, CA).
 3. ABI Prism 7000 Sequence Detection System (Applied 
Biosystems, Foster City, CA).
2.4. Polymerase Chain 
Reaction
2.5. Agarose Gel
2.6. Real-Time PCR 
Analysis
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 1. Pregnant C57BL/6J females: To calculate the developmental 
time point for harvesting embryos, the morning that the vag-
inal plug is first detected is considered embryonic day (E) 0.5. 
For instance, E11.5 embryos are collected 11 days following 
the day of plug detection (E0.5). For detailed information 
about embryo collection, see ref. (14).
 2. Harvesting tissue for RNA extraction requires precautions to 
avoid RNase contamination. Before starting to dissect the 
pregnant female, treat all instruments with RNase inhibitor 
solutions (RNaseZap), and prepare the solutions needed for 
this procedure with DEPC-treated molecular biology grade 
water. A separate set of tweezers, which has not been used 
during mouse dissection, is used for the dissection of the eye 
tissue. Two sets of appropriately labeled 1.5 ml microcentri-
fuge tubes are stored in dry ice.
 3. Euthanize the pregnant females according to methods 
approved by your Animal Care and Use Committee (for 
instance CO2). Harvest embryos using 27 mm scissors and 
tweezers and place the embryos in cold 1× PBS in a 10-cm 
dish. Remove the placenta and the chorionic membranes 
from each embryo, one at a time, using a pair of 15 mm scis-
sors, and transfer the embryos to cold 1× PBS in a second 
10 cm dish.
 4. Using the clean set of tweezers, carefully remove both eyes 
from an embryo under a dissection scope and transfer the 
eyes to cold 1× PBS in a 3.5 cm dish. While holding the eye-
ball with one tweezer, use the other tweezer to enlarge the 
optic pit hole at the back of the eye. Push the retina/lens 
through the optic pit hole by squeezing/pushing at the ante-
rior part of the eye. Collect the separated RPE/mesenchyme 
and retina/lens tissue into separate 1.5 ml microcentrifuge 
tubes stored on dry ice (see Note 1). Freeze these tubes 
at −80°C until further processing.
 5. For other tissues, proceed accordingly.
 1. Human embryonic kidney cells (HEK293) are cultured in 
DMEM medium with 10% FBS and 1% Penicillin/
Streptomycin at 37°C in an incubator with 6% CO2/air. 
Passage the cells as they approach 70% confluency, using 
0.05% trypsin/EDTA, and replate at a dilution of 1:5 (see 
Note 2).
 2. The methods described here are applicable to analyzing the 
relative and absolute levels of different splice isoforms of 
3. Methods
3.1. Sample 
Preparation for 
Isoform Analysis
3.1.1. Harvesting 
Embryonic Tissue for 
Detection of Alternate 
Promoter Isoforms of Mitf 
at Different Developmental 
Stages. Example Eye 
Tissue
3.1.2. Harvesting 
Transfected Cells for 
Assaying Alternative 
Splicing of Different Mitf 
Exons
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endogenous Mitf mRNAs. Because one of the goals is to 
analyze the sequence requirements for regular and alternative 
splicing, we use wild type and various mutated minigene con-
structs that are transfected into cultured cells. Generally, these 
minigene constructs contain a part of the gene where the 
exon to be tested for alternative splicing is flanked, at least, by 
the two neighboring introns and adjacent exons. For instance, 
to analyze alternative splicing of exon 2B of Mitf, the reporter 
construct contains part of the gene from exon 1M to exon 3, 
including introns 1 and 2 (see Fig. 2). For expression, these 
minigenes are placed under the control of a CMV promoter 
and contain a 3¢ untranslated region and polyadenylation signal. 
The strength of alternate splicing is analyzed by comparison 
with constructs where splice junctions or splice enhancer and 
silencer sequences are mutated.
 3. For transfection, plate one million of freshly trypsinized cells 
in a 6 cm dish and transfect them the following morning 
using the Effectene Transfection Kit (Qiagen). Dilute 1 µg of 
the minigene construct dissolved in TE into 150 µl of DNA 
condensation buffer (Buffer EC) in a 1.5 ml microcentrifuge 
tube. Add 8 µl of enhancer solution and vortex the tubes for 
1 s (see Note 3).
 4. Incubate at room temperature for 2–5 min, then briefly spin 
the tubes to collect drops from the tube top.
 5. Add 25 µl of effectene reagent to the tubes and vortex for 
10 s. Incubate tubes at room temperature for 10 min.
 6. While the DNA-transfection complexes are forming, aspirate 
the medium from the cells and gently wash cells with 4 ml 1× 
PBS. Add 4 ml fresh DMEM medium to the cells and return 
the dishes to the incubator.
 7. Add 1 ml DMEM medium to the tube containing the DNA-
transfection complex and mix gently by pipetting up and 
down. Add the transfection mix to the cells and gently swirl 
the dish to ensure uniform distribution of the DNA-
transfection mix. Return the dishes to the incubator.
 8. After 16 h of incubation, collect cells for RNA extraction. 
Aspirate the medium from the dish and wash cells with 4 ml 
1× PBS. Trypsinize cells with 1 ml 0.05% trypsin/EDTA. 
Add 5 ml of fresh medium to the cells and transfer detached 
cells to a 15 ml centrifuge tube and pellet by centrifugation at 
300 × g for 5 min. Aspirate the medium from the cell pellet 
without disturbing the pellet. Wash the cells with 1× PBS and 
spin the tubes again at 300 × g for 5 min. Aspirate the super-
natant fluid and flash freeze the tubes in dry ice. Store tubes 
at −80°C until further processing.
245The Basic Helix-Loop-Helix-Leucine Zipper Gene Mitf
 1. To grind embryonic tissue, use plastic tissue grinders fitting 
the conical bottom of a 1.5 ml microcentrifuge tube. Before 
grinding, clean the grinders with RNase inhibitor solution 
(RNaseZap) and store at −20°C to keep them cold. Add 50 µl 
of RLT buffer from the Kit (add 10 µl of b-mercaptoethanol 
to 1 ml RLT buffer before use) to the frozen tissue and grind 
it on dry ice using the prechilled plastic grinders. After grind-
ing, add an additional 300 µl of RLT buffer to the tissue and 
freeze on dry ice until other tubes are processed. Once all the 
tubes are processed, thaw them on ice and process for RNA 
extraction starting at step 3.
 2. To lyse frozen tissue culture cells, add 350 µl RLT buffer to 
the cell pellet immediately after taking it from the freezer. 
Vortex the tube to ensure a homogenous suspension of the 
cells and proceed to step 3.
 3. Pipette the tissue lysate from step 1 or the cell suspension 
from step 2 onto a QIAshredder column placed in a 2 ml col-
lection tube. Centrifuge tubes for 2 min at maximum speed 
to lyse the cells.
 4. Add 350 µl of 70% ethanol to the homogenized cell lysate 
and mix thoroughly by pipetting up and down. Do not vor-
tex or centrifuge the samples at this step.
 5. Pipette all 700 µl of the sample mixture, including any pre-
cipitates that may have formed in the previous step, to an 
RNeasy mini spin column placed in a 2 ml collection tube. 
Centrifuge the samples for 30 s at 9,300 × g.
 6. Discard the flow-through. Add 500 µl of buffer RW1 from 
the kit to the RNeasy column and spin the columns for 30 s 
at 9,300 × g.
 7. Discard the flow-through along with the collection tube and 
transfer the column to a new collection tube.
 8. Add RNase-free-DNase, in a mixture of 75 µl of buffer RDD 
from the kit and 5 µl of DNase (15 Kunitz units totally), onto 
each column. Make sure that the DNase solution covers the 
entire surface of the membrane and incubate columns at 
room temperature for 30 min.
 9. Add another 500 µl of buffer RW1 to the column and spin 
the columns for 30 s at 9,300 × g.
 10. Transfer RNeasy column to a new collection tube, add 500 µl 
of buffer RPE from the kit to the column, and spin for 30 s at 
9,300 × g.
 11. Add another 500 µl of buffer RPE onto each column and 
spin for 2 min at 9,300 × g to dry the column.
3.2. Preparation  
of RNA and cDNA 
From Embryonic 
Tissue or Transfected 
Cells
3.2.1. RNA Extraction 
Using RNeasy Mini RNA 
Extraction Kit From Qiagen
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 12. Transfer the column to a 1.5 ml microcentrifuge tube and 
add 50 µl of 65°C RNase-free water onto the membrane. 
Incubate at room temperature for 5 min and spin the col-
umns for 30 s at 9,300 × g.
 13. The eluate contains pure RNA. Measure concentration using 
a nanodrop spectrophotometer using 1.3 µl of the undiluted 
RNA solution.
 1. Mix 1 µg of RNA with 1 µl of 10 mM dNTP mix, and 2 µl of 
random hexamers (50 ng/µl) in a 0.2 ml PCR tube. Adjust 
the final volume of the mixture to 10 µl with DEPC-treated 
water (see Note 4).
 2. Incubate tubes at 65°C for 5 min and then transfer them to 
ice for 2–3 min.
 3. While the samples are cooling on ice, prepare a second reac-
tion mix containing 2 µl of 10× RT buffer, 4 µl of 25 mM 
MgCl2, 2 µl of 0.1 M DTT, 1 µl of RNaseOUT recombinant 
(Ribonuclease inhibitor) and 1 µl of Superscript II Reverse 
Transcriptase (50 units). Add 10 µl of the reaction mixture to 
each RNA/primer mixture. Mix the solutions gently and spin 
the tubes briefly to collect all of the solution at the bottom.
 4. Incubate the tubes for 2 min at 25°C. Transfer the tubes to 
42°C for 1 h.
 5. Terminate the reaction by incubating tubes at 70°C for 
15 min and then place tubes on ice.
 6. Add 1 µl of RNase H to each tube and incubate at 37°C for 
20 min.
 7. Dilute the cDNA 1:5 in water. The cDNA is now ready for 
PCR.
 8. Before using this cDNA for real-time analysis, check the qual-
ity of each sample by PCR amplification of an unrelated 
cDNA.
 1. For a 20 µl PCR reaction, mix 2 µl of 10× reaction buffer, 
2 µl of 2 mM dNTPs, 2 µl of 10 pmole/µl of each forward 
and reverse primers, 1 µl of the cDNA template, 11.75 µl of 
molecular biology grade water, and 1 unit (0.25 µl) of Taq 
Polymerase in a 0.2 ml PCR tube. For primer choice, see 
Figs. 1 and 2 and ref. (6).
 2. Place the tubes in the thermocycler block and set up a cycling 
program as follows: 92°C, 2 min (step 1), 92°C, 20 s; 55°C, 
30 s; 72°C, 1 min (step 2, repeat for 29 cycles), 72°C, 7 min 
(last step). Start the cycling program. The program is 
designed for DNA Engine DYAD thermocycler from MJ mini 
(see Note 5).
3.2.2. cDNA Preparation 
Using Superscript 
First-Strand Synthesis 
System for RT-PCR
3.2.3. Setting Up a PCR
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 3. Once the PCR is finished, add 5 µl of 5× DNA gel loading 
buffer to each tube. The samples are now ready to load on an 
agarose gel.
 1. The agarose gel set up is described for Sub-Cell GT agarose 
gel electrophoresis unit from Bio-Rad.
 2. To prepare a 1.5% agarose gel for a chamber that holds 150 ml 
of gel solution, weigh 2.25 g of agarose in a 250 ml 
Erlyenmeyer flask and add 150 ml of 1× TAE. Heat the solu-
tion with intermittent shaking until agarose dissolves com-
pletely. Let the gel solution cool to about 50°C. Add ethidium 
bromide at a final concentration of 1 µg/ml. Pour the gel 
solution into the gel tray with stoppers on each side. Add the 
combs to the tray and let the gel solidify.
 3. Remove the combs and the stopper from the solidified gel 
and submerge the gel into 1× TAE running buffer in the 
gel electrophoresis unit.
 4. Load 10 µl total of sample and 1× loading buffer per well.
 5. In a corner well, load 3 µl of DNA ladder mix as a molecular 
weight marker.
 6. Run the gel at constant 75 V. Stop the gel when the dye front 
has reached 2/3rd of the total running distance. Take a pic-
ture of the gel, using a UV-gel documentation unit.
To detect alternative promoter choice for the Mitf gene in differ-
ent tissues at various developmental stages, forward primers spe-
cific for the alternative exons are used in combination with a 
reverse primer that is common to all isoforms. Forward primers 
are designed in a way that the PCR products amplified for the 
different isoforms are of similar size. For details, see ref. (6).
To detect alternatively spliced exons, forward primers are unique 
to the exon–exon junctions of the differently spliced products. 
For the situation where the alternative exon is spliced-in, the 
forward primer is positioned at the exon junction in a way that 
part of the primer hybridizes with the 3¢ end of the upstream 
exon, and part with the 5¢ end of the downstream exon. For the 
situation where the alternative exon is spliced-out, forward primers 
are placed accordingly in a way that they span the expected 
junction formed by the absence of the alternative exon. Hence, 
the 5¢ parts of both types of forward primers are identical, but 
because their 3¢ parts are different, cross-priming is not usually a 
problem. For reverse primers, sequences in the downstream 
common exon are chosen at locations that assure a similar length 
of the two expected products (Fig. 2).
3.2.4. Agarose Gel 
Electrophoresis
3.3. Quantitative 
Real-Time PCR
3.3.1. Primer Design  
for Alternative Promoter 
Isoforms
3.3.2. Primer Design for 
Alternatively Spliced Exons
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 1. Amplify standard cDNA products corresponding to each 
isoform, using primer pairs as described in Subheading 3.3.1, 
step 1. Using amplified DNA allows for the generation of 
linear standard DNAs of a size similar to the cDNAs present 
in the test samples and is to be preferred over the use of plas-
mids for standard curve purposes.
 2. Quantify the amounts of standard DNA products both spectro-
photometrically and by agarose gel electrophoresis (see below).
 3. Dilute appropriate concentrations of the standard DNA, for 
instance in steps of tenfold dilutions, into a cDNA source that 
does not contain the isoforms to be tested. For instance, in 
the case of Mitf-promoter isoforms, cDNA from hearts of 
Mitf mi-rw/mi-rw animals was used (6). These mutant mice lack 
the exon corresponding to the common reverse primer (exon 
1B) but provide a complexity of cDNAs similar to that 
expected in the test sample. This is critical as primer efficiency 
differs depending on the amplification environment. In the 
absence of appropriate mutants, use heterospecific cDNA and 
species-specific primers.
 4. Perform real-time PCR on these samples using a set of prim-
ers that represent a nested set to the original pair used to 
amplify the standard DNAs (for details, see ref. (6). An ABI 
Prism 7000 real-time PCR machine is used for the real-time 
analysis.
 5. A log of the amount of standard DNA (weight/reaction) 
is plotted against the threshold cycle (cT) values obtained 
for each concentration. A best-fit regression plot is drawn for 
each standard curve. Using the average molecular weight of a 
basepair as 660 Daltons, the weight can be converted into the 
number of DNA molecules.
 6. Generate standard curves for each isoform, and separately for 
each repeat assay performed with the test samples.
 7. Perform the real-time PCR of the test samples (for instance, 
cDNA obtained from E11.5 RPE and retina), by using the 
same set of nested primers as used in step 4. Normalize each 
sample by quantifying an unrelated cDNA, again using real-
time PCR (see Note 6). The absolute amount of cDNA mol-
ecules in test samples is determined by using the appropriate 
previously determined isoform-specific standard curves and 
linear regression plots.
 1. The principles of standard curve determination are according 
to the methods described above for promoter choice deter-
mination (see Note 7).
 2. Standard templates of mouse cDNA are diluted in a cDNA 
mixture from a human cell line (see Notes 2 and 7). 
3.3.3. Generation  
of Standard Curve  
and Real-Time Analysis  
of Alternative Promoter 
Isoforms
3.3.4. Generation  
of Standard Curve  
and Real-Time Analysis  
of Alternatively Spliced 
Exons
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The primers used for this analysis are made specific to mouse 
sequences so that human Mitf cDNA is not amplified in this 
mixture of mouse standard cDNAs and human cell line 
cDNA. An example of a standard curve determination is 
shown in Fig. 3A. Note that inappropriate cross-priming (for 
instance, 2B+ primers on 2B− cDNA) for cDNA concentra-
tions above 1 pg/reaction gives results that are 1–4 logs 
below those obtained for appropriate priming (for instance 
2B+ primers on 2B+ cDNA).
 3. Using the above methods of standard curve determination, 
test samples are subjected to real-time PCR as mentioned. 
Use quantification of an unrelated cDNA for normalization 
of the test samples (see Note 6). Results can be expressed in 
absolute numbers of cDNA molecules, or, as shown in Fig. 3B 
and 3C, as relative amounts of exon 2B-lacking cDNAs com-
pared to the sum of exon 2B-lacking and exon 2B-containing 
cDNAs.
 1. If embryos need to be genotyped, separate each embryo into 
an individual tube and remove a portion from each embryo 
for PCR or other appropriate genotyping reaction.
 2. Instead of using heterospecific cells to prepare cDNA to be 
used during standard curve determination, one may also use 
cell types in which the gene of interest is not expressed (or 
expressed below threshold levels for the chosen PCR 
conditions).
 3. The method of transfection has to be adapted to the type of 
cell line used.
 4. The amount of RNA used for the RT reaction can be lower 
but each test sample should contain the same amount of 
total RNA.
 5. The annealing temperature may vary with the efficiency of 
the primer sets, and the number of cycles for step 2 may vary 
depending on the abundance of the cDNA of interest in the 
sample. An optimum number of cycles is considered to be 
that which gives amplification in the linear range.
 6. For normalization, use an unrelated cDNA whose threshold 
cycle time is similar to that of the test cDNA. For the analysis 
of exon 2B splice variants, for instance, we used USF, a cDNA 
whose relative abundance is similar to that of Mitf exon 2B− 
cDNA in wild type, and does not change significantly between 
samples obtained from different genotypes.
4. Notes
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 7. If one wants to avoid the use of nested primer set-PCR to 
generate standard DNAs from appropriate plasmids, one can 
use the respective plasmids directly as standard cDNAs. In 
this case, only one primer set is used both for the generation 
of the standard curve and for the analysis of the test samples.
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2 – Les interactions génétiques entre Mitf et Kit sont allèle-spécifiques et 
mettent en évidence de nouveaux éléments sur la nature moléculaire de 
l’allèle murin Mitfmi-bws. 
 
Le récepteur tyrosine kinase KIT et le facteur de transcription MITF, tous deux 
requis dans le développement des mélanocytes, ont été démontrés comme interagissant de 
façon fonctionnelle in vitro et in vivo. In vitro, l’activation de la voix de signalisation KIT 
entraine la phosphorylation de MITF, ce qui affecte son activité ainsi que sa stabilité. In 
vivo, la présence de l’allèle « mi-white » MitfMi-wh accentue le phénotype de 
dépigmentation associé aux mutations hétérozygotes du gène Kit. Ici nous démontrons 
que parmi une série d’autres allèles de Mitf, seul l’allèle récessif « mi-black-and-white 
spots » ou Mitfmi-bws parvient à reproduire l’interaction génétique observée entre l’allèle 
MitfMi-wh et Kit. De façon intéressante, Mitfmi-bws a été caractérisé au niveau 
transcriptionnel par une réduction du niveau d’inclusion de l’exon 2B, qui code, entre 
autres, pour la Serine 73, qui se trouve être un des sites de phosphorylation de la voix de 
signalisation KIT. Cependant, d’autres allèles de Mitf qui génèrent des altérations 
similaires de l’inclusion de l’exon 2B ou qui altèrent le niveau d’expression du gène, ne 
présentent pas d’interactions similaires avec Kit in vivo. De ce fait, nous supposons que 
l’allèle récessif Mitfmi-bws est un allèle complexe et non complètement caractérisé qui peut 
présenter un effet dominant-négatif lorsqu’il est présent sur un fond génétique sensibilisé 
par Kit. Nous suggérons ainsi que la variabilité de certaines pathologies génétiques 
humaines peuvent, elles aussi, être liées à l’interaction allèle-spécifique de variants 
alléliques complexes de différents gènes. 
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Les résultats expérimentaux liés à cette étude sont présentés dans l’Article 2. 
 
 
In the following study, we characterized a new genetic interaction between the Mitfmi-bws 
and the KitW-LacZ alleles, showing a similar effect as the interaction of MitfMi-wh with KitW-
LacZ. The Mitfmi-bws allele is characterized by an exon 2B splice defect which promotes the 
exclusion of exon 2B in about 50% of Mitf transcripts compared to the normally ~5% in 
wild type Mitf. In contrast, mice carrying the Mitfmi-S73A allele, which also presents a 
significant exclusion of Mitf exon 2B at the mRNA level, do not show similar interactions 
with Kit. In this study, we show that in addition to the exon 2B exclusion, Mitfmi-bws mice 
display abnormally reduced levels of Mitf messages. Nonetheless the attempt to mimic 
the molecular phenotype observed in Mitfmi-bws; KitW-lacZ/+ mice by further reducing the 
Mitf levels in Mitfmi-S73A by genetic means still did not lead to mice with phenotypes 
similar to Mitfmi-bws/Mitfmi-bws ; Kitw-LacZ/+. The results suggest that the Mitf exon 2B 
exclusion cannot be the only reason for the observed interaction seen with Kit and Mitfmi-
bws. Hence, the Mitfmi-bws allele may have additional genetic and functional alterations 
besides what is currently known about this allele. 
The experimental work related to this study is presented in the following Article 2. 
 
 
 
 
 
 
 
 
 
Article 2 
Allele-specific genetic interactions between Mitf and Kit 
affect melanocyte development. 
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Summary
The tyrosine kinase receptor KIT and the transcription factor MITF, each required for melanocyte develop-
ment, have been shown to interact functionally both in vitro and in vivo. In vitro, KIT signaling leads to MITF
phosphorylation, affecting MITF activity and stability. In vivo, the presence of the MitfMi-wh allele exacerbates
the spotting phenotype associated with heterozygosity for Kit mutations. Here, we show that among a series
of other Mitf alleles, only the recessive Mitf mi-bws mimics the effect of Mitf Mi-wh on Kit. Intriguingly, Mitf mi-bws
is characterized by a splice defect that leads to a reduction of RNAs containing MITF exon 2B which encodes
serine-73, a serine phosphorylated upon KIT signaling. Nevertheless, other Mitf alleles that generally affect
Mitf RNA levels, or carry a serine-73-to-alanine mutation that specifically reduces exon 2B-containing RNAs,
do not show similar interactions with Kit in vivo. We conclude that the recessive Mitf mi-bws is a complex allele
that can display a semi-dominant effect when present in a Kit-sensitized background. We suggest that human
disease variability may equally be due to complex, allele-specific interactions between different genes.
Introduction
Interactions between different genes are often difficult
to assess because they may be subtle and the corre-
sponding phenotypes not easily visible to the naked
eye. Such interactions can be probed readily, however,
for genes affecting pigmentation because pigmentary
alterations can serve as a highly sensitive read-out of
the modification of the action of one gene by another
(Barsh, 1996; Baxter et al., 2009; Quevedo and Holstein,
1992; Spritz, 1997). In fact, given that over 200 loci
are known to affect pigmentation in mice alone, pig-
mentation may be among the first phenotypes for which
an extensive if not complete genetic network can be
established (Baxter et al., 2004; Bennett and Lamoreux,
2003; Hearing and Jimenez, 1989; Hou and Pavan,
2008).
Genetic interactions often reflect functional interac-
tions where the gene products in question feed into
common molecular pathways (Drees et al., 2005). This
is perhaps best illustrated by interactions between tran-
scription factor genes on the one hand and genes con-
trolling signaling pathways that modify the activities of
these transcription factor genes or their products on the
other. For instance, mice that are heterozygous for a
mutation in the gene encoding the signaling receptor Kit
and also heterozygous for a mutation in the gene encod-
ing the microphthalmia-associated transcription factor
Mitf (a basic-helix-loop-helix-leucine zipper protein which
binds DNA as homo- or heterodimers) can show much
more extensive white spotting than would be expected
from heterozygosity for mutations in either gene alone
(Beechey and Harrison, 1994; Diwakar et al., 2008; Hou
et al., 2000). This phenomenon may indeed reflect func-
tional interactions as it is well documented in vitro that
Mitf is needed for the maintenance of KIT expression in
melanoblasts and that Kit signaling affects Mitf both at
the transcriptional and post-translational levels (Hemes-
ath et al., 1998; Opdecamp et al., 1997; Price et al.,
1998). Interactions have also been observed between
the transcription factor PAX3 and KIT (Guo et al., 2010),
between genes encoding signaling components, such
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as endothelin receptor B (Ednrb) and Kit ligand (Kitl ), or
between transcription factors, such as Sox10 and Mitf
(Hou et al., 2006; Potterf et al., 2000; Rhim et al.,
2000). Moreover, an interaction has been observed
between Mitf and Bcl2, a gene that is involved in the
cell death pathway and is regulated by Mitf (McGill
et al., 2002).
The fact that pigmentation defects caused by muta-
tions in one gene can be affected by mutations in a sec-
ond gene have also made it possible to search for
mutant pigmentation genes that by themselves would
hardly produce a visible phenotype in heterozygotes.
For example, a number of novel mutations affecting the
pigment cell lineage have recently been identified in
mice by combining a null mutation for Sox10 with germ-
line mutations obtained after treatment with N-ethyl-N-
nitrosourea (Matera et al., 2008). When designing such
sensitized genetic screens, however, one has to take
into account that gene interactions may be allele-spe-
cific. The above mentioned interaction between Kit and
Mitf, for instance, although seen with several Kit alleles
(Beechey and Harrison, 1994; Diwakar et al., 2008;
Hou et al., 2000), has so far been tested only for the
semi-dominant Mitf Mi-wh (Microphthalmia-white) allele.
Mitf Mi-wh is characterized by a codon change in exon 7
and produces at least one protein isoform that is unable
to bind DNA but still able to form dimers with wild-type
dimerization partners (Hemesath et al., 1994). The
enhanced spotting phenotype of Mitf Mi-wh ⁄Kit mutant
mice could be explained, therefore, by reduced phos-
phorylation, and hence increased stability and dominant-
negative action, of this isoform (Arnheiter et al., 2006).
If so, Mitf alleles lacking dominant-negative characteris-
tics might not show similar interactions with Kit. In fact,
as demonstrated here, many other Mitf alleles showed
no interactions with the Kit null allele Kittm1Alf (Bernex
et al., 1996; Hou et al., 2000), with the intriguing excep-
tion of a recessive allele, Mitf mi-bws (microphthalmia-
black and white spots), prompting us to analyze this
allele and its interactions with Kittm1Alf in more detail.
Mitf mi-bws, when homozygous, produces extensive
white spotting but when heterozygous, there is no visi-
ble phenotype. The allele is characterized by a point
mutation in the Mitf intron preceding exon 2 but other-
wise the coding region remains wild-type (Hallsson
et al., 2000). Mitf mi-bws is associated with a severe
reduction of Mitf RNA levels when measured in an
organ that shows no obvious phenotype, the heart
(Bauer et al., 2009). It is also associated with a skewed
splicing pattern that enriches RNAs excluding a part of
exon 2, called exon 2B, at the expense of RNAs includ-
ing this particular subexon (Hallsson et al., 2000).
Intriguingly, exon 2B contains the codon for a serine,
serine-73, that is phosphorylated in response to Kit sig-
naling and whose phosphorylation affects the transcrip-
tional activity and stability of MITF protein (Hemesath
et al., 1998). Therefore, we used additional Mitf alleles
that separately probe changes in Mitf RNA levels and
changes in splicing patterns and mutations in serine-73,
and analyzed the effects of these alleles in mice hetero-
zygous for Kit. The results imply that Mitf mi-bws is a
complex allele that may act in a semi-dominant fashion
similar to Mitf Mi-wh, but that is dissimilar from Mitf Mi-wh
in that its semi-dominant activity may only be revealed
when placed on a Kit-sensitized background.
Results and discussion
The Kit allele used in this study, Kittm1Alf, is character-
ized by an in-frame insertion of the bacterial LacZ gene,
encoding nuclear LACZ, in the first exon of Kit in a way
that the Kit gene becomes a functional null allele (Ber-
nex et al., 1996; Hou et al., 2000). Homozygotes usually
die in utero but heterozygotes display a belly spot,
white feet and a white tail tip. Such mice were crossed
with mice carrying either one of the following Mitf
alleles: microphthalmia-brownish (Mitf Mi-b), microphthal-
mia-vga9 (Mitf mi-vga9), microphthalmia-eyeless-white
Mitf mi-ew, microphthalmia red-eyed white (Mitf mi-rw),
Mitf tm1.1Arnh (here called Mitf S73A), and microphthalmia-
black and white spots (Mitf mi-bws). Their molecular char-
acteristics are schematically shown in Figure 1 and their
phenotypes described in Table 1. Mitf Mi-b is inherited
semi-dominantly and contains a point mutation in exon
8 that affects DNA binding. Homozygotes have a white
coat and red eyes while heterozygotes have a brownish
coat color, and pale ears and tails (Steingrimsson et al.,
1996). The recessive allele Mitf mi-vga9 is a transgenic
insertional null allele and its homozygotes are
white with small eyes (Hodgkinson et al., 1993). The
recessive allele Mitf mi-ew has a point mutation close to
the exon 6B ⁄ intron 6 splice junction, and its mRNA is
1A
ATG ATG
Mitfmi-rw
Mitfmi-vga-9
Mitfmi-bws
MitfS73A Mitfmi-ew
MitfMi-b
ATG
Point mutations
Insertions
Deletions
ATG ATG ATG
1J1C 1MC 1E 1H 1D 1B 1M 2A/B 6A/B3 4 5 7 8 9
Figure 1. Schematic diagram of the mouse Mitf gene and the mutations used in this study. Filled boxes represent coding exons, and open
boxes non-coding exons or non-coding parts of exons.
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characterized by the absence of exon 6A ⁄B and reten-
tion of the open reading frame between exons 5 and 7.
The resulting protein affects DNA binding, with homo-
zygotes showing a similar phenotype as Mitf mi-vga9 ho-
mozygotes (Nakayama et al., 1998; Opdecamp et al.,
1997). The recessive allele Mitf mi-rw contains a genomic
deletion that encompasses the exons 1H, 1D, and
1B1a ⁄1B1b and their flanking sequences (Bharti et al.,
2008). Mitf mi-rw homozygotes have eyes of variable
sizes and a coat that is white except for a black spot on
the head and ⁄or belly or the base of the tail. The allele
Mitf S73A has been generated by gene targeting and
encodes a non-phosphorylatable alanine instead of the
phosphorylatable serine at position 73 (Bismuth et al.,
2008). Because the codon change affects an exonic
splice enhancer sequence (Wang et al., 2009), it leads
to efficient skipping of exon 2B. Nevertheless, the cor-
responding mice, heterozygous or homozygous, have
no visible phenotype. Mitf mi-bws is characterized by a
point mutation in intron 1 that results in partial skipping
of exon 2B (Hallsson et al., 2000). Homozygotes have
widespread white spotting but normal eyes.
It was possible that in contrast to the previously
observed strong Mitf Mi-wh ⁄Kit interactions, the reces-
sive Mitf alleles may show no or only mild (additive)
interactions with Kit. Indeed, the recessive Mitf mi-ew or
Mitf mi-rw, for instance, were unable to enhance the
extent of the white spotting of Kit tm1Alf ⁄+, and even the
mildy semi-dominant Mitf Mi-b showed no interactions
with Kittm1Alf (Figure 2A). In contrast, Mitf mi-bws ⁄+;
Kit tm1Alf ⁄+ mice were extensively spotted (Figure 2B),
and Mitf mi-bws ⁄mi-bws;Kittm1Alf ⁄+ mice were either
completely white or occasionally retained just small
pigmented spots on the head or the rump (Figure 2C,
compare with Mitf mi-bws ⁄mi-bws;Kit+ ⁄+ mouse in Fig-
ure 2B). To assay whether this interaction is Kit-specific
or can also be seen with alterations in a different signal-
ing pathway critical for melanocyte development, we
generated double heterozygous combinations of
Mitf mi-bws and Ednrbtm1Myks in which the receptor for
endothelin-3, a G protein-coupled receptor, is non-func-
tional (Lee et al., 2003; Hou et al., 2004; Saldana-
Caboverde and Kos, 2010). These mice, however, did
not show the exacerbation of white spotting seen in
Mitf mi-bws ⁄+; Kittm1Alf ⁄+ mice (Figure S1A).
Because Mitf mi-bws reduces both the overall Mitf RNA
levels (as measured in the heart) and the relative
amounts of Mitf RNA that contains exon 2B (for short,
2B+) versus Mitf RNA that lacks exon 2B (for short,
2B)), it was not a priori clear whether the above men-
tioned interaction with Kit was brought about by the gen-
eral or the exon-specific reduction of Mitf RNA levels.
Hence, we used additional alleles allowing us to test
overall RNA levels separately from changes in exon 2B
splicing. The allele Mitf mi-vga9 eliminates the production
of Mitf RNA entirely so that in Mitf mi-vga-9 ⁄+ heterozyg-
otes, Mitf RNA, all of which contributed from the
remaining wild-type allele, accumulates to approximately
50% of what is seen in a normal animal, measured
either in heart or skin (Bauer et al., 2009). However, Mitf
mi-vga-9 ⁄+;Kit tm1Alf ⁄+ mice showed a spotting phenotype
just as Mitf+ ⁄+; Kittm1Alf ⁄+ mice, suggesting that the
Table 1. Allele-specific interactions between Mitf alleles and the Kit tm1Alf allele visualized by white spotting of the coat
Genotype 1 Inheritance Genotype 2 Inheritance Spotting phenotype Interaction Reference
Mitf+ ⁄+ – Kit+ ⁄+ – None –
Mitf+ ⁄+ – Kit tm1Alf ⁄+ Sd Belly spot, white feet and tail – Bernex et al., 1996
Mitf Mi-b ⁄+ Sd Kit+ ⁄+ – None – Steingrimsson et al., 1996
Mitf mi-ew ⁄+ Re Kit+ ⁄+ – None – Nakayama et al., 1998
Mitf mi-rw ⁄+ Re Kit+ ⁄+ – None – Bharti et al., 2008
Mitf mi-vga-9 ⁄+ Re Kit+ ⁄+ – None – Hodgkinson et al., 1993
Mitf S73A ⁄+ Re Kit+ ⁄+ – None – Bismuth et al., 2008
Mitf mi-bws ⁄+ Re Kit+ ⁄+ – None Hallsson et al., 2000
Mitf Mi-b ⁄+ Sd Kit tm1Alf ⁄+ Sd Belly spot, white feet and tail NI This study
Mitf mi-ew ⁄+ Re Kit tm1Alf ⁄+ Sd Belly spot, white feet and tail NI This study
Mitf mi-rw ⁄+ Re Kit tm1Alf ⁄+ Sd Belly spot, white feet and tail NI This study
Mitf mi-vga-9 ⁄+ Re Kit tm1Alf ⁄+ Sd Belly spot, white feet and tail NI This study
Mitf S73A ⁄+ Re Kit tm1Alf ⁄+ Sd Belly spot, white feet and tail NI This study
Mitf mi-bws ⁄+ Re Kit tm1Alf ⁄+ Sd Extensive spotting around trunk,
white feet, white tail
IN This study
Ednrbtm1Myks ⁄+ Re Kit+ ⁄+ – Occasional belly spot NI This study
Ednrbtm1Myks ⁄+ Re Kit tm1Alf ⁄+ Sd Occasional belly spot NI This study
–, not applicable; NI, no gene interaction; IN, gene interaction; Sd, semi-dominant; Re, recessive.
Mice containing the indicated alleles were obtained by appropriate crosses to yield 14–18 doubly heterozygous mice. Note that while many
mutant Mitf alleles, when homozygous, cause small eyes (microphthalmia), there were no obvious eye phenotypes in Mitf heterozygotes
alone or in combination with Kit tm1Alf ⁄+.
Backgrounds of parental strains: Mitf + ⁄+;Kit + ⁄+ (C57BL ⁄ 6), Mitf+ ⁄+; Kit tm1Alf (mixed C57BL ⁄ 6;C3H ⁄He), Mitf Mi-b (C57BL ⁄ 6J;C3H ⁄RI),
Mitf mi-ew (C57BL ⁄ 6Bn), Mitf mi-rw (C57BL ⁄ 6J), Mitf mi-vga9 (mixed C57BL ⁄ 6J;C3H ⁄He), Mitf S73A (129S1 ⁄ Sv;C57BL ⁄ 6), Mitf mi-bws (C57BL ⁄ 10).
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exacerbated phenotype in Mitf mi-bws ⁄+; Kit tmAlf ⁄+ mice
is not simply due to a reduction in total Mitf RNA.
Because the above mentioned exon 2B splicing alter-
ation in Mitf mi-bws mice has not so far been demon-
strated specifically for melanocytes, we analyzed by
standard RT-PCR reactions the exon distribution in the
melanocyte-specific M-Mitf RNA. For these tests, we
used dorsal skin from C57BL ⁄6 control mice, and dorsal
black skin from Mitf mi-bws ⁄mi-bws and Kit tm1Alf ⁄+ mice
(Figure S2). The results showed exon 2B splicing pat-
terns as expected from the analysis of heart RNA from
the respective mice. There was, however, no obvious
reduction in M-Mitf RNA levels in black Mitf mi-bws ⁄mi-bws
skin. Conceivably, the corresponding melanocytes repre-
sent a pool of cells with higher Mitf levels which have
allowed them to escape the developmental demise of
Mitf mi-bws melanoblasts which on average may express
lower levels of Mitf. In Kit tm1Alf ⁄+ skin, however, M-Mitf
and total Mitf RNA were indeed reduced, consistent
with the pigment dilution characteristics of these mice.
To test whether a skewed exon 2B splicing might
contribute to the Mitf ⁄Kit interaction independently of
overall M-Mitf RNA level changes, we used the
Mitf S73A allele. This allele produces normal levels of
total Mitf RNA in heart or skin, normal levels of M-Mitf
in skin (not shown), but a 2B+ ⁄2B) ratio of approxi-
mately 0.1, as compared to wild type, where this ratio
is approximately 0.9 (Bismuth et al., 2008). The pheno-
type of Mitf S73A ⁄+; Kit tm1Alf ⁄+ and Mitf S73A ⁄ S73A;
Kittm1Alf ⁄+ mice (Figure S1B), suggests, however, that
the exon 2B splice change can also not account sepa-
rately for the Mitf mi-bws ⁄Kit interaction, with the only
caveat that the remaining 10% of 2B+ RNA derived
from the Mitf S73A allele contains the serine-to-alanine
mutation while in Mitf mi-bws, the serine residue is
unchanged. Given the above results, we also tested
whether a combination of splice changes and a reduc-
tion in overall RNA levels would mimic the Mitf mi-bws ⁄
Kit gene interactions. To this end, we generated com-
pound heterozygotes between Mitf mi-vga9 and Mitf S73A
and combined them with Kit tmAlf ⁄+, but even this allelic
combination (Mitf mi-vga9 ⁄ S73A;Kit tm1Alf ⁄+) yielded mice
with just the Kit phenotype (not shown). Quantitations
of Mitf RNA (total, 2B+ and 2B)) for heart and skin of
mice carrying the various alleles alone and in some
combinations are shown in Figure S3.
Finally, to determine whether the extensive white
spotting in post-natal Kittm1Alf ⁄+;Mitf mi-bws ⁄+ mice
already originates during development, at the melano-
blast stage, or, conversely, whether the absence of
enhanced white spotting in the other crosses might be
the result of a post-natal compensation of an early devel-
opmental alteration, we made use of the fact that the
Kittm1Alf allele produces melanoblasts that can be labeled
by the X-GAL reaction. Figure 3 shows examples of
labeled embryos at day 12.5 of gestation from groups
that contained 9–15 embryos and that showed little
embryo-to-embryo variation within one genotypic cohort.
As shown in Figure 3A, in Kittm1Alf ⁄+ embryos, individual
b-Gal-positive cells in the area of the trunk are normally
distributed in the dorsolateral migration pathway under-
neath the surface ectoderm where earlier studies have
A
B
C
Figure 2. Genetic interactions between Mitf and Kit. (A) Lack of
genetic interactions between Mitf Mi-b and Kit tm1Alf. The
corresponding genotypes are indicated in the figure. Note that
Mitf Mi-b ⁄+;Kit tm1Alf ⁄+ mice show a phenotype indistinguishable
from that of Mitf+ ⁄+;Kit tm1Alf ⁄+ mice. (B) Interaction between
Mitf mi-bws and Kit tm1Alf. Mice of the indicated genotypes were
crossed and their offspring genotyped. Note that Mitf mi-bws ⁄+;
Kit+ ⁄+ mice are fully pigmented whereas Mitf mi-bws ⁄+;Kit tm1Alf ⁄+
offspring show extensive white spotting in the trunk area, different
from Mitf+ ⁄+;Kit tm1Alf ⁄+ mice. (C) Mitf mi-bws ⁄ mi-bws;Kit tm1Alf ⁄+
mice are either totally white or retain just small pigmented spots.
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identified MITF-positive cells (Nakayama et al., 1998)
that depend on functional MITF (Hou et al., 2000).
Double heterozygous embryos for Kittm1Alf and either
Mitf Mi-b, Mitf mi-vga9, Mitf mi-ew, Mitf mi-rw or Mitf S73A dis-
played a distribution pattern of b-Gal-positive melano-
blasts that was similar to that observed in Mitf wild-type
embryos heterozygous for Kittm1Alf (Figure 3B–E, and
data not shown). In contrast, the numbers of labeled
cells were severely reduced in the middle trunk region
of Kittm1Alf ⁄+;Mitf mi-bws ⁄+ embryos (Figure 3F). Hence,
these latter embryos, but not the former ones, have a
severe defect in melanoblasts, suggesting that the adult
white spotting of Kit tm1Alf ⁄+;Mitf mi-bws ⁄+ mice is set at
an early developmental stage.
Earlier results have clearly indicated that Kit-mediated
phosphorylation of serine-73 regulates MITF protein
activity and stability in vitro (Hemesath et al., 1998). Nev-
ertheless, neither direct targeting of the corresponding
codon in the endogenous gene or in transgenic, bacterial
artificial chromosome rescue constructs have been able
to demonstrate a clear role for this serine in vivo (Bauer
et al., 2009; Bismuth et al., 2008). An isolated serine-to-
alanine change, with no effect on exon 2B splicing, how-
ever, has not so far been obtained, and so the exact role
of serine-73 in an otherwise entirely normal gene has
not been formally addressed. Nevertheless, as here
demonstrated genetically, neither RNA level changes,
nor exon 2B splice changes associated with the ser-
ine73-to-alanine mutation, alone or in combinations, can
account for the Mitf mi-bws ⁄Kit interaction phenotype.
Hence, Mitf mi-bws is an allele that is likely altered in one
or several more ways than would be suggested solely
from its point mutation in intron 1. In fact, an explanation
for the Mitf mi-bws phenotype may be found only when
additional promoter- and splice-isoforms have been ana-
lyzed, an undertaking that may require the sequencing of
the entire 200 kb Mitf mi-bws gene.
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Supporting information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. (A) The Mitf mi-bws ⁄Kit interaction is Kit-
specific as no interaction is seen between Mitf mi-bws
and Ednrbtm1Myks, an Ednrb null allele. (B) No interaction
between Kittm1Alf and Mitf S73A. Note white feet charac-
teristic of the Kittm1Alf ⁄+ genotype but no extensive
spotting, unlike what is seen in Mitf mi-bws ⁄+; Kittm1Alf ⁄+
mice.
Figure S2. RT-PCR using RNA from black dorsal skin
of C57BL ⁄6 wild type (wt), Mitf mi-bws ⁄mi-bws (mi-bws ⁄
mi-bws), and Kittm1Alf ⁄+ mice. Primers mapped to Mitf
or Usf1 (upstream stimulatory factor-1) exons as indi-
cated. Note that wt contains more M-Mitf exon 2B+
compared to M-Mitf exon 2B) cDNA while the M-Mitf
exon 2B+ ⁄2B) cDNA ratio is reversed in mi-bws ⁄
mi-bws (primers 1M-3). The total levels of M-Mitf cDNA
is, however, similar for wt and mi-bws ⁄mi-bws skin and
only lower for Kit tm1Alf ⁄+ skin for which, because of the
lower levels, it becomes difficult to assess the relative
2B+ ⁄2B) ratio. Total Mitf cDNA levels (measured using
primers 6B-8, amplifying Mitf from melanocytes and the
remainder of skin tissue), are only slightly lower in
mi-bws ⁄mi-bws or Kit tm1Alf ⁄+ skin compared to wt. Note
similar levels of control Usf1 cDNA for all samples.
Figure S3. Real time RT-PCR for the tissue samples
and genotypes indicated. Separate quantitation was per-
formed for exon 2B+ and exon 2B) cDNA, using prim-
ers giving equal length products as described in Bharti
et al., in press. (A) Wild type, and heterozygous and
homozygous single-gene mutant genotypes. (B) Wild
type and Mitf mi-vga9 ⁄ S73A compound mutants either lack-
ing or carrying Kittm1Alf.
Please note: Wiley-Blackwell are not responsible for
the content or functionality of any supporting materials
supplied by the authors. Any queries (other than missing
material) should be directed to the corresponding author
for the article.
Allele-specific genetic interactions between Mitf and Kit
ª 2010 John Wiley & Sons A/S 447
Résultats 
 39 
3 – Les transgènes de type BAC qui expriment les mutants MITF S73A, 
MITF S409A, MITF 2B- et le double mutant MITF S73/409A sont tous 
capables de restaurer la fonctionnalité de MITF. 
 
Le facteur de Transcription Mitf apparaît comme un modèle important pour la 
régulation génique chez les organismes eucaryotes. Chez les vertébrés, Mitf régule le 
développement de plusieurs types cellulaires parmi lesquels se trouvent les melanocytes, 
et a été démontré comme ayant un rôle important dans le mélanome. In vitro, parmi les 
voix de signalisations qui régulent l’activité de MITF, se trouve la voix des MAP Kinases 
qui a pour conséquence la phosphorylation de MITF aux postions S73 et S409. 
Cependant, le rôle précis de cette voix de signalisation reste mal caractérisé in vivo. Ici 
nous utilisons une approche « BAC rescue » afin d’introduire des mutations spécifiques 
du gène Mitf dans le but d’étudier l’importance de ces sites de phosphorylation et des 
domaines protéiques qui les environnent. Nous démontrons que des transgènes mutés sur 
un seul acide aminé peuvent restaurer le phénotype de souris qui portent un allèle nul de 
Mitf de façon homozygote. Ainsi, ces résultats jouent un rôle dans l’intégration des 
interactions entre les voix de signalisations extra-cellulaires et de l’activité de facteurs de 
transcription. De plus, MITF ainsi que la voix des MAP Kinases jouent des rôles cruciaux 
dans le mélanome ; ces résultats peuvent donc apporter de nouveaux éléments dans la 
compréhension de cette pathologie.  
Ce travail est présenté dans l’Article 3. 
 
 
Here we use a bacterial artificial chromosome (BAC) transgenic rescue strategy to probe 
the role of S73 and S409 phosphorylation as well as exon splicing of Mitf. BACs were 
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modified by a “hit and fix” strategy using homologous recombination in bacteria. We 
demonstrate for instance, that a S73A/S409A double mutant still rescues Mitfmi-vga9/Mitfmi-
vga9 homozygous mutants. Because of the variability of expression levels seen with 
different BAC transgenics, however, we cannot conclude from these experiments that 
S73A/S409A double mutated MITF has an activity equivalent to wild-type. Nevertheless 
it is clear that it retains considerable DNA binding capacity and transcriptional activity in 
vivo. S409 phosphorylation has been suggested to play a role in the interaction with the 
Protein Inhibitor of activated STAT3 (PIAS3). Experiments performed by Levy et al. 
showed that the presence of a charged amino acid like aspartate at position 409, which 
mimics constitutive phosphorylation, prevents the PIAS3/MITF interaction (Levy et al., 
2006b). This interaction has been shown to play an important role in the inhibition of Mitf 
activation of the mMCP-6 promoter in mast cells. 
Corroborating the previous results observed in Mitfmi-S73A knock-in mouse, the BAC 
transgenic lines expressing MITF S73A also display an abnormally high rate of exon 2B 
exclusion in both heart and skin tissue.  
Additional transgene constructs carrying various internal intron and exon deletions all 
show partial to almost complete rescue of the Mitfmi-vga9/Mitfmi-vga9 phenotype. 
The details of this research study are described in the following Article 3. 
 
 
 
 
 
 
 
 
 
 
 
Article 3 
The role of MITF phosphorylation sites during coat color 
and eye development in mice analyzed by bacterial 
artificial chromosome transgene rescue. 
Genetics. 2009 Oct;183(2):581-94 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ABSTRACT
The microphthalmia-associated transcription factor (Mitf) has emerged as an important model for gene
regulation in eukaryotic organisms. In vertebrates, it regulates the development of several cell types in-
cluding melanocytes and has also been shown to play an important role in melanoma. In vitro, the activity of
MITF is regulated by multiple signaling pathways, including the KITL/KIT/B-Raf pathway, which results in
phosphorylation of MITF on serine residues 73 and 409. However, the precise role of signaling to MITF
in vivo remains largely unknown. Here, we use a BAC transgene rescue approach to introduce specific mu-
tations in MITF to study the importance of specific phospho-acceptor sites and protein domains. We show
that mice that carry a BAC transgene where single-amino-acid substitutions have been made in the Mitf
gene rescue the phenotype of the loss-of-function mutations in Mitf. This may indicate that signaling from
KIT to MITF affects other phospho-acceptor sites in MITF or that alternative sites can be phosphorylated
when Ser73 and Ser409 have been mutated. Our results have implications for understanding signaling to
transcription factors. Furthermore, as MITF and signaling mechanisms have been shown to play an im-
portant role in melanomas, our findings may lead to novel insights into this resilient disease.
THE bHLH-Zip transcription factor MITF (microph-thalmia-associated transcription factor) was ini-
tially found as the gene mutated at the mouse
microphthalmia locus (Hodgkinson et al. 1993). Sub-
sequent work has led to the proposal that MITF acts as a
master regulator of melanocyte development by regu-
lating proliferation, survival, and differentiation of this
cell type (reviewed by Hou and Pavan 2008). MITF has
also been implicated as a regulator of melanocyte stem
cell maintenance (Nishimura et al. 2005) as well as
a melanoma oncogene (Levy et al. 2006). In addition,
the human MITF gene is mutated in individuals with
Waardenburg syndrome type 2 and Tietz syndrome
(reviewed in Steingrı´msson et al.2004). Clearly, MITF is
an important decision maker in melanocytes and may be
an important player in melanomas as well.
The many mutations at the mouse Mitf locus have
provided key insights into the structure–function re-
lationship of this transcription factor. All of the mouse
Mitf mutations affect melanocytes to a varying degree,
resulting in animals with coat color phenotypes rang-
ing from white spotting and coat color dilution to a
completely white coat due to lack of melanocytes (re-
viewed in Steingrı´msson et al. 2004). Some of the
mutations also affect retinal pigment epithelial (RPE)
cells, resulting in unpigmented or hypopigmented
microphthalmic eyes. Other cell types affected by Mitf
mutations include osteoclasts and mast cells as well as
natural killer cells, basophils, macrophages, and B cells
(reviewed in Steingrı´msson et al. 2004). Interestingly,
the phenotypes of Mitf mutations overlap partly with the
phenotypes of mutations in the Kit and Kitl genes in the
mouse. Mutations in these three genes affect melano-
cyte development, resulting in pigmentation defects
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(often leading to white coat color), and all have effects
on mast cells. However, only mutations in Mitf, and not
Kit or Kitl, affect eye development. On the other hand,
Kit and Kitl mutations affect hematopoiesis and germ-
cell development whereas mutations in Mitf do not, at
least not to the same degree.
As Kit and Kitl encode a receptor tyrosine kinase and
its ligand, respectively, it was proposed that they form a
signaling cascade that culminates in effects on the MITF
protein (Dubreuil et al. 1991). Indeed, a number of
signaling pathways, including KITL and KIT, have been
shown to regulate the activity of the MITF protein. In a
landmark series of experiments, David Fisher’s group
showed that MITF is an important downstream target of
the KIT tyrosine kinase receptor. They showed that
treating human 501-mel melanoma cells with KIT ligand
(KITL) resulted in the phosphorylation of the Ser73 and
Ser409 amino acids of MITF (Hemesath et al. 1998; Wu
et al. 2000). Signaling to MITF involved the receptor ty-
rosine kinase KIT, the mitogen-activated protein kinase
ERK2, and the serine–threonine kinase p90RSK and
resulted in the phosphorylation of Ser73 by ERK2 and of
Ser409 by p90RSK (Hemesath et al. 1998; Wu et al.
2000). Phosphorylation of Ser73 increased the trans-
activation potential of MITF by specifically recruiting
the co-activator p300/CBP to the phosphorylated pro-
tein (Price et al. 1998). KITL stimulation was also shown
to result in the ubiquitination of MITF and its sub-
sequent proteasome-mediated degradation (Wu et al.
2000; Xu et al. 2000). Interestingly, when either Ser73 or
Ser409 alone are mutated to alanine in vitro, transcrip-
tion activation potential is only mildly affected, whereas
mutating both sites simultaneously obliterates the tran-
scription activation ability of the MITF protein in in vitro
assays (Wu et al. 2000). These findings, together with the
fact that mice that carry mutations in Kit and Kitl are
white with normal eye development, have suggested that
this signaling pathway is essential for MITF function in
melanocytes.
Here, we use a BAC transgene rescue strategy to in-
vestigate the in vivo role of signaling to MITF in the
mouse. Recombineering was used to generate specific
mutations in a BAC clone containing theMitf gene. BAC
transgenic animals were made and then crossed to Mitf
loss-of-function mutants to determine if the BAC could
rescue the Mitf phenotype. Using this method, we show
that mutating either Ser73 or Ser409 to alanine leads to
rescue of the melanocyte and RPE defects associated
withMitfmutations. Similarly, deletion studies show that
the domains encoded by exons 1A, 2A, and 2B do not
seem to be essential for MITF function. Our results
present a novel and rapid method for analyzing the role
of individual amino acids and functional domains in the
mouse. The results have implications for our under-
standing of transcription factor function in general and
for melanocyte development in particular. And as MITF
and signaling mechanisms have been shown to play an
important role in melanoma, our findings may lead to
novel insights into this disease.
MATERIALS AND METHODS
Recombineering and generation of transgenic mice: The
BAC-Mi1 (RP23-9A13) and BAC-Mi2 (RP23-21E20) clones
were selected from the RPCI-23 BAC library (female C57BL/
6J mouse). The BAC-Mi1 clone was introduced into the DY380
strain of Escherichia coli, and the Ser73Ala and Ser409Ala mu-
tations were introduced using the two-step hit-and-fix method
as described in Yang and Sharan (2003) and outlined in
Figure 1. The deletion mutations were made using the method
of Warming et al. (2005). The oligos used for recombineering
and BAC screening are listed in Tables 1 and 2. The BACs were
screened for the presence of the hit-and-fix sequences using
PCR, and the mutated regions were sequenced to verify that
the correct changes had been introduced. BAC DNA was pre-
pared for pronuclear injections according to Sharan et al.
(2004), and pronuclear injections of supercoiled BAC DNA
were performed as described by Hogan et al. (1994).
Analysis of mutations: Genomic DNA was extracted from
mouse tail tips according to Jenkins et al. (1982). For detecting
the MITF mi-vga9 transgene, we used the primers vga9-for and
mitf-rev, and for detecting the CMr sequence of the BAC
transgene, we used the primers CMr-F and CMr-R (see primers
in Table 1). To verify that the mutations had been correctly
introduced into the transgenic mice, RT–PCR was performed
on heart tissue using the appropriate Mitf primers, and the
resulting product was sequenced.
Analysis of alternative splicing: Tissues were collected and
deposited directly into liquid nitrogen and total RNA ex-
tracted using TRIZOL reagent (Invitrogen). RNA quantity was
measured on a Nanodrop spectrophotometer, and integrity
was determined on an Agilent 2100 Bioanalyzer RNA Nano
chips. RNA with an RNA integrity number .7.0 was treated
with DNase (Qiagen) to remove genomic contamination and
purified on an RNeasy MinElute column (Qiagen). RNA
quantity was measured again, and integrity was determined.
RNA samples were then reverse transcribed using the Revertaid
H first-strand synthesis kit (Fermentas) with both oligo(dT) and
random hexamer primers, and the two reactions were com-
bined for subsequent analysis. PCR was performed using the
primers indicated in each case and listed in Tables 1–3.
Relative quantification by quantitative PCR: RNA was
isolated as described above. The presence of inhibitory factors
in the RNA samples was tested using the SPUD assay (Nolan
et al. 2006). Two micrograms of total RNA were reverse tran-
scribed into cDNA using Superscript III reverse transcriptase
and anchored oligo(dT)20 primers (Invitrogen). To find ap-
propriate reference genes, the expression of 12 housekeeping
genes (TATAA Biocenter, Go¨teborg, Sweden) was evaluated in
cDNA samples prepared from heart tissues of six wild-type
mice, and GeNorm software (Vandesompele et al. 2002) used
to identify the most stable reference gene. Quantitative real-
time PCR was performed using the SybrGreen I MasterPLUS mix
and the LightCycler (Roche Diagnostics) and normalized to
the expression of the most stable reference gene (Hprt1).
Three mice from each group of BAC transgenic lines were
analyzed for Mitf expression. Primers were designed using the
Primer3 program (Rozen and Shaletsky 2000). Each sample
assay included a cDNA template equivalent to 50 ng of total
RNA; each PCR assay was performed in duplicate. Negative
controls consisting of non-reverse transcribed samples were
included in each set of reactions. Amplification efficiency was
determined for the primers using a dilution-curve fivefold
series of 6 points) and was 1.03 and 0.978, respectively, for the
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Mitf (mmitf-e6-8qF and mmitf-e6-8qR) and Hprt1 (Hprt1-F2
and Hprt1-R2) primers. Cycling conditions were the following:
denaturation at 95 for 10 min, followed by 45 cycles at 95 for
10 sec, 59 for 10 sec, and 72 for 25 sec. Melting curve analysis
and agarose gel electrophoresis were performed to confirm
the specificity of the product. Data were analyzed using the
Genex program (Vandesompele et al. 2002). Quantitation of
Mitf isoforms containing or lacking exon 2B was performed
as described in Bharti et al. (2009).
RESULTS AND DISCUSSION
BAC transgene strategy: To determine the in vivo role
of signaling to MITF, we used a BAC rescue strategy. Two
BACs that contain the Mitf gene were obtained and
characterized with respect to end sequences and the
presence of the Mitf gene. The BACs, termed BAC-Mi1
(rpci-23-9a13t7) and BAC-Mi2 (rpci-23-21e20sp6), are
TABLE 1
Primers used in the study for BAC recombineering
Primer Sequence
Ser73
Ser73HitF 59-ACATGCCAGCCAAGTCCTGAGCTCACCATGTCCAAACCAGCCTGGCGACCATGCCATGCCA
CCAGTGCCGGGGAGCAGCGAAGCTTACTGTCAGCTCGAG-39
Ser73HitB 59-AGTTAATGGAATGTAAGAAACAGAGGAGAAGAGGAGACGTGAATTACCTCTTTTTCACAGT
TGGAGTTAAGAGTGAGCATCTCGAGCTGACAGTAAGCTT-39
Ser73FixF 59-ACATGCCAGCCAAGTCCTGAGCTCACCATGTCCAAACCAGCCTGGCGACCATGCCATGCCA
CCAGTGCCGGGGAGCAGCGCACCCAACGCCCCTATGGCT-39
Ser73FixB 59-AGTTAATGGAATGTAAGAAACAGAGGAGAAGAGGAGACGTGAATTACCTCTTTTTCACAGT
TGGAGTTAAGAGTGAGCATAGCCATAGGGGCGTTGGGTG-39
Ser409
Ser409HitF 59-GGACGATGCCCTCTCACCTGTTGGAGTCACCGACCCACTGCTGTCATCAGTGTCGCCAGG
AGCTTCAAAAACAAGCAGCCAAGCTTACTGTCAGCTCGAG-39
Ser409HitB 59-AGTCTCCTGAAGAAGAGAGGGAGCGGTCCGTGCAGAGGCAGAGCAAGGCAGGCTCGCTA
ACACGCATGCTCCGTTTCTTCCTCGAGCTGACAGTAAGCTT-39
Ser409FixF 59-GGACGATGCCCTCTCACCTGTTGGAGTCACCGACCCACTGCTGTCATCAGTGTCGCCAGG
AGCTTCAAAAACAAGCAGCCGGAGGAGCGCTATGAGCGCA-39
Ser409FixB 59-AGTCTCCTGAAGAAGAGAGGGAGCGGTCCGTGCAGAGGCAGAGCAAGGCAGGCTCGCTA
ACACGCATGCTCCGTTTCTTCTGCGCTCATAGCGCTCCTCC-39
Del(int1/2A)
Mitf galK F CTGCCTGAAACCTTGCTATGCTGGAAATGCTAGAATACAGTCACTACCAGCCTGTTGACAATT
AATCATCGGCA
Mitf galK R ACTTGGCTGGCATGTTTATTTGCTAAAGTGGTAGAAAGGTACTGCTTTACTCAGCACTGTCC
TGCTCCTT
galK del(int1/2a)up CTGCCTGAAACCTTGCTATGCTGGAAATGCTAGAATACAGTCACTACCAGGTAAAG
CAGTACCTTTCTACCACTTTAGCAAATAAACATGCCAGCCAAGT
galK del(int1/2a)low ACTTGGCTGGCATGTTTATTTGCTAAAGTGGTAGAAAGGTACTGCTTTACCTGGTAGTGAC
TGTATTCTAGCATTTCCAGCATAGCAAGGTTTCAGGCAG
Del(2B/int2)
Mitf2B galK F ACCTGGAAAACCCCACCAAGTACCACATACAGCAAGCTCAGAGGCACCAGCCTGTTG
ACAATTAATCATCGGCA
Mitf2B galK R CCTGGGCACTCACTCTCTGCCCTGCTCTGCTCCTCAAACTTATAAAATGCTCAGCACTGTC
CTGCTCCTT
Mitf2B S ACCTGGAAAACCCCACCAAGTACCACATACAGCAAGCTCAGAGGCACCAGGCATTTTATAAGT
TTGAGGAGCAGAGCAGGGCAGAGAGTGAGTGCCCAGG
Mitf2B AS CCTGGGCACTCACTCTCTGCCCTGCTCTGCTCCTCAAACTTATAAAATGCCTGGTGCCTCTGA
GCTTGCTGTATGTGGTACTTGGTGGGGTTTTCCAGGT
Del(int2)
Mitf intr2 galK F CCAACAGCCCTATGGCTATGCTCACTCTTAACTCCAACTGTGAAAAAGAGCCTGTTGACAATT
AATCATCGGCA
Mitf2B galK R CCTGGGCACTCACTCTCTGCCCTGCTCTGCTCCTCAAACTTATAAAATGCTCAGCACTGTC
CTGCTCCTT
Mitf intr2 S CCAACAGCCCTATGGCTATGCTCACTCTTAACTCCAACTGTGAAAAAGAGGCATTTTATAAG
TTTGAGGAGCAGAGCAGG
Mitf intr2 AS ATGCACGACGCTCGAGAGTGCGTGTTCATACCTGGGCACTCACTCTCTGCCCTGCTCTGC
TCCTCAAACTTATAAAATGC
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shown in Figure 1A. Although they differ at the 59- and
39-ends, they contain the entire Mitf gene except exon
1A. We used a two-step recombineering protocol called
‘‘hit and fix’’ (outlined in Figure 1B) for introducing
specific mutations into the BAC (Yang and Sharan
2003) and the GalK recombineering strategy (Warming
et al. 2005) for introducing deletion mutations.
Phenotypic rescue of wild-type BACs: To test if the
wild-type BAC clones can rescue the Mitf mutant pheno-
type, transgenic mice that carry the BAC-Mi1 clone were
made. The transgenic mice were made using Mitf mi-ew
heterozygous embryos, and the resulting carriers were
then crossed to Mitf mi-ew homozygous animals to generate
Mitf mi-ew/Mitf mi-ew animals, which also carry the BAC clone.
Homozygous Mitf mi-ew/Mitf mi-ew animals are completely
white, due to a lack of melanocytes, and have severe
microphthalmia due to developmental defects in the
retinal pigment epithelium (Figure 1C) (Steingrı´msson
et al. 2004). However, homozygous Mitf mi-ew mice that are
also homozygous for the BAC-Mi1 clone are normally
pigmented and have normal eyes (Figure 1C), suggesting
that the BAC-Mi1 clone can rescue the phenotype
completely, despite lacking exon 1A; they are normally
pigmented in every respect, including the belly region
(Figure 2A). Transgenic mice were also made using the
BAC-Mi2 clone and, again, the BAC can rescue theMitf mi-ew
mutant phenotype with respect to both coat color and
eye developmental defects (Figure 2B). The Mitf mi-ew
mutation results in a MITF protein that lacks the DNA-
binding domain (Steingrı´msson et al. 1994; Hallsson
et al. 2000), and in vitro studies suggest that the protein
acts in a dominant-negative fashion (Hemesath et al.
1994); detailed phenotypic characterization has sug-
gested a mild dominant-negative action of the mutant
protein in osteoclasts (Steingrı´msson et al. 2002). To
avoid possible problems with dominant-negative behav-
ior of the Mitf mi-ew mutation, we also performed rescue
studies using the recessive Mitf mi-vga9 mutation, a trans-
gene insertion mutation that obliterates Mitf expression
in most tissues (Hodgkinson et al. 1993) and is
TABLE 2
Primers used in this study for BAC and genomic screening
Primer Sequence Function
Hit ScreenF 59-AAGCTTACTGTCAGCTCGAG-39 For screening Hit clones
S73FixScr 59-GGGAGCAGCGCACCCAACGCCCCTATGGCT-39 For screening 73 fixed clones
S409FixScr 59-ACAAGCAGCCGGAGGAGCGCTATGAGCGCA-39 For screening 409 fixed clones
Ex2/F 59-TGTTGGTCAACTGGTCAGTCT-39 For sequencing exon 2
Ex2/R 59-AGGACAGAGGTTGGTGACAAT-39 For sequencing exon 2 and for
screening hit-and-fix clones
RecEx9Scr5A 59-CCTGATCTGGTGAATCGGATCATCAAGC-39 For sequencing part of exon 9
RecEx9Scr3A 59-CAGATACTGCACGCTGAAGGTACAATAC-39 For sequencing part of exon 9 and
for screening hit-and-fix clones
vga9-for 59-CTGCAGCACGGACAATAAACCTCC-3 Mitf: specific for vga9 mutation
mitf-rev 59-AAACAAGGCATCCCGAGGCACC-39 Mitf: for screening vga9 mutation
Mitf-2BtestF 59-CAGGGACGTTAAACAGGATAGT-39 For screening deletions
Mitf-2BtestR 59 -AGGTCCTGAAGTCATCAGGA-39 For screening deletions
CMr-F 59-AGCATTCTGCCGACATGGAAGC-39 BAC clone forward
CMr-R 59-CACGACGATTTCCGGCAGTTTC-39 BAC clone reverse
TABLE 3
Primers used in this study for RT–PCR and qPCR
Primer Sequence Position
Exon 1bF 59-GACACCAGCCATAAACGTCA-39 Exon 1b forward
Exon 9R 59-TGCTTGATGATCCGATTCAC-39 Exon 9 reverse
Exon 3R 59-TGTTCATACCTGGGCACTCA-39 Exon 3 reverse
Mitf-q3-rev 59-CATCAATTACATCATCCATCTGC-39 Exon 4 reverse
Mitf-1M-e4F 59-ACTAAGTGGTCTGCGGTGTCTC-39 Exon M forward
Mitf 1M-e4R 59-TAACTTGATTCCAGGCTGATGA-39 Exon 4 reverse
Mitf-1H-e9F 59-TGAGTCAGACACCAGCCATAA-39 Exon 1H forward
Mitf-1H-e9-Rev 59-TGCTTGATGATCCGATTCAC-39 Exon 9 reverse
Mitf-e6-8qF 59-AGCAAGAGCATTGGCTAAAGA-39 Exon 6 forward
mMitf-e6-8qR 59-GCATGTCTGGATCATTTGACTT-39 Exon 8 reverse
mHPRT1-for2 59-GTTGGATACAGGCCAGACTTTGTTG-39 Hprt control
mHPRT1-rev2 59-GATTCAACTTGCGTCATCTTAGGC-39 Hprt control
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therefore considered a null mutation. Homozygotes are
white and have severe microphthalmia although there is
no evidence of a dominant or semidominant phenotype
in any tissue, including bone (Hodgkinson et al. 1993;
Steingrı´msson et al. 2004). Two different transgenic
lines were made on the Mitf mi-vga9 mutant background
and, as can be seen in Figure 2, C and D, the BAC-Mi1
clone fully rescues the Mitf mi-vga9 mutant phenotype, with
respect to both coat color and eye development. Both
linesare maintainedas homozygotes for both theMitf mi-vga9
mutation and the BAC transgenes. Thus, we conclude
that the BAC clones Mi1 and Mi2 rescue the Mitf mu-
tant phenotype fully and therefore contain all the
sequences necessary for normal Mitf expression and
function in melanocytes and RPE cells. These results
suggest that exon 1A is not necessary for Mitf function in
these cell types. This is interesting in light of the
relatively high level of conservation of amino acid
sequence in this exon between different mammalian
species (.95% amino acid conservation between mice
and humans) (Hallsson et al. 2007).
Phenotypic rescue of serine-mutant BACs: To de-
termine the in vivo significance of the Ser73 and Ser409
phosphorylation sites of MITF, we mutated these sites in
the BAC-Mi2 clone to alanine using the recombineering
strategy described in Figure 1B. We generated three dif-
ferent mutant BAC clones: a Ser73Ala mutation (chang-
ing AGC to GCC), a Ser409Ala mutation (changing
AGT to GCC), and a clone containing the Ser73Ala and
Ser409Ala mutations. After confirming the presence of
each mutation, the BACs were used to generate trans-
genic mice using Mitf mi-vga9/1 heterozygous zygotes, and
the resulting transgenic animals were mated to generate
animals that were homozygous for the Mitf mi-vga9 muta-
tion and for the BAC transgene.
Three independent lines that carry the BAC contain-
ing the Ser73Ala mutation were generated (Figure 3,
A–C). These lines all rescue the Mitf mi-vga9 phenotype
Figure 1.—The BAC clones and recombineering strategy. (A) The two BAC clones isolated in the study are shown with respect
to the structure of the Mitf gene. The size of the two clones are indicated in parentheses. Also indicated is the distance from the
ends of the first and last known exons of Mitf to the ends of each clone. BAC Mi1 lacks 14.2 kb of DNA with respect to the first
nucleotide of exon 1A whereas it contains an additional 47.5 kb of DNA from the last known nucleotide of exon 9. Similarly, BAC
Mi2 lacks 76 kb with respect to the first nucleotide of exon 1A and contains additional 93.9 kb at the 39-end. The relative sizes of
the exons and introns are indicated but are not shown in the correct proportional sizes. The locations of amino acid residues
Ser73 and Ser409 are indicated. (B) The two-step recombineering strategy used for generating the Ser73 and Ser409 mutations.
The hit oligo was recombineered into the Mitf locus, and successful recombinants were screened using Hit-specific primers. After
verifying the recombineered Hit clone, the Fix oligo was recombineered into the positive Hit-BAC and screened by PCR using fix-
specific oligos. The resulting mutated BAC clones were further screened for the presence of the mutation and the absence of the
Hit sequences before they were used for generating transgenic mice. (C) BAC transgene rescue of the Mitf mi-ew mutation. All three
mice are homozygous for the Mitf mi-ew mutation, and therefore all should have the phenotype of the mouse on the left showing a
white coat and microphthalmia. However, the two mice on the right also carry the BAC Mi1 clone, which fully rescues both phe-
notypes.
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significantly, but to a different extent. The TG21055-
Ser73Ala line fully rescues the eye developmental phe-
notype whereas coat color is partially rescued, resulting
in mice with normal eyes, a white belly, and white spots
over the rest of the coat (Figure 3A). The TG8260-
Ser73Ala line fully rescues the eye defect of the Mitf mi-vga9
mutation, and the coat color is rescued apart from a
belly spot (Figure 3B). The TG8250-Ser73Ala line does
not rescue the eye developmental defect but rescues the
coat color defect nearly fully, leaving a small white belly
spot (Figure 3C). Together, the rescue observed with
these lines suggests that the Ser73Ala mutant BAC can
rescue the eye developmental phenotype and the coat
color defects of Mitf mutations, apart from leaving an
unpigmented belly spot. Small belly spots are commonly
seen in the C57BL/6J strain (Arnheiter 2007), on
which the Mitf mi-ew and Mitf mi-vga9 mutations are main-
tained, suggesting that in fact we observe almost full
rescue with the TG8260-Ser73Ala line and full rescue
with respect to coat color in the TG8250-Ser73Ala line.
The difference in the ability of these three lines to res-
cue the phenotype probably reflects the integration
sites involved.
We obtained one line each of transgenic mice that
carry the Ser409Ala single mutant and the Ser73Ala;
Ser409Ala double-mutant BAC clones (Figure 3, D and
E). Both the TG11223-Ser409 transgenic line and the
double-mutant TG32643-Ser73/409Ala transgenic line
rescue the eye and coat color phenotype of the Mitf mi-vga9
mutation fully, resulting in normally pigmented mice
(Figure 3, D and E). In the TG11223-Ser409 line, some
animals show a belly spot (Figure 3D) whereas a belly
spot is rarely seen in the double-mutant TG32643-
Ser73/409Ala line. Together, these data suggest that
the Ser73Ala and Ser409Ala mutations can fully rescue
the Mitf mi-vga9 mutation, even in a double-mutant com-
bination. This indicates that these two serines are not
essential for MITF function during mouse melanocyte
development.
Splicing of Mitf is affected in the Ser73Ala BACs: A
knock-in mutation has been made in the Mitf gene
where Ser73 was replaced with alanine (Bismuth et al.
2008). This knock-in mutation is the very same mutation
that we made in the BAC mice, except it also introduced
a silentApaLI restriction site a few base pairs upstream of
the Ser73Ala mutation and a LoxP site in the down-
stream intron (Bismuth et al. 2008). Mice homozygous
for this knock-in mutation are normally pigmented and
have normal eyes, supporting our conclusions from the
BAC rescue experiments. However, the knock-in muta-
tion affected splicing of the Mitf gene such that a nor-
mally minor alternative product lacking exon 2B
became the major product (Bismuth et al. 2008). We
used RT–PCR on heart tissue to determine if the splicing
of Mitf was affected in the BAC transgenic mice. Heart
tissue expresses the Mitf mRNA at a significant level
in wild-type mice as well as in most of the available
Mitf mutants but is absent in hearts from animals carry-
ing the Mitf mi-vga9 mutation (Hodgkinson et al. 1993;
Steingrı´msson et al. 1994). As all the BAC clones are
maintained on the Mitf mi-vga9 mutant background, the
onlyMitfmRNA expressed in the BAC transgenic mice is
derived from the BAC clone. The primers used span
from exon 1B to exon 3 and resulted in two bands in
wild-type mice: a 359-bp full-length band and a 191-bp
band that represents a product lacking exon 2B (Figure 4).
Figure 2.—Wild-type BAC clones rescue Mitf mutant phe-
notypes. The two wild-type BAC clones rescue Mitf mutant
phenotypes completely. (A and B) The BAC Mi1 and Mi2
wild-type BAC clones rescue the phenotype of the Mitf mi-ew mu-
tation fully; no belly spot is visible in the mice (right panels).
(C and D) The BAC Mi1 clone also rescues the Mitf mi-vga9 loss-
of-function phenotype fully as seen in two independent trans-
genic lines. Again, not even a belly spot is visible, suggesting
full rescue. The inserts show the eyes of the BAC transgenic
mice.
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The same bands are present in all the transgenic lines,
and all show the same ratio of the two bands, except in
the BAC lines that contain the Ser73Ala mutation, either
alone or in the double-mutant combination with Ser409.
Quantitative PCR (qPCR) analysis shows that in the two
lines containing the Ser73Ala mutation there is ap-
proximately three times more of the smaller 198-bp
band lacking exon 2B than in either the other BAC lines
or wild-type mice (Figure 4). This suggests that the
presence of the Ser73Ala mutation alone is sufficient to
affect splicing of exon 2B such that the shorter product
becomes more abundant than in the other lines. This is
consistent with the splicing defect observed in the
Ser73Ala knock-in mice and with the idea that the
sequence around the Ser73 codon represents an exon
splice enhancer sequence (Bismuth et al. 2008). The
only difference between the Ser73Ala knock-in and BAC
transgene mutations is the ratio of the two bands. In the
knock-in mice, the shorter band represents a majority
(90%) of the resulting Mitf products whereas in the
BAC mice it is 40–45%. This difference may be due to
the more extensive changes introduced in the knock-in
mutation than in the BAC as the knock-in mutation
generated an ApaLI restriction site (changing a C to a T
10 bp upstream of the Ser73Ala codon) and placed a
floxed neo-cassette in a nearby intron, in addition to the
Ser73Ala modification.
Exon 2 deletion mutations: Ser73 is located in exon
2B of the Mitf gene. The phenotype of the Ser73Ala
knock-in (Bismuth et al. 2008) and BAC transgenic
mice suggests that the absence of exon 2B in a majority
of the Mitf transcripts produced is not detrimental for
the function of the MITF protein. To detail the func-
tional role of exon 2 of Mitf, we created three different
deletion mutations in the BAC and generated trans-
genic mice on the Mitf mi-vga9 background. The mutations
represent a deletion of intron 1 and exon 2A, resulting
in a fusion of exon 1M with exon 2B [del(int1/2A)];
deletion of exon 2B and intron 2, creating a fusion of
exon 2a and exon 3 [del(2B/int2)]; and deletion of
only intron 2, creating a fusion of exon 2B and exon 3
[del(int2)] (Figure 5A). For the del(int1/2A) and
del(2B/int2) deletions, we obtained one transgenic
line each, whereas for del(int2) we obtained two in-
dependent lines (Figure 5, B–E). The transgenic line
carrying the del(int1/2A) deletion fully rescues the eye
developmental defect of the Mitf mi-vga9 mutation as well
as the coat color, except for a belly spot (Figure 5B).
Similarly, the del(2B/int2) transgene rescues the eye
and coat color phenotype, apart from a small belly spot
seen in most of the mice (Figure 5C). The two different
del(int2) lines fully rescue the eye developmental
phenotype of the Mitf mi-vga9 mutation and the coat color
phenotype, leaving a large belly spot and occasional
white spots on other body regions (Figure 5, D and E).
Interestingly, the two independent del(int2) lines have
near-identical phenotypes.
We used RT–PCR to characterize expression and
splicing of the Mitf gene in mice carrying the BAC-
deletion mutations. First, we characterized expression
of Mitf in heart tissue using primers extending from
exon 1B to exon 3 or exon 4 (Figure 6A). In wild-type
hearts, both primer sets produced two bands, represent-
ing a full-length transcript and a transcript lacking exon
2B, at a ratio of 20:1 (Figure 6A). This is consistent
with previous results (Hallsson et al. 2000). In the
Figure 3.—The mutant BAC clones Ser73Ala
and Ser409Ala rescue the Mitf mutant pheno-
type. The BAC clones containing the Ser73Ala
and Ser409Ala mutations rescue the phenotype
of the Mitf mi-vga9 loss-of-function mutation fully
in either single or double-mutant combination.
(A–C) Three different transgene lines that con-
tain the Ser73Ala mutation were obtained. The
line 21055 fully rescues the microphthalmia asso-
ciated with the Mitf mi-vga9 mutation whereas the
coat color phenotype is rescued only partially
(A). These animals lack pigmentation on the
belly and have small unpigmented spots over
the rest of the body. However, a significant pro-
portion of the coat is pigmented, suggesting sig-
nificant rescue in this line; the spots on the back
are rather small, suggesting failure to rescue dur-
ing late melanocyte development or differentia-
tion. (B) The line 8260 rescues the phenotype
fully, apart from a small belly spot (right). (C)
The line 8250 rescues the coat color phenotype
fully except for a minor belly streak seen in most
of the animals. However, eye development is not
rescued. The phenotypic differences in these three lines are most likely due to differences in the integration event of the transgenes.
(D) The Ser409Ala mutant BAC clone can rescue the phenotype of the Mitf mi-vga9 mutation completely, although many animals show a
significant belly spot. (E) The BAC clone containing the double mutation Ser73Ala; Ser409Ala can also rescue the phenotype of the
Mitf mi-vga9 mutation completely, and in this case belly spots are rarely seen. The inserts show the eyes of the BAC transgenic mice.
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del(int1/2A) transgenic mice, each primer set resulted
in the production of only one product. The size of these
products suggests that they are missing exons 2A and
2B, and this was further confirmed by sequencing.
These results were expected in this line as exons 2A
and 2B are not split by an intron; in wild-type mice, the
mRNA product lacking exon 2B is produced by the use
of an alternative splice donor. As the deletion removes
intron 1 and exon 2A, this alternative splice donor is not
present and the only possible product in this case fuses
exon 1B to exon 3. RT–PCR performed on hearts from
the del(2B/int2) deletion mutation also results in only
one product for each primer set (Figure 6A). Sequenc-
ing shows that, as expected, these products lack exon 2B
whereas exon 2A is present.
The two del(int2) transgenic lines (13627 and 13628)
affect mRNA splicing similarly, with some minor differ-
ences. Using primers from exon 1B to exon 3, only one
product is produced, representing a full-length Mitf
transcript (Figure 6A, top). This transcript is produced
from the transgene by the splicing of exon 1B to exon
2A/B, which is then fused directly to exon 3 due to the
deletion of intron 2. No alternative product is detected
lacking exon 2B using this primer combination because
such a product is not possible when intron 2 has been
removed. RT–PCR performed using primers from exon
1B to exon 4 results in two products in the transgenic
line TG13628, representing a full-length product and a
truncated product lacking exons 2B and 3 (Figure 6A,
bottom). This smaller PCR product is produced by alter-
native splicing from exon 2A to exon 4 using the alter-
native splice donor at the juncture of exons 2A and B,
which is then spliced to the acceptor in exon 4 rather
than the acceptor in exon 3 as it is lacking due to the
deletion. In transgenic line TG13627, only the smaller
product lacking exons 2B and 3 is detected using the
primer set from exon 1B to exon 4, whereas in line
TG13628, the full-length product is also detected.
Clearly, the full-length product is expressed in both
transgenic lines at some level since a product is observed
using the primers extending from exon 1B to exon 3.
However, the absence of such a product in the TG13627
line using the exon 1B to exon 4 primer set suggests that
this is a minor product and that the majority of tran-
scripts are lacking exons 2B and 3. Nevertheless, the
phenotypes of both transgenic lines are nearly identical
(Figure 5, D and E), suggesting that, although a MITF
protein lacking exons 2B and 3 is able to rescue eye
development fully, it is not quite able to fully rescue the
coat color phenotype of theMitf mi-vga9 mutation. Because
the transgene deleting only exon 2B can rescue the
phenotype, this would indicate that the simultaneous
absence of both domains encoded by exons 2B and 3 is
detrimental to function. Alternatively, it is possible that
exon 3 plays a more important functional role than
exon 2B. Sequence comparison of representative spe-
cies of the mammalian, avian, amphibian, fish, and
echinoderm lineages reveals that exon 3 is found only
in mammals and birds. Although this means that exon 3
is not evolutionarily conserved in all species, it is possible
that the recruitment and retention of this sequence in
mammalian and avian species indicates a functional role.
At this point, however, this function is not known.
The deletion del(int1/2A) fuses exons 1M and 2B of
Mitf, and as exon 1M is melanocyte specific and thus not
expressed in the heart, we also performed RT–PCR on
skin tissue from all deletion strains using primers
extending from exon 1M to exon 4. As seen in Figure
6B, the RT–PCR results indicate the presence of the
expected Mitf transcripts in skin. Using primers extend-
ing from exon 1M to exon 4 results in a 440-bp normal
band whereas in the transgenic strain carrying the
del(int1/2A) deletion this results in two bands: one
major 380-bp band missing exon 2A and one minor 212-
bp band missing both exons 2A and 2B. This suggests
that the splice donor in exon 1M is functional when
fused to exon 2B. This is consistent with the fact that the
splice donor sequence remains the same (ACCAG/GT).
In the del(2B/int2) strain, the primer pair resulted in a
major 272-bp band missing exon 2B and a minor band
lacking also exons 2A and 3. This smaller product
Figure 4.—Splicing of exon 2 of Mitf is affected in the BAC
transgenic mice containing the Ser73Ala mutation. RT–PCR
was used to determine if splicing of exon 2 was affected in
the BAC transgenic mice. Primers spanning from exons 1B
to exon 3 (bottom) were used to amplify cDNAs isolated from
the indicated BAC transgenic mice (top). No products were
amplified in the homozygous Mitf mi-vga9 mice whereas two
bands were amplified in Mitf mi-vga9 heterozygotes and in
wild-type mice as well as in all the other BAC transgenic lines.
The 359-bp top band represents the full-length product
whereas the 191-bp bottom band represents an alternative
product lacking exon 2B. Quantitative PCR using exon-
specific primers was used to determine the relative amount
of these two products in the different BAC transgenic lines.
The results are indicated as the percentage of the product
lacking exon 2B over the total amount of products lacking
and containing exon 2B. The shorter product is relatively
more abundant in the lines that contain the Ser73Ala
mutation.
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represents a rare alternative Mitf transcript, where exon
1M has been spliced directly to exon 4. A similar Mitf
transcript, extending from exon 1A to exon 4, has been
shown to exist in heart (Hallsson et al. 2000). In the
two del(int2) transgenic strains, the only product pre-
sent is a 188-bp band lacking exons 2B and 3. This is the
major band seen in skin from the mutants, suggesting
that the full-length transcript observed in heart is rarely,
if at all, expressed in skin.
Our analysis of Mitf expression and splicing in skin is
consistent with the results obtained using heart tissue.
Because the del(int1/2A) and del(2B/int2) BAC trans-
genes rescue the Mitf mi-vga9 phenotype (Figure 5, B and
C), we conclude that neither exon 2A nor exon 2B is
essential for MITF function in eye or melanocyte develo-
pment in the mouse. Exon 2B contains the codon for
amino acid Ser73, so these results are consistent with
results obtained by the Ser73Ala knock-in mutation
(Bismuth et al. 2008) and the Ser73Ala BAC transgenes
described above. These results are rather surprising
because a section of exon 2A (amino acids 11–39) is
highly conserved among different species (Hallsson
et al. 2007).
The Mitf mi-enu22(398) mutation: Analysis of a novel Mitf
mutation called Mitf mi-enu22(398) provides independent
support for the molecular and phenotypic character-
istics of the deletion mutations. This mutation was
induced by treatment with ethylnitrosourea as part of
a genetic screen performed at the Novartis Institute for
Functional Genomics. Animals homozygous for this
mutation have normally developed eyes, a white belly,
and large unpigmented spots over the rest of the coat
(Figure 7A). The phenotype is remarkably similar to the
phenotype of the del(int2) transgenic lines on the
Mitf mi-vga9 background (compare Figure 7A to Figure 5,
D and E), except Mitf mi-enu22(398) has a bit more extensive
white spotting. Sequence analysis shows that the muta-
tion is a C-to-T change at nucleotide position 205 of the
cDNA, which introduces a stop codon in exon 2A,
Figure 5.—Generation and analysis of exon 2 deletion mu-
tations. Several different deletion mutations were generated to
analyze the role of exons 2A and B in Mitf function. (A) The
genomic structure of the deletion mutations that were gener-
ated. The exons are indicated as colored boxes. (B–E) The
transgenic mice carrying the different deletion mutations.
The left panels show a side view of the mice and the right panels
show the belly region. The inserts in the upper right corner of
the left panels show the eyes of the BAC transgenic mice. (B)
The BAC carrying the del(int1/2A) mutation rescues the phe-
notype of the Mitf mi-vga9 mutation to a large extent, leaving a
sizable belly spot. (C) The BAC carrying the del(2B/int2) mu-
tation also rescues the phenotype of the Mitf mi-vga9 mutation; a
small belly spot is visible in most of the animals. (D and E) Two
different transgenic lines were generated which carry the BAC
with the del(int2) mutation. These lines fully rescue the micro-
phthalmia associated with the Mitf mi-vga9 mutation whereas coat
color is rescued only partially. These animals have an extensive
belly spot in addition to white spots over the rest of the coat.
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changing glutamine at position 26 of the MITF protein to
STOP (Figure 7B). This would terminate the MITF
protein prematurely, producing only a short peptide.
RT–PCR analysis using primers that extend from exon 1B
to exon 9 results in multiple bands in wild-type hearts,
indicating the multiple alternative splice products made;
sequencing confirms that the full-length product is the
most prominent product and that another prominent
product lacks exon 2B (Figure 7C). However, in hearts
from Mitf mi-enu22(398) homozygous animals, the major Mitf
product lacks exons 2A, 2B, and 3, resulting in a product
in which exon 1B is fused to exon 4 (Figure 7C). A
functional protein can be made although it lacks the
domains encoded by these three exons. The molecular
characteristics of this mutation are similar to the del(int2)
transgenic lines on the Mitf mi-vga9 background in that all
are lacking exons 2B and 3. They are different, however,
in that the del(int2) lines retain exon 2A and express the
full-length wild-type transcript at a low level, at least in
heart, whereas in Mitf mi-enu22(398) hearts, exon 2A is largely
missing. The full-length RNA product is also made in
Mitf mi-enu22(398) animals, as well as a product lacking exons
2A and 2B (Figure 6A). However, the full-length transcript
can be translated only into a truncated peptide. The
phenotypic similarity of animals carrying the del(int2)
BACs and the Mitf mi-enu22(398) mutations suggests that the
transgenic approach accurately reflects the functional
aspect of Mitf during melanocyte and eye development.
The Mitf mi-black-and-white spot (Mitf mi-bws) mutation also results
in black and white animals (Hallsson et al. 2000). The
molecular defect described in this mutation is an
alteration in a splice acceptor site 12 bp upstream of
Figure 6.—Analysis of splicing in BAC trans-
genic mice carrying Mitf deletion mutations.
RT–PCR analysis was performed on both heart
and skin to characterize Mitf transcripts in mice
carrying the BAC deletion mutations. (A) Splic-
ing of Mitf in heart tissue was characterized using
two primer sets. The first primer set (top) ex-
tended from exon 1B to exon 3. In wild-type
mice, these primers result in two bands: a full-
length 359-bp band and a shorter 191-bp band
lacking exon 2B. The full-length band is more
prominent, representing 90–95% of the product.
In the del(int1/2A) mutation, a single 131-bp
PCR product was made, representing a transcript
lacking both exons 2A and 2B. Because exon 2A
is missing, the only product possible is made by
splicing exon 1B directly to exon 3. In the
del(2B/int2) mutation, only the 191-bp product
lacking exon 2B is generated, as expected. The
two del(int2) lines generate only the full-length
product. The Mitf mi-enu22(398) mice express both
the full-length product and the 131-bp product
missing both exons 2A and 2B. The second
primer pair (bottom) extended from exon 1B
to exon 4. The results are largely the same as
above. The only exception is that the two
del(int2) lines produce a smaller band in addi-
tion to the full-length product observed in line
TG13628. The smaller product represents tran-
scripts that lack exons 2B and 3, suggesting that
exon 2B is spliced directly to exon 4 in these
mice. (B) Splicing of Mitf in skin was analyzed us-
ing primers extending from exon 1M to exon 4.
In control (B6) animals, this primer set results in
the production of a single 440-bp full-length
product. These primers result in two products
in skin from mice carrying the del(int1/2A) de-
letion mutation, a 380-bp band representing a
transcript lacking exon 2A, and a smaller 212-
bp band lacking exons 2A and 2B. This deletion
fuses exon 1M directly to exon 2B so none of the
products will contain exon 2A. However, the smaller product suggests that the splice donor in exon 1M is still active and that this
exon can be fused directly to exon 3. The del(2B/int2) deletion also results in the production of two fragments using this primer
set: a 272-bp fragment lacking exon 2B and a fragment lacking exons 2A, 2B, and 3. In these mice, exon 2A is fused directly to exon
3 so all products will lack exon 2B. The small alternative product indicates that exon 1M can also be spliced directly to exon 4. Both
del(int2) lines result in only one product, representing a transcript lacking exons 2B and 3. Clearly, the absence of intron 2 leads
to the skipping of the two flanking exons, and the only product produced fuses exon 2A directly to exon 4.
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exon 2A, which results in partial exon skipping such that
exon 2B is missing in a significant portion of the
transcripts (Hallsson et al. 2000). This is therefore
not consistent with our BAC results or with our analysis
of the Mitf mi-enu22(398) mutation. Thus, we used quantita-
tive PCR to characterize the expression of the Mitf gene
in the Mitf mi-bws mutation. This shows that 40% of Mitf
transcripts in the hearts of Mitf mi-bws animals lack exon
2B. However, the total expression of the Mitf transcript
is only 9.5% inMitf mi-bws animals as compared to wild type
when analyzed using primers from exon 6 to exon 7 or
from exon 7 to exon 8. Thus, the level of Mitf expression
is significantly affected in Mitf mi-bws animals. At present, it
is not well understood how the intron mutation found
in Mitf mi-bws results in the alternative splicing of a down-
stream exon or how it affects expression of the gene.
Relative quantification of MITF expression in BAC
transgenic mice: To determine the expression level of
the Mitf gene in BAC transgenic mice, we performed
qPCR analysis on tissues from the transgenic animals as
well as from controls. We followed the protocols and
recommendations of Nolan et al. (2006) and tested for
inhibitory factors using the SPUD assay, tested 12 dif-
ferent housekeeping genes to identify the most stable
reference gene (we used Hprt1), and determined ampli-
fication efficiency for each primer pair used. The pri-
mers used for quantifying Mitf extend from exon 6 to
exon 8 and should quantify all currently know splice
forms of the gene. We measured expression in hearts
from three animals and skin from two animals of each
genotype, and each reaction was performed in duplicate
using identical amounts of total RNA in each case.
Expression of Mitf was first determined in heart, a tissue
that expresses significant levels of Mitf in wild-type
mice, as well as in mutants that lack melanocytes and
show severe microphthalmia (Steingrı´msson et al.
1994). In the Mitf mi-vga9 mutants, however, we detected
no Mitf expression because no significant difference was
found in Mitf expression between cDNA samples pre-
pared from Mitf mi-vga9 homozygotes and from no-
template controls (average cycle threshold values were
32.5 6 0.95 and 33.2 6 1.34, respectively). Thus, the
Mitf mi-vga9 mutants do not express the Mitf gene in heart,
and the only transcripts detected in the BAC transgenic
lines must therefore be expressed from the transgenes
and not from the Mitf mi-vga9 locus.
The results of the qPCR analysis in heart are pre-
sented in Table 4 as the fold change of Mitf expression
as compared to the control after normalization. The data
show that expression of the Mitf transcript in heart from
the BAC transgenic lines ranges from1.15-fold to 0.55-
fold as compared to controls. Interestingly, expression
of Mitf in Mitf mi-vga9 heterozygotes is 0.9-fold less than
in controls, indicating that they have half the amount
of the Mitf transcript as compared to controls. This is
exactly as expected, given that these animals express
Mitf from only one copy of the gene. Expression of Mitf
in the BAC-Mi1 transgene, which contains the wild-type
BAC, is very similar to controls or 0.17-fold. This
suggests that the BAC construct truly replicates expres-
sion of the wild-type Mitf gene in heart. These data
confirm both the robustness of our qPCR analysis and
the BAC transgene rescue method. Analysis of Mitf
expression in the remaining BAC transgenic lines shows
that expression in heart is in most cases similar to wild
type, or lower [the Ser73Ala, Ser73Ala; Ser409Ala double
mutant, del(2B/int2), Ser409Ala, del(int2)13628, and
del(int1/2A) transgenic lines]. In only one case is Mitf
expressed at a level higher than seen in the controls [the
Figure 7.—Molecular and phenotypic characterization
of the Mitf mi-enu22(398) mutation. (A) The phenotype of the
Mitf mi-enu22(398) mutation. The mice have normal eye size. How-
ever, although they have extensive white belly spots and white
spots over the rest of the body, a significant portion of their
coat is normally pigmented. (B) The mutation associated with
this phenotype is a stop codon in exon 2A of the Mitf gene.
The position of the Ser73 amino acid is also indicated. (C)
Characterization of splicing of the Mitf gene in normal and
Mitf mi-enu22(398) mutant mice using primers extending from
exon 1B to exon 9. In normal mice, this results in the produc-
tion of a major 997-bp full-length band and several alternative
splice products, including the 829-bp product lacking exon
2B. In the Mitf mi-enu22(398) mutation, the major 685-bp product
is lacking exons 2A, 2B, and 3.
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BAC transgene line del(int2)13627]. This line, however,
shows a phenotype identical to the phenotype of the
del(int2)13628 line, suggesting that expression levels
are less important for phenotypic expression than the
molecular defect involved. The results suggest that the
BAC transgenes more or less replicate the wild-type
expression of the Mitf gene in heart.
Melanocytes are the cells responsible for pigmenta-
tion. To determineMitf expression levels in melanocytes
of the BAC transgenic mice, skin of transgenic 5-day-old
mice was prepared for RNA isolation, cDNAs were
prepared, and qPCR analysis was performed as de-
scribed above. The results are shown in Table 4 and
show that in all the lines but one, Mitf is expressed at
lower levels than seen in controls, ranging from 0.19- to
4.80-fold lower expression. Again, the expression of Mitf
in Mitf mi-vga9 heterozygotes is at half the level seen in the
controls, suggesting that our method accurately meas-
ures expression of the gene in skin. In conclusion, the
gene expression data in both heart and skin show that
most of the transgenes expressMitf at a level similar to or
lower than what is seen in wild-type mice. Thus, we
conclude that the rescue observed is not due to over-
expression of the Mitf gene. The level of transcripts is of
course only one parameter in determining the levels of
functional protein, and it is possible that the cells can
compensate for the lack of transcripts through regulat-
ing translation, activity, or other aspects of producing a
transcriptionally active MITF protein.
Conclusions: We have used a BAC transgene rescue
method to determine the in vivo functional role of two
phospho-acceptor sites in the MITF protein, serine 73
and serine 409, as well as of two domains encoded by
exons 2A and 2B. These two phospho-acceptor sites had
previously been suggested to be important for MITF
function, although the effects observed differed de-
pending on the cell type used. Hemesath et al. (1998)
showed that in baby hamster kidney (BHK) cells the
wild-type and Ser73Ala mutant MITF proteins can ac-
tivate expression of the tyrosinase promoter at equal
levels. However, in BHK cells harboring constitutively
active Raf, the wild-type protein was a 2.5 times more
potent activator of tyrosinase than the Ser73Ala mutant
protein, suggesting that the Raf signaling pathway
affects transactivation specifically through this phos-
pho-acceptor site. Price et al. (1998) showed that the
increased transcription activity was due to the recruit-
ment of the co-activator p300 to the phosphorylated
protein; a protein containing the Ser73Ala mutation
failed to activate expression. Wu et al. (2000) then
showed that in NIH3T3 cells the Ser73Ala mutant
protein is significantly less able to activate transcription
than the wild-type protein whereas the Ser409Ala muta-
tion is similar to wild type. In these cells, the Ser73Ala;
Ser409Ala double-mutant protein is not able to activate
transcription at all. In 501mel melanoma cells, the wild
type, Ser73Ala, and Ser409Ala proteins are similar in their
transcription activation potential whereas the double
mutant is transcriptionally inactive (Wu et al. 2000). From
these data and the fact that the phenotypes of Mitf, Kitl,
and Kit mutations all affect coat color, we would have
expected that mutations in these phospho-acceptor sites
in mice would result in mice with a white coat color. Our
results, however, indicate that, in vivo, neither of the two
phospho-acceptor sites is essential for MITF function.
We believe that our results accurately depict the
in vivo roles of these amino acids and domains. First,
the BAC transgene rescue strategy clearly works because
wild-type BACs rescue the Mitf mi-vga9 phenotype fully and
replicate the endogenous expression of the Mitf gene. It
should be emphasized that this strategy calls for the
rescue of a severe phenotype, where melanocytes are
missing and where RPE cells have lost their normal
identity. The strategy therefore represents a ‘‘positive’’
test of Mitf function in vivo. Second, expression of the
Mitf gene in heart and skin from the BAC transgenic
mice is in the range (or less) observed in wild-type and
Mitf mi-vga9 heterozygous mice, which have normal coat
color and eye development. This suggests that the
transgenes have not resulted in overexpression of the
Mitf gene, which might have confounded the results.
Third, our results are consistent with a previous charac-
terization of the role of Ser73 using a knock-in strategy
(Bismuth et al. 2008). Fourth, the phenotype and
molecular defect of the Mitf mi-enu22(398) mutation is con-
sistent with the phenotype of the del(int2) mutations,
suggesting that the BAC constructs can replicate the
phenotype of Mitf mutations.
So how can we then explain the discrepancy between
the in vitro and the in vivo observations? One possible
explanation is that in vivo, alternative phospho-acceptor
sites take over when Ser73 and Ser409 have been mu-
tated to alanine, thus leading to total rescue of the phe-
notype. Due to differences in the environment (culture
conditions vs. in vivo development) this compensation
may not take place in the in vitro assays, leading to the
TABLE 4
Relative expression of Mitf in heart and skin
Fold changea
Heart Skin
B6 0 60,62 0 61.51
B6-vga9/1 0.90 60,26 1.05 60.33
BAC-Mi1 0.17 60,62 0.22 61.70
Ser73Ala 0.50 60,32 1.31 61.53
Ser409Ala 0.82 60,19 2.04 62.55
Ser73/409Ala 0.13 60,60 4.80 60.25
del(int2)13627 0.55 60,25 0.19 61.73
del(int2)13628 0.88 61,40 1.27 61.68
del(int1/2A) 1.15 60,53 1.70 63.45
del(2B/int2) 0.52 60,60 2.18 62.00
a Relative to the reference gene Hprt1.
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observed effects on transcription activation and protein
stability. This would imply that there is a redundancy in
the signaling mechanisms to ensure that the protein
receives the signal. Detailed analysis of MITF phosphor-
ylation would need to be performed to test this. Another
possibility is that KITL and KITsignal to other phospho-
acceptor sites in the MITF protein. Several other
phospho-acceptor sites are known in the MITF protein,
including Ser307, which has been shown to be phos-
phorylated by p38 upon RANKL/RANK signaling in
osteoclasts (Mansky et al. 2002), and Ser298, which was
shown to be phosphorylated by GSK3b (Takeda et al.
2000). In contrast to KIT signaling to MITF in melano-
cytes, the RANKL/RANK signaling to Ser307 of MITF in
osteoclasts appears to be persistent and not transient
(Mansky et al. 2002). Little is known about the bio-
chemical consequences or in vivo significance of this
signaling event, and currently it is not known if it is also
active in melanocytes. Studies seem to indicate that
Ser298 is crucial for normal DNA binding and tran-
scription activation of the MITF protein and that this
phosphorylation is an important regulatory event. At
present it is not clear whether Ser298 is constitutively
phosphorylated or regulated in a cell-specific or de-
velopmental manner or whether it is a bona fide GSK3b
phospho-acceptor site (Frame and Cohen 2001). In
addition to Ser307 and Ser298, additional, yet unchar-
acterized phosphorylation sites of functional impor-
tance may exist in the MITF protein. A third
explanation for the differences observed between the
in vivo and in vitro results might be that the in vitro assays
used to determine protein stability and transcription
activation (Wu et al. 2000; Xu et al. 2000) are more
sensitive to subtle differences between the different
mutations than the in vivo assay. This higher sensitivity
would lead to significant differences in cell assays,
whereas no such differences would be detected in the
organism. The mice do not appear to be sensitive to Mitf
dose as the phenotype of some of the mutant BAC-
transgenic mice is normal although the Mitf gene is
expressed at lower levels as compared to wild-type
controls. In some cases, only30% of the Mitf transcript
is sufficient for a normal phenotype, and in Mitf mi-bws
mutant mice the Mitf gene is expressed at only 9.5%
level in heart as compared to wild-type controls. Reduced
expression would presumably enhance the sensitivity of
Mitf to mutations that affect the function of the gene.
Finally, it is possible that the stability of the MITF protein
is affected in the Ser73Ala and Ser409Ala BAC mutant
mice such that the protein is more stable and therefore
present for a longer time in the BAC mice than in wild-
type mice. This would be consistent with the observation
that the Ser73Ala; Ser409Ala double-mutant protein is
more stable in cell culture than the wild-type protein (Wu
et al. 2000; Xu et al. 2000). Despite being a poor tran-
scription activator in vivo (due to the Ser73 and Ser409
mutations), a more stable protein might be able to rescue
the phenotype as it persists for longer in the cells. If this
were the case, one would not necessarily expect Kitl and
Kitmutant mice to share a phenotype withMitfmutations
as the lack of signaling would presumably lead to a more
stable MITF protein. This requires further studies on
protein stability in the transgenic mice.
Our studies have also addressed the roles of several
different exons in the Mitf gene. The lack of exon 1A
from both BAC constructs used in these studies indi-
cates that this exon is dispensable for Mitf function in
melanocytes as well as during eye development. Like
exon 1A, exons 2A and 2B seem to be dispensable for
Mitf function. This is consistent with the normal phe-
notype of Ser73Ala mutant mice. The del(int2) BACs,
together with the del(int1/2A) and del(2B/int2) muta-
tions, suggest that exon 3 may play a more important
role than exon 2. However, the role of exon 3 is currently
not known.
In summary, our studies imply that signaling to
Mitf may be more complex in vivo than the in vitro
experiments would suggest. It may involve alternative
phospho-acceptor sites or even alternative signaling
mechanisms downstream of the Kit and Kitl signaling
pathway. Further studies on this fascinating transcrip-
tion factor are needed to characterize the role of
signaling in melanocyte development.
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4 – Le codon S73 du gène Mitf fait partie d’une séquence d’enhancer 
exonique d’épissage impliquée dans la régulation de l’incorporation de l’exon 
2B. 
 
Le facteur de transcription MITF, connu principalement pour ses implications 
dans la biologie des melanocytes et du mélanome, représente une famille d’isoformes 
générées par l’utilisation alternative de différents promoteurs, par épissage alternatif et 
par modification post-traductionnelles. Ici nous démontrons que le codon 73 de Mitf ne 
code pas seulement pour une serine, dont la phosphorylation contrôle l’activité et la 
stabilité de la protéine, mais fait également partie d’une séquence d’enhencer exonique 
d’épissage, qui régule l’incorporation de l’exon 2B sur lequel il se situe. D’ailleurs, de 
nombreuses permutations de ce codon dans des mini gènes, y compris un codon alternatif 
codant pour une serine, provoquent tous une augmentation de l’exclusion de l’exon 2B. 
L’exclusion de cet exon est favorisée par un membre de la famille des SR protéines 
SRp30c et son inclusion par SF2/ASF, SRp55, SC35 et SRp40. Ce dernier facteur 
présente une affinité de fixation à l’enhancer exonique différente entre le codon témoin et 
le codon muté pour une alanine non-phosphorylable à cette position. Les résultats 
présentés ici confirment les observations précédentes chez la souris avec l’allèle Mitfmi-
S73A et suggèrent que la phosphorylation de MITF est non seulement régulée par les 
kinases correspondantes mais aussi de façon indirecte par les activités relatives de SR 
protéines spécifiques. 
Les travaux liés à cette étude sont décrits dans l’Article 4. 
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The following results present the identification of the molecular mechanism involved in 
the linkage between the Mitfmi-S73A allele and the large exclusion of exon 2B, which 
contains the mutated codon.  
We first determined that the alteration of the exon 2B inclusion, originally observed in 
vivo in the Mitfmi-S73A knock-in mice, can be reproduced in an heterologous context in 
vitro using an artificial pCMV driven Mitf minigene, which contains only the genomic 
sequence from exon 1M to exon 3. We then demonstrated that the splice alteration is 
solely caused by the S73A mutation and many of the 14 possible additional 
permutations leading to amino acid changes at this position. Hence, a S73S mutation 
displays a similar reduction of exon 2B inclusion in vitro. Hence, the splice alterations 
observed in Mitfmi-S73A mice is unlikely due to the mutated protein itself as it can be 
reproduced with expression of wild-type protein. 
 In silico prediction tools reveal that the S73 codon sequence is part of an Exonic Splice 
Enhancer sequence (ESE) for several splice regulatory serine/arginine rich proteins. In 
fact in silico, the tools predict that one of them, SRp40, has a reduced binding score for 
all of the 15 distinctly mutated codons.  
We then characterized a number of SR proteins for their effects on the splicing pattern of 
the Mitf minigene by co-transfection of SR protein expression vector and the minigene in 
HEK293 cells. The results show that SRp40 in addition to SRp55 and SC35, is able to 
correct exon 2B exclusion in presence of the S73A mutation; SRp30c increases exon 2B 
exclusion. 
Additional biochemical tests indicate that SRP40 indeed shows reduced affinity for short 
mutated RNA compared to wild type RNA on RNA affinity columns. 
We, therefore, propose a straightforward mechanism involving SR proteins to explain the 
fine-tuning of Mitf exon 2B alternative splicing regulation. A relative excess of SRp40 
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(and some others) over SRp30c leads to exon 2B inclusion, and a relative excess of 
SRp30c over SRP40 (and others) to its exclusion. In experiments not shown, we find 
that different cell lines, or cells in different proliferative stages, change the ratios of these 
proteins and that their relative ratios correlate with the relative inclusion or exclusion of 
exon 2B from Mitf. Because the absence of exon 2B is associated with a reduced anti-
proliferative activity, relative SR protein abundance would be predicted to regulate cell 
proliferation. The equilibrium between exon 2B inclusion and exclusion can therefore be 
easily switched by tweaking the relative activity of SR protein, ultimately affecting the 
proliferative state of melanocytes. 
The experimental work related to this study is presented in the following Article 4. 
 
 
 
 
 
 
 
 
Article 4 
The codon for a phosphoacceptor site in the 
microphthalmia-associated transcription factor MITF 
has a role as regulator of splicing. 
(DRAFT)  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ASSOCIATED TRANSCRIPTION FACTOR MITF HAS A ROLE AS REGULATOR OF 
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The transcription factor MITF, known 
primarily for its roles in pigment cell biology 
and melanoma, represents a family of 
isoforms generated by alternative promoter 
use, alternative splicing, and post-tanslational 
modifications. Here we show that MITF 
codon-73 not only encodes a serine whose 
phosphorylation regulates the protein’s 
activity and stability, but is also part of an 
exonic splice enhancer sequence that 
regulates the splicing of its own exon, exon 
2B. In fact, multiple permutations of the 
codon in corresponding minigenes, including 
an alternative serine codon, all lead to 
enhanced exclusion of this exon. Exon 2B 
exclusion is favored by the serine/arginine-
rich protein SRp30c and its inclusion by 
SF2/ASF, SRp55, SC35 and SRp40, the latter 
showing differential binding to the splice 
enhancer sequence containing the wild-type 
codon versus one encoding a non-
phosphorylatable alanine at this position. The 
results are consistent with previous 
observations in knock-in mice with serine-73-
to-alanine mutations and suggest that MITF 
phosphorylation is not only regulated directly 
by the corresponding kinases and 
phosphatases but also indirectly via the 
relative activities of specific serine/arginine-
rich splicing factors. 
  
The vertebrate microphthalmia-associated 
transcription factor MITF is a basic-helix-loop-
helix-leucine zipper protein that controls many 
cellular processes, most notably specification, 
proliferation and differentiation of melanin-
bearing pigment cells. Mutations in Mitf, which 
have been found from fish to man, commonly 
affect pigmentation of the integument and, 
depending on the species, also the development 
of the eye and inner ear. In humans, 
heterozygosity for MITF mutations are 
associated with Waardenburg type IIa and Tietz 
syndrome which are characterized by pigment 
abnormalities in skin and iris, premature hair 
greying, and varying degrees of congenital 
hearing loss (1,2). Recently, MITF has also been 
found to function as a “lineage addiction” 
oncogene during melanoma formation (3).  
Over the years it has become clear that 
MITF is not a single protein but a family of 
isoforms which are generated by alternative 
promoter use, alternative splicing, and post-
translational modifications. For instance, based 
on in vitro data, MITF serine-73 is 
phosphorylated by the MAP kinase pathway 
through the action of ERK1/2 (4). Serine-73 
phosphorylation increases the protein's activity 
but also promotes, along with phosphorylation at 
serine 409, its degradation (5). To assess 
whether serine-73 phosphorylation would play a 
role in vivo, we have previously generated 
knock-in mice in which two basepairs of the 
highly conserved codon for serine-73 were 
changed in such a way that a non-
phosphorylatable alanine-73 is encoded instead 
(hereafter called S73A mutation) (6). To our 
surprise, this codon change led to a change in 
the extent of alternative splicing of subexon 2B, 
the very subexon that harbors codon-73. In mice 
and other mammals, exon 2 of Mitf is comprised 
of two subexons, subexon 2A (hereafter called 
exon 2A) containing 20 codons and subexon 2B 
(hereafter called exon 2B) containing 56 codons. 
Quantitative real-time RT-PCR assays and direct 
cDNA cloning have shown that normally, 
approximately 90% of Mitf mRNAs from heart, 
skin, or melanocytes of mice contain both exons 
and about 10% lack exon 2B, meaning that in 
this case, exon 2A is spliced directly into exon 3 
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(6-9). In contrast, in the knock-in mice, only 
10% of Mitf mRNAs contain both exons 2A and 
2B and 90% lack exon 2B. This splice alteration 
was confirmed in BAC rescue transgenics 
carrying the S73A mutation (7). Although the 
splice change does not lead to an overt 
phenotype, it does affect, at least in vitro, cell 
proliferation: MITF containing exon 2B is anti-
proliferative whilst MITF lacking exon 2B 
leaves cell proliferation untouched (unpublished 
observation). Intriguingly, a line of metastatic 
human melanoma has also recently been found 
to generate MITF mRNAs lacking exon 2B as a 
result of a mutation at the 5' splice site of this 
exon (10). Presumably, this mutation is one of 
many that has arisen to allow for increased rates 
of melanoma cell proliferation.  
The above findings, together with the 
recognition that alternative splicing is an 
important parameter of eukaryotic gene function 
in general, prompted us to analyze the MITF 
codon-73-associated splice change in greater 
detail. The formation of mature mRNAs from 
intron-containing pre-mRNAs has been shown 
to depend on both cis-acting RNA elements and 
trans-acting factors. The main cis-acting 
elements are short, degenerate sequences around 
the 5' splice site, the 3' splice site, the 
polypyrimidine tract, and the branch point, and 
they are recognized by a set of trans-acting 
factors which together form the catalytically 
active spliceosome (11,12). Splice site selection 
is influenced by a family of conserved 
serine/arginine-rich (SR) proteins, which interact 
with specific RNA sequences via their RNA 
recognition domains and with spliceosomal 
proteins via their RS domains. Specific RNA 
sequence elements are called exonic or intronic 
splice enhancer elements (ESEs or ISEs) when 
they lead to inclusion of a particular exon, and 
exonic or intronic splice silencer elements (ESSs 
or ISSs) when they lead to exon skipping. In 
fact, the splicing of most alternative exons is 
controlled by multiple enhancer and silencer 
elements. It has to be kept in mind, however, 
that many of these elements are not strict 
silencers or enhancers but can act in one way or 
the other depending on the context, including 
their position relative to an alternatively spliced 
exon (13). 
Given the above information, it was 
conceivable that codon-73 of Mitf is part of a 
splice regulating cis-acting sequence and as such 
might interact with specific SR proteins. Indeed, 
we found that the mutated two bases are part of 
an ESE and that they regulate the interaction 
with SRp40. Moreover, we found that while 
overexpression of SRp40 and other SR proteins 
leads to enhanced inclusion of exon 2B, 
overexpression of SRp30c leads to its enhanced 
exclusion. The results suggest that distinct SR 
proteins and their relative activities in a given 
cell are part of the regulatory splicing machinery 
that determines MITF alternative splicing and 
hence, potentially, the rate of cell proliferation 
both during development and in malignancies.  
 
Experimental Procedures 
 
Mice and preparation of melanocyte lines- Mice 
carrying the Ser-73-Ala mutation along with a 
silent ApaLI site have been described 
(designation: Mitftm1.1Arnh, kept on a background 
that involves 129S1/Sv*C3H/He*C57BL/6). 
They were crossed with mice carrying a targeted 
mutation in the Ink4a/Arf locus (designated 
Cdkn2atm1Rdp, background C57BL/6) to generate 
mice homozygous for both mutations. Dorsal 
skin of one-day old pups from these latter mice 
and homozygous Cdkn2atm1Rdp mice were used 
to produce melanocyte cultures according to 
established protocols. The cells were kept in 
RPMI 10% fetal calf serum, 1% non-essential 
amino acids, 1% penicillin/streptomycin, 1% L-
Glutamine, 200 nM 12-O-tetradecanoylphorbol-
13-acetate (TPA) (Sigma), 40 pM hFGF2  
(Peprotech), 20 ng/ml mSCF (Peprotech) and 10 
nM EDN3 (Sigma). After 2-5 days, cultures 
were trypsinized and approximately 100 
pigmented cells were picked microscopically, 
using a 40x objective. These were designated 
passage 1 of pure melanocytes. Cells were 
usually used between passage 10 and 20 to 
assess splicing of endogenous Mitf RNAs.  
Cell culture and transfections- For most 
transfection experiments, HEK293 cells which 
do not express MITF were used. Some 
experiments were done in ARPE19 cells which 
are MITF expressing spontaneously 
immortalized human retinal pigment epithelium 
cells. The cells were grown in DMEM 
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supplemented with 10% fetal bovine serum and 
penicillin-streptomycin (Invitrogen, Carlsbad, 
CA, USA). Cotransfections in HEK293 cells 
were done at 60-70% confluence in 60 mm 
dishes, using Effectene reagent (Qiagen) and one 
µg each of minigene DNA and SR protein 
expression vector. ARPE19 cell transfections 
were done with two µg of the respective 
minigene constructs in 30 mm wells. 
Melanocytes were transfected with one µg each 
of minigene DNA, SR protein expression vector, 
and a green fluorescent protein (GFP) 
expression vector. Twenty-four to 48h after 
transfection, the cells were harvested and 
processed for RNA isolation. RNAs were 
analyzed by regular and real time reverse 
transcriptase (RT)-PCR.  
RT-PCR- Total RNA was isolated from 
transfected cells, using RNA easy mini kit 
(QIAGEN), and converted into cDNA using 
superscript III reverse transcriptase (Invitrogen). 
The location of Mitf primers used for regular 
and qRT-PCR are shown in Fig. 1A, and their 
sequences along with those of primers specific 
for control genes and used for normalizations are 
shown in Suppl. Table S1. qRT-PCR reactions 
were performed as recently described in detail 
(14). 
Immunoblotting- Extracts from transfected 
HEK293 cells and purified SR fusion proteins 
were separated by 4-12% Bis-Tris SDS-PAGE 
and transferred to nitrocellulose membranes 
(Bio-Rad Laboratories). Splicing factor-specific 
primary antibodies were: Rabbit-anti-SC35 
(1:2,000 dilution, Abcam), Goat anti-SRp40 
(1:200 dilution, Santa Cruz Biotechnology), and 
mouse monoclonal anti-SRp30c (1:500 dilution, 
Abcam). A mouse anti-His Tag (1:1,000 
dilution, Millipore) was used to detect the tag-
only E. coli-derived protein. Horseradish 
peroxidase-conjugated goat anti-rabbit, goat 
anti-mouse, or mouse anti-goat IgG (Thermo 
scientific) were employed as secondary 
antibodies. In addition, the mouse monoclonal 
antibody MAb104, which recognizes a 
phosphoepitope on SR proteins, was produced 
from a corresponding hybridoma line (ATCC 
CRL-2067) and used in conjunction with a 
horseradish peroxidase-conjugated goat anti-
mouse IgM antibody (1:20,000, Thermo 
scientific). A mouse monoclonal anti-β-actin 
antibody (1:25,000 dilution, Sigma) was used 
for control purposes. Positive bands were 
detected using the chemiluminescent blotting kit 
(SuperSignal West Pico, Thermo scientific).  
Constructs and plasmids- Minigene constructs: 
A 2.55 kb fragment containing exon 1M to exon 
3 of the Mitf gene was generated by PCR 
amplification from mouse Mitf Bac 369-C11  
(6,7). This fragment was cloned into the 
pcDNA3.1/V5-His TOPO TA mammalian 
expression vector (Invitrogen) following the 
manufacturer's instructions. Mutated minigenes 
were engineered using appropriate mutated 
primers and the quickchange site-directed 
mutagenesis kit (Stratagene). Plasmids were 
verified by sequencing. SRp20, SRp30c, SRp40, 
SRp55, SC35, SF2, and 9G8 pCG expression 
vectors were a gift from Dr. Thomas Misteli.  
Synthesis of DIG-labelled riboprobes- Synthesis 
of the Mitf wild-type or mutated exon 2B DIG-
labelled riboprobe was carried out by in vitro 
transcription of an Mitf wild-type or mutated 
exon 2B cDNA inserted into pBluscript II. To 
generate sense probes, the plasmid was 
linearized with XhoI and transcribed with T3 
RNA polymerase in the presence of DIG-UTP 
(Roche). The 3xCE9 plasmid (kindly provided 
by Benoit Chabot) was linearized with ClaI and 
transcribed with T3 RNA polymerase 
(EPICENTRE Biotechnologies) to serve as a 
positive control for binding of SRp30c protein. 
The h 3'int and ESE2-DSX plasmids (kindly 
provided by Francisco E. Baralle and James G. 
Patton) were linearized with NdeI and MluI 
separately and transcribed with T7 RNA 
polymerase (EPICENTRE Biotechnologies) to 
serve as positive controls for binding of SRp40 
or SC35 protein, respectively.  
Cloning, expression and purification of SR 
fusion proteins- The sequences for the respective 
SR proteins were amplified by PCR from 
corresponding plasmids, digested with SalI and 
NotI, and cloned into a modified pET30a 
(Novagen) vector allowing for expression of 
fusion proteins with GB1 and NusA protein and 
an 8x His tag. Coding frames were verified by 
DNA sequencing. The respective plasmids were 
expressed in E. coli BL21 (DE3). The cultures 
were grown at 370C and induced by using auto-
induction LB media (Novagen) for 12 h. The 
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cells were harvested by centrifugation at 4000 
rpm, 30 min, at 40C, resuspended in 25 mM Tris 
pH 8.0, 125 mM NaCl, 10 mM imidazole, lysed 
by sonication, and centrifuged at 30,000 rpm for 
25 min at 40C. The lysate, supernatant, and 
pellet were subjected to SDS–PAGE followed 
by Coomassie staining. The supernatant was 
then loaded onto HisPrep™ FF 16/10 affinity 
columns (GE Healthcare). The columns were 
washed, and using an imidazole gradient on an 
AKTA-FPLC system, the proteins were eluted at 
60-100 mM imidazole at 40C. Desalting was 
done with ZebaTM Micro Desalt spin columns. 
Nitrocellulose filter binding assays- RNA-
protein filter-binding assays (15) were adapted 
to accommodate the use of DIG-labelled RNA 
probes instead of radioactive probes in the 
following ways. Mixes between protein and 
DIG-labeled RNAs were incubated in a total 
volume of 50 µl binding buffer for 30 min at 
300C and spotted onto the pretreated MF 
membranes. The filters were then washed with 4 
ml binding buffer, and 1 µl of this solution were 
spotted at 2-fold dilutions (in triplicates) onto 
nitrocellulose membranes. The membranes were 
then subjected to chemiluminescent detection of 
the DIG labeled probe following the 
manufacturer's instructions (Roche). We found 
that unlike purified E.coli-derived SRp40 and 
SC35, purified E.coli-derived SRp30c had no 
measurable binding activity to positive control 
3xCE9 probes. However, after incubation with a 
HeLa cytosolic S100 extract lacking SR proteins 
but containing all other required splicing 
components (Protein One), SRp30c showed 
binding activity.  
RNA affinity chromatography- Chromatography 
columns were prepared and coupled with 
modified RNAs as described (16,17) (wild-type 
sequence: 5'-N6-GCA CCC AAC AGC CCU 
AUG GCU A-3'; mutant sequence: 5'-N6-GCA 
CCC AAC GCC CCU AUG GCU A-3', 100 
nmol each, Thermo scientific Dharmacon). 
Control columns were prepared in the same way 
except that RNA was omitted in the coupling 
step. Purified SR proteins (10 µg each) were 
applied to the columns and incubated at room 
temperature for 20 min in binding buffer (20 
mM Tris-HCl [pH 8.0], 100 mM KCl, 0.5 mM 
dithiothreitol [DTT], 0.2 mM EDTA, 5% 
glycerol), and the flow-through reapplied for 10 
min. After two washes with the binding buffer, 
bound proteins were eluted by step-wise 
application of binding buffer containing 0.2, 0.5, 
0.75 and 1.0 M KCl concentrations, followed by 
a final elution in 8 M urea-20 mM Tris-HCl (pH 
8.0). Fractions were separated on 4-12% Bis-
Tris SDS-polyacrylamide gels, and the proteins 
analyzed by silver staining. 
 
 
RESULTS 
 
The S73A codon change is sufficient to 
affect exon 2B splicing. The original observation 
of the splice alteration associated with the S73A 
mutation in Mitf was made in vivo in knock-in 
mice. In these mice, the mutated allele also 
contains a silent ApaLI restriction site close to 
the S73A mutation and a loxP site in intron 2 
(6). Therefore, we first tested which of these 
alterations were responsible for the splice 
change, using appropriate mini-genes transfected 
into cultured cells. To this end, we engineered 
constructs that placed genomic mouse Mitf 
sequences spanning exon 1M to exon 3 between 
a CMV promoter and a bovine growth hormone 
polyadenylation site. As shown in Fig. 1, these 
sequences contained either the wild-type serine 
codon at position 73 or the S73A change alone 
or in conjunction with the ApaLI site. We did 
not include the loxP site as we reasoned that this 
site was unlikely to influence exon 2B splicing 
because mice harboring just the loxP site or the 
full loxP-neomycine resistance cassette showed 
similar 2B+/2B- ratios. The minigene constructs 
were expressed in HEK293 cells and the RNAs 
subjected to an RT-PCR assay that allowed 
distinction between Mitf RNAs containing or 
lacking exon 2B. Fig. 1C shows the results using 
primers a and g from Fig. 1A. In wild type, a 
predominant band of 345 bp was seen, 
corresponding to the sequence containing exon 
2B, and a barely visible band of 177 bp, 
corresponding to the sequence lacking exon 2B. 
The three mutant constructs all showed a clearly 
visible band of 177 bp in addition to one of 345 
bp, with the lowest apparent ratio of 2B+/2B- 
seen with the S73A mutation alone. These 
results indicated that the in vivo splice alteration 
could be reproduced in heterologous cells in 
vitro and that the S73A codon change was 
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sufficient to affect the respective splice choices 
in the context of a minigene.  
Additional S73 codon changes, including 
an S73S codon change, affect exon 2B splicing. 
The original S73A change involved the first two 
bases of the respective codon (AGC to GCC). 
Hence, we tested, again in minigenes, whether 
any of the additional 14 possible permutations of 
these two bases would affect splicing. The 
corresponding plasmids were generated by in 
vitro PCR site-directed mutagenesis, sequence-
confirmed, and transfected into HEK293 and 
ARPE19 cells. The latter cells were chosen 
because they are derived from an MITF 
expressing, pigmented cell type, the human 
retinal pigment epithelium, express low amounts 
of endogenous MITF, and can be transfected 
with high efficiency. For HEK293 cells, RT-
PCR was performed using the primer pair a/g 
(Fig. 1A,C), and for ARPE19 cells, the 
minigene-specific primer pair b/f  (Fig. 1A) was 
used. The results showed that in both cell types, 
all mutations affected the exon 2B+/2B- ratio of 
Mitf RNAs to some extent (Fig. 2A, shown for 
ARPE19 cells). For quantification, we 
performed real time PCR assays as previously 
described in detail (14). For these assays, we 
used primers specific for either mouse Mitf exon 
2A-3 (primer d, spanning the exon 2A-3 
junction, and primer f in Fig. 1A) or exon 2B-3 
(primer c, spanning the exon 2A-2B junction, 
and primer e in Fig. 1A) that yielded single 
bands when assayed by gel electrophoresis and 
did not show significant cross-priming on the 
inappropriate splice form (i.e. exon 2A-3 
primers on 2B+ cDNA and vice versa) (three 
independent transfections, each assayed in 
triplicates). As shown at the bottom of Fig. 2A, 
the quantifications of splicing isoforms showed 
relatively large standard deviations, suggesting 
that splicing may be sensitive to slight variations 
in culture conditions between experiments. 
Nevertheless, the quantifications largely 
confirmed the observation made by gel 
electrophoresis. For instance, the average 2B-
/(2B+ + 2B-) ratio was nearly 0 in wt but 0.15 in 
S73A. Intriguingly, the most prominent change 
was seen with TCC, one of the alternative serine 
codons, which showed an average 2B-/(2B+ + 
2B-) ratio of 0.35. Hence, even a “silent” serine-
to-serine mutation may not easily be tolerated at 
this position. 
The S73 codon is predicted to be part of an 
ESE that interacts with SR proteins. Given that 
all tested codon mutations altered exon 2B 
splicing, we concluded that the S73 codon is part 
of an ESE affected by mutation rather than that 
the different mutations would each have created 
a novel ESS. Using a bioinformatics approach, 
we next assessed whether the respective wild 
type sequence might indeed serve as an ESE, 
and, if so, which SR protein would be predicted 
to consistently show reduced binding when the 
sequence was mutated in any of the 15 ways 
tested above. To this end, we used the web-
based ESE finder tool (18,19) and identified 
several putative sequence motifs in exon 2B 
predicted to bind SR proteins, among them also 
the sequence that included codon 73. As shown 
in Fig. 2B, above-threshold scores were noted 
for this sequence with respect to binding SRp40 
and SF2/ASF, though not for SC35 and SRp55, 
the other two SR proteins represented by this 
informatics tool. Interestingly, all mutations 
reduced the binding scores for SRp40 while the 
scores for SF2/ASF were changed by some but 
not other mutated sequences. Furthermore, some 
of the mutations gave an above-threshold score 
for SC35 and SRp55 (Fig. 2B). Given these 
predictions, we proceeded to test the role of 
these SR proteins for alternative Mitf splicing 
and the potential interaction of these proteins 
with the corresponding Mitf RNA sequences. 
SR proteins affect exon 2B splicing in 
transfected cells. To test the effects of 
overexpression of SR proteins on exon 2B 
splicing, we co-transfected the wild-type and 
S73A minigene constructs along with various 
SR protein expression vectors, alone and in 
combinations, into HEK293 cells and assessed 
the effciency of exon 2B splicing by regular and 
real time RT-PCR. As shown in Fig. 3A, 
western blot assays using antibodies specific for 
SRp30c, SC35 or SRp40 indicated that the 
individual SR proteins were expressed above the 
levels of the respective endogenous proteins. In 
fact, the endogenous proteins were below 
detection limit using these antibodies and 
exposure times although their corresponding 
RNAs could be revealed by RT-PCR (not 
shown). Using the monoclonal antibody 
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mAB104, which detects the phosphorylated, 
active forms of SR proteins, suggested that the 
overexpressed proteins were indeed active. As 
shown in Fig. 3B, overexpression of SC35, 
SRp40, SF2/ASF and SRp55 led to an increase 
in exon 2B inclusion compared to control, as did 
SRp20 (not shown), and this regardless of 
whether the minigene contained the wild-type or 
the S73A codon. Overexpression of 9G8, 
however, had little if any effect (not shown). 
Interestingly, overexpression of SRp30c led to a 
relative decrease in exon 2B inclusion, again 
regardless of whether the wild-type or S73A 
codon was present in the minigene. To assess 
whether these proteins were co-dominant or not, 
we then co-transfected equal amounts of 
expression vector for the negatively acting 
SRp30c with those for the positively acting 
SRp40 or SC35. As shown in Fig. 3C, in these 
assays, SC35 and SRp40 dominated over 
SRp30c. Furthermore, the effect of transfected 
SRp30c, SRp40 and SC35 on exon 2B splicing 
was dose-dependent (Suppl. Fig. S1A). Because 
splicing efficiency may depend in part on the 
amount of pre-mRNA a cell expresses, we also 
tested whether splicing of minigene-derived 
RNA depended on the amount of minigene DNA 
used for transfection. We did not, however, 
observe significant changes in the exon 2B 
splice ratio over a 19-fold concentration range of 
S73A minigene DNA, resulting in a 10-fold 
range of Mitf RNA levels (not shown) (Suppl. 
Fig. S1B). Taken together, the results suggested 
that Mitf minigene splicing was influenced by 
the relative levels of specific SR proteins.  
SR proteins affect exon 2B splicing of 
endogenous Mitf RNA. To test whether the 
above experiments showing the effect of SR 
protein overexpression on splicing of minigene-
derived RNA can be extended to endogenous 
Mitf RNA, we used lines of skin-derived 
melanocytes that were prepared from either Mitf 
wild-type or S73A mutant mice. Using a growth 
factor-enriched medium supplemented with 
TPA, such melanocytes can be propagated as 
pure cultures of pigmented cells. Because of 
their high expression of Mitf, however, non-
transfected cells would contribute a high 
background of unaltered Mitf RNA, and so we 
used co-transfection of a green fluorescent 
protein expression vector along with the 
respective SR protein expression vector and 
standard fluorescence activated cell sorting to 
obtain a highly enriched population of 
transfectants before RT-PCR analysis. As shown 
in Fig. 3D, when SR protein expression vectors 
were omitted, sorted wild-type cells showed a 
ratio of exon 2B-/(2B+ +2B-) RNA of 
approximately 0.3 while this ratio was about 0.7 
in cells carrying the S73A mutation. Ectopic 
expression of SRp30c increased this ratio in both 
types of cells, to 0.45 and 0.95 respectively, and 
ectopic expression of SRp40 or SC35 decreased 
the ratio to less than 0.05 in wild-type and 0.35-
0.4 in S73A cells. We conclude, therefore, that 
as observed for minigene constructs, the 
respective SR proteins affect exon 2B splicing 
also of endogenous Mitf RNA. 
Differential binding of SRp40 to wild type 
and S73A mutated Mitf RNA. The above 
experiments indicate that ectopically expressed 
SR proteins influence the efficiency of exon 2B 
inclusion in mature Mitf mRNA. They do not, 
however, address the question of whether this 
effect is mediated by direct binding of these 
proteins to Mitf RNA, and in particular to the 
sequence around codon-73, or whether it is due 
to indirect effects on other factors involved in 
the splicing reaction. To test for direct 
protein/RNA interactions, we first used a filter 
binding assay modified to allow for non-
radioactive measurements. Digoxigenin-labeled 
target RNA corresponding to the wild-type or 
S73A exon 2B sequence (168 bases) was first 
prepared in vitro using appropriate plasmids. 
SRp40, SC35 and SRp30c fusion proteins were 
prepared in E.coli and purified by affinity 
chromatography, using the 8x His tag and 
appropriate His columns (Fig. 4A). After 
interaction of purified protein with labeled RNA, 
the mixtures were spotted onto MF filters. The 
filters were then washed, the flow-through 
collected, and an aliquot in serial dilutions 
assayed for the amount of free labeled RNA, 
using a filter spotting assay and antibody-
mediated detection of digoxigenin. Each assay 
was done in triplicate and included published SR 
protein-specific positive controls and a bacterial 
neomycin resistance gene-derived RNA as 
negative control. The results are shown in Fig. 
4B-E. SRp40 (Fig. 4B) showed high affinity 
binding to positive control and wild-type exon 
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2B RNA, lower affinity to S73A mutated RNA, 
and base line binding to the negative control 
RNA. This was consistent with the functional 
assays performed with SRp40 and suggested that 
indeed, SRp40 interacted with exon 2B RNA 
and that even though it might interact with 
multiple sites on this piece of RNA, codon-73 
was likely part of a major binding site. SC35 
(Fig. 4C) showed lower affinity binding 
compared to SRp40, but no significant 
difference was seen between binding to the wild-
type or the S73A sequence. This was also 
consistent with the above functional assays. 
Nevertheless, as mentioned earlier, the ESE 
finder program predicted a high score for SC35 
binding to the S73A sequence, though not the 
wild-type sequence. It was conceivable, 
therefore, that SC35 binding to other sites on 
exon 2B masked potential differences at the site 
of codon-73. Alternatively, the site at this codon, 
or its mutation, were irrelevant with respect to 
SC35 binding despite the binding score 
difference assigned to this site by the ESE finder 
tool. Unlike SRp40 and SC35, SRp30c (Fig. 4D) 
had to be activated by an SR protein-free Hela 
S100 extract in order to render it capable of 
interacting with the positive control RNA. 
Nevertheless, even when activated in this way, it 
showed no binding to exon 2B RNA, suggesting 
that exon 2B does not contain a binding site for 
SRp30c. Likewise, no binding was seen to a 
probe representing exon 2A (not shown). The 
results also indicated that the presence of the 
fusion tag on the recombinant proteins did not 
provide for unspecific interaction with exon 2B 
RNA. This latter point was confirmed in assays 
in which the tag alone, with no SR protein 
sequence, was used (Fig. 4E).  
Differential binding of SRp40 to short 
RNAs containing codon-73. The above filter 
binding assays suggested that SRp40 binds to 
exon 2B target RNA and that this binding is 
influenced by the S73A mutation but do not 
positively identify the S73 codon as being part 
of the direct SRp40/RNA interaction. To define 
the binding site more precisely, we finally 
prepared RNA affinity columns containing equal 
amounts of covalently attached wild-type or 
S73A mutated, 22-base RNA sequences and 
used the columns to assess the binding and step-
wise salt elution profile of the respective 
recombinant SR proteins. The results are shown 
in Fig. 5. After washing with 100 mM KCl, 
SRp40 could be eluted from the wild-type RNA 
column with 200-1000 mM KCl, giving positive 
signals on silver-stained polyacrylamide gels. In 
contrast, most of the SRp40 bound to the mutant 
RNA was eluted already with 500 mM KCl (Fig. 
5A). The results suggested that the recombinant 
protein apparently consists of different 
subpopulations that bind RNA with different 
affinities, but that high affinity binding (resisting 
500 mM KCl) was seen only on wild type but 
not mutant RNA. In contrast, SC35 gave similar 
elution profiles from wild-type and mutant 
RNA, suggesting similar affinities of this SR 
protein to the two types of RNAs (Fig. 5B). 
Only minimal amounts of SRp30c could be 
eluted from either of the two RNA columns (Fig. 
5C). We did not, however, test Hela cell extract-
activated SRp30c as we reasoned that the 
presence of the extract might interfere with 
binding on the columns. Figures 5A-C also show 
the elution profiles of the respective proteins 
from a column to which no RNA was coupled. 
While little if any SR proteins could be eluted 
from this column using KCl, stripping with 8 M 
urea eluted a small amount of residual protein 
(particularly SRp40 and SC35), suggesting that 
at least part of the proteins eluted with 8M urea 
from the RNA-containing columns was bound 
non-specifically. As expected, little if any 
SRp30c protein could be eluted from the RNA-
free column (Fig. 5C), and the purified tag alone 
did also not show any binding (not shown). In 
sum, the results are in line with those obtained 
from filter binding assays and suggest that the 
effect of SRp30c on exon 2B skipping is 
mediated either by binding to another sequence, 
or sequences, of Mitf pre-mRNA, or indirectly 
by affecting other genes influencing the exon 
2A/B splice choice. 
 
DISCUSSION 
 
Here we show that an AGC codon of the 
pigment cell transcription factor gene Mitf plays 
a crucial role not only as the codon for a 
functionally relevant phosphoacceptor serine but 
also as a part of an exonic splice enhancer (ESE) 
sequence regulating the alternative splicing of its 
own exon 2B. As shown in Fig. 6, this codon 
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and its surrounding sequence are largely 
conserved throughout vertebrate evolution, and 
so are the respective exon 2A/2B and exon 
2B/intron 2 splice junctions. Nevertheless, 
neither of these splice junctions fully 
corresponds to consensus splice sequences 
(C/AAG▼GUA/GAGU) and hence, they may be 
suboptimal, rendering them particularly 
susceptible to regulation by transacting factors. 
Indeed, we find that splicing of this exon is 
antagonistically regulated by SRp30c on the one 
hand and SF2/ASF, SRp55, SC35 and SRp40 on 
the other. Among the latter, SRp40 binds the 
wild-type ESE sequence more efficiently than 
one containing a codon for a non-
phosphorylatable alanine. 
Interestingly, the opposing effects by 
SRp30c and the other SR proteins on exon 2B 
splicing appear to be independent of the cell 
type or the type of gene (minigene or 
endogenous gene) that we tested. This is in a 
way surprising given that overexpression (or 
knock-downs, for that matter) of these proteins 
would be expected to simultaneously affect the 
splicing patterns of RNAs of many genes, even 
genes encoding other splicing factors. It is 
reasonable to assume, therefore, that the SR 
proteins analyzed in this study all regulate exon 
2B splicing by directly binding Mitf pre-mRNA, 
notwithstanding the fact that we have not so far 
been able to identify an SRp30c binding site 
near the alternative 5’ splice site. In fact, it is 
likely that when ESE/SRp40 interactions are 
weak, SRp30c would guide the splicing 
machinery to the alternative 5’ site and thereby 
favor exon 2A incorporation at the expense of 
still other potential splice events that would skip 
the entire exon 2 (2A and 2B).  In this context, it 
is important to note that all Mitf isoforms, 
regardless of whether expressed from the M-
promoter in melanocytes or additional upstream 
promoters in other cell types, usually contain 
exon 2A. Nevertheless, BAC rescue transgenics 
lacking intron 1/exon 2A have normal eyes and 
are normally pigmented, except for a white belly 
spot, indicating that exon 2A is largely 
dispensible (7).  
ESE mutations can result in both reduced 
or enhanced interactions with specific RNA-
binding SR proteins. As mentioned, the AGC-to-
GCC (Ser-to-Ala) mutation led to a reduced 
binding of SRp40, both predicted by the ESE 
finder informatics tool and confirmed in direct 
biochemical assays. In contrast, the ESE finder-
predicted increase in affinity of the mutated site 
for SC35 could not be substantiated 
biochemically. Nevertheless, SC35 did show 
moderate binding to both the wild-type and the 
mutated ESE sequence, and when 
overexpressed, it increased incorporation of 
exon 2B expressed from minigenes or the 
endogenous gene. Because the predicted binding 
sites for SRp40 and SC35 overlap, it is unlikely 
that both proteins bind simultaneously to this 
site. One might assume, therefore, that because 
of the high avidity of SRp40 to the wild-type 
sequence and the similar avidities of SRp40 and 
SC35 to the mutated sequence, the wild-type 
sequence would preferentially be bound by 
SRp40 and the mutated sequence by either one 
of the two. Hence, if SC35 were expressed at 
higher levels than SRp40, it should be able to 
compensate for the loss of binding of SRp40 on 
the mutated sequence. In fact, in the cells tested, 
some codons showing relatively high SC35 
binding scores (for instance GAC, encoding 
Asp, or AGC, encoding Thr, Fig. 2B) led to 
relatively modest increases in exon 2B 
exclusion, but others (for instance GCC, 
encoding alanine, or UCC, encoding serine, Fig. 
2B) did not show this effect. These findings 
underscore the importance of functionally 
testing predicted ESE sequences and suggest 
that the regulation of splice site choices may 
involve additional factors and mechanisms 
besides the ones shown in the current study.  
Our observations nevertheless suggest a 
straightforward model for the regulation of exon 
2B splicing and hence the portion of MITF 
protein that contains exon 2B and can potentially 
be phosphorylated at serine-73. A high activity 
of SF2/ASF, SRp55, SC35 or SRp40 relative to 
that of SRp30c would favor exon 2B 
incorporation, and conversely, a low activity of 
these proteins relative to that of SRp30c would 
favor its exclusion. In turn, this regulation may 
then affect the balance between cell proliferation 
and differentiation as previous observations 
show that MITF without exon 2B lacks the anti-
proliferative activity that is associated with 
MITF containing exon 2B (20, and unpublished 
observations), and that serine-73 phosphory-
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lation is involved in the regulation of MITF 
protein activity and stability (4,5). This scenario 
suggests the further, intriguing possibility that 
MITF might regulate its own splicing if it were 
somehow capable of influencing the levels or 
activities of splicing factors. Currently, however, 
we have no experimental evidence for this 
possibility.  
Given that the above model of exon 2B 
splicing regulation is entirely based on in vitro 
studies, it is finally important to discuss the 
relevance of our observations for the intact 
organism. In fact, mouse embryos and their 
pigment cells express both exon 2B-containing 
and exon 2B-lacking RNAs, and forced exon 2B 
incorporation throughout development and after 
birth, achieved by targeted mutation of the exon 
2A/B splice junction, results in a pigmentary 
change (Debbache et al., unpublished). 
Nevertheless, targeted mice with partial exon 2B 
exclusion due to sequence changes in the ESE 
identified in our study show little if any 
phenotype in vivo although their isolated 
pigment cells have abnormally high proliferation 
rates in vitro (unpublished observation). Such in 
vitro/in vivo discrepancies, however, are not 
without precedent and suggest the existence of 
compensatory mechanisms that operate 
efficiently only in vivo and that may have been 
selected evolutionarily to safeguard organisms 
against natural fluctuations in gene expression. 
Such compensatory mechanisms might 
eventually be identified using splice-mutants as 
sensitized backgrounds for further mutagenesis 
screens. In sum, the results from our study not 
only suggest additional tests for the in vivo role 
of specific SR proteins but may also lead to 
wider studies exploring the role of alternative 
splicing of Mitf for development and for 
malignancies. 
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FIGURE LEGENDS 
 
Fig. 1. The codon for Mitf S73 regulates exon 2B alternative splicing. A. Schematic representation of 
minigene constructs. Minigenes contain Mitf genomic DNA sequences from exon 1M to exon 3 fused to a 
bovine growth hormone polyadenylation site (BGH-PA) and are placed under the control of a CMV 
promoter. They are either wild type or contain a silent ApaLI site and/or the S73A mutation. The position 
of primers (see text and Supplementary Table S1) used for regular and real time RT-PCR assays are 
indicated. B. Minigene sequences around codon-73 in wild type and the three different mutations. The 
blue box marks the position of where the ApaLI site (GTGCAC) was introduced, and the red box the 
position of the serine-73 or alanine-73 codon. C. Alternative exon 2B splicing in HEK293 cells 
transfected with minigene constructs. RNA was assayed by RT-PCR, using primers a and g. The 345 bp 
band represents the sequence containing exon 2B, and the 177 bp band the sequence lacking exon 2B. 
Beta-actin was used as control.  
 
Fig. 2. A. Effect of the 16 possible permutations of the first two bases of the S73 codon on exon 2B 
splicing after transfection of minigenes into ARPE19 cells. RNA was isolated 24 h after transfection and 
analyzed by RT-PCR, using minigene-specific primers b and g (see Fig. 1A). The bars underneath the gel 
picture indicate the quantitated percentage of exon 2B+/(2B- + 2B+) determined from real time PCR 
results, using primer pairs c/e for exon 2B+ and d/f for exon 2B- (see Fig. 1A). Note that only the wild 
type sequence (AGC) allows for high efficiency inclusion of exon 2B. B. ESE finder scores (version 3.0) 
for each of the 16 permutated sequences for predicted binding of SRp40, SF2/ASF, SC35 and SRp55. 
Values are indicated if they lie above the default threshold scores given by ESE finder for each of the four 
SR proteins. 
 
Fig. 3. A-C. Ectopic expression of SR proteins influences exon 2B splicing in wild-type and S73A 
minigene transfected HEK293 cells. A. Western blot of HEK 293 cells, either untransfected or transfected 
with expression vectors for SRp30c, SC35 or SRp40 and probed with the corresponding specific 
antibodies or the monoclonal antibody MAb104, which recognizes phosphorylated SR proteins. Note that 
both total and phosphorylated (active) SR proteins are expressed at similar levels and above those of the 
endogenous proteins (the endogenous proteins are below the level of detection at the given exposure 
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times). Western blots for β-actin are shown as loading control. B. Top: Representative experiment 
showing effect of expression of indicated SR proteins on exon 2B inclusion. RT-PCR based on using 
primer pair a/g (Fig. 1A). Bottom: Quantitation based on RT-PCR as described for Fig. 2A. Results are 
given as mean and standard deviation based on three independent experiments. Note that SRp30c leads to 
increased exon 2B skipping on both wild-type and S73A mutant minigene-derived RNA, and SC35, 
SRp40, SF2/ASF and SRp55 to an increase in exon 2B incorporation. C. Top/Bottom: Cotransfections 
indicate dominance of SRp40 and SC35 over SRp30c. The respective expression vectors were 
cotransfected along with the indicated minigenes and RNAs were analyzed as for B, Top and Bottom. 
Quantification based on three independent experiments. D. Top: SR proteins influence exon 2B splicing 
of the endogenous Mitf RNA. Wild-type and S73A melanocytes were cotransfected with a GFP 
expression vector and expression vectors for either SRp30c, SRp40 or SC35, sorted for GFP expression 
using a fluorescence activated cell sorter, and RNAs assayed as for B-C. For quantification, the means of 
two independent experiments are shown. Note that similar to the effects on minigene-derived RNA, 
SRp30c favors exon 2B skipping in endogenous Mitf RNAs, and SRp40 and SC35 favor exon 2B 
inclusion. 
 
Fig. 4. Demonstration of RNA/SR protein interactions using filter binding assays. A. SDS/Polyacrylamide 
gel electrophoresis of crude and His-affinity-purified extracts of E.coli expressing SR proteins fused with 
guanylate binding protein and an 8x His tag. Coomassie blue stained gel. B-D. Relative amount of RNA 
bound to the indicated recombinant SR proteins. Digoxigenin-labeled RNA corresponded to wild-type or 
S73A mutated exon 2B (168 bases), corresponding positive control RNAs, or a negative control RNA. 
Filter binding assays performed as described in Experimental Procedures. E. Control binding assay 
performed with purified fusion tag lacking SR protein sequences. 
 
Fig. 5. Affinity chromatography of recombinant SR proteins on RNA columns. Equal amounts of 22-base 
RNAs corresponding to the portion of exon 2B surrounding codon-73 (either wild type or S73A, 
sequences, see Experimental Procedures) were covalently attached to thiol-modified NHS-activated 
Sepharose columns. Control columns were treated similarly but contained no RNA. Purified recombinant 
protein (see Fig. 4A, 10 µg each) was applied and the columns were then washed with binding buffer. 
Proteins were eluted with step-wise increasing KCl concentrations and finally stripped with 8 M urea as 
indicated. An aliquot of the eluates was subjected to SDS/polyacrylamide gel electrophoresis followed by 
silver staining. A. SRp40. Note that even 1M KCl and 8 M urea can elute substantial amounts of residual 
protein bound to the wild type column but not the S73A column, suggesting lower affinity of SRp40 
protein to the mutated sequence. B. SC35 protein. Note similar elution profiles on both columns. C. 
SRp30c protein. Note similarly low level binding to either column. Also note that 8M urea was able to 
elute some residual SR proteins from the non-RNA control column, suggesting that a portion of the 
respective proteins binds non-specifically to the column material. 
 
Fig. 6. Conservation of Mitf exon 2A/2B and 2B/intron 1 splice junctions (marked with inverted triangles 
on top of the mouse sequence) as well as the serine-73 codon (bold) and surrounding sequence in various 
vertebrates. Colored nucleotides mark changes from the mouse sequence. (---) no sequence available. 
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Species 2A-2B Junction 
Ser73 codon and 
surrounding sequence 2B-Intron 2 Junction 
 ▼            Ser ▼ 
Mus musculus CACCAGGUAAAG CCCAACAGCCCUAUGG AAAGAGGUAAUU 
Rattus norvegicus CACCAGGUAAAG CCCAACAGCCCCAUGG AAAGAGGUAAUU 
Cavia porcellus CAGCAGGUAAAG CCCAACAGCCCCAUGG AAAGAGGUAAUU 
Homo sapiens  CAGCAGGUAAAG CCCAACAGCCCCAUGG AAAGAGGUAAUU 
Pan troglodytes CAGCAGGUAAAG CCCAACAGCCCCAUGG AAAGAGGUAAUU 
Pongo pygmaeus CAGCAGGUAAAG CCCAACAGCCCCAUGG AAAGAGGUAAUU 
Macaca mulatta CAGCAGGUAAAG CCCAACAGCCCCAUGG AAAGAGGUAAUU 
Callithrix jacchus CAGCAGGUAAAG CCCAACAGCCCCAUGG AAAGAGGUAAUU 
Canis familiaris CAGCAGGUAAAG CCCAACAGCCCCAUGG AAAGAGGUAAUU 
Felis catus CAGCAGGUAAAG CCCAACAGCCCCAUGG AAAGAGGUAAUU 
Equus caballus CAGCAGGUAAAG CCCAACAGCCCCAUGG AAAGAGGUAAUU 
Bos taurus CAGCAGGUAAAG CCCAACAGCCCCAUGG AAAGAGGUAAUU 
Loxodonta africana CAGCAGGUAAAG CCCAACAGCCCCAUGG AAAGAGGUAAUU 
E. europaeus CAGCAGGUAAAG CCCAACAGCCCCAUGG AAAGAGGUAAUU 
D. novemcinctus CAGCAGGUAAAG CCCAACAGCCCCAUGA ------------  
M. domestica CAACAGGUAAAG CCAAAUAGCCCCAUGG AAAGAGGUAAUU 
O. anatinus CAGCAGGUAAAG CCCAACAGCCCAAUGG AAAGAGGUAAUA 
Gallus gallus CAGCAGGUAAAG CCCAACAGUCCGAUGG AAAGAGGUAAUA 
Anolis carolinensis CAGCAGGUCAAG CCCAACAGCCCCAUGG AAAGAGGUAAGA 
Xenopus tropicalis CAGCAGGUAAAG CCAAACAGUCCAAUGG AAAGAGGUAACU 
Takifugu rubripes CAGCACGUCCGG CCCAGCAGUCCCAAAG AAAGAGGU---- 
Danio rerio CAGCAGGUGAAG CCCAACAGCCCUAUGG AAAGAGGUACAU 
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Supplemental Fig. 1. Effect of ectopic SR protein expression on exon 2B splicing of minigene-derived 
RNA is dose-dependent.  Graded doses of expression vectors for the indicated SR proteins were 
transfected along with a constant amount of the wild-type or S73A minigene into HEK 293 cells. 
Twenty-four hours later, RNA was subjected to regular and real time RT-PCR as indicated in Fig. 3. A. 
Regular RT-PCR. B. Quantitative RT-PCR, showing means from two independent experiments.
Supplemental Fig. 2. Exon 2B splicing of minigene-derived RNA does not depend on concentration 
of transfected DNA. Graded doses of the S73A mutated minigene were transfected into HEK293 cells 
and RNA assayed for exon 2B splicing as indicated for Fig. 3. No significant differences in the relative 
amounts of exon 2B inclusion were seen over a 19-fold concentration range of transfected DNA, 
resulting in a 10-fold difference in levels of Mitf RNA (not shown). Results are given as means from 
two independent experiments.
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Supplemental Table S1: Primer Sequences 
 
 
RT-PCR 
 
 
 
Gene 
 
Comb. 
Code  
Fig 1 
 
 
 
Location 
 
 
 
Sequence 
 
 
 
Product length 
(bp) 
Mitf a Exon 1M-F 5'-CACCATGCTGGAAATGC-3' 
 g Exon 3-R 5’-CTGCATGCACGACGCTCGAGAGTGC-3’ 
2B+ : 345 
2B-  : 177 
     
Mitf b Exon 1M-F 5'-AATTGCCCTCACCATGCTG-3' 
 f Exon 3-R 5'-GACGCTCGAGAGTGCGTGTT-3' 
2B+ : 348  
2B - :180  
     
β-actin N/A β -actin-F 5'-GATGACGATATCGCTGCG-3' 
 N/A β -actin-R 5'-GTGGCCATCTCCTGCTCG-3' 
682 
     
Gapdh N/A Gapdh-F 5'-GCATTGTGGAAGGGCTCATGACC-3' 
 N/A Gapdh-R 5'-CGGCATCGAAGGTGGAAGAGTGG-3' 
386 
 
qRT-PCR 
Mitf c Exon 2A/B-F 5'-AAGCTCAGAGGCACCAGGTAAAG-3' 
 e Exon 2B-R 5'-AGGCTGGTTTGGACATGGTGAG-3' 
2B+ : 81 
2B - : N/A 
     
Mitf d Exon 2A/3-F 5'-GCTCAGAGGCACCAGGCATTTT-3' 
 f Exon 3-R 5'-GACGCTCGAGAGTGCGTGTT-3' 
2B+ : N/A 
2B - : 89 
     
Usf1 N/A Exon5-F 5’-CAGGGCTCAGAGGCACTACT-3’ 
 N/A Exon6 -R 5’-GCTCCCTCCCTGCAATACTT-3’ 
96 
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5 – Une alanine non phosphorylable située au codon 73 de l’isoforme M-
MITF induit un gain de fonction de la protéine MITF in vivo. 
 
Nous avons préalablement montré que le codon de la Serine 73 du gène Mitf est 
implique directement dans la régulation de l’épissage alternatif de l’exon 2B qui contient 
ce site de phosphorylation. Les tentatives de mutation de cette serine de façon endogène 
ou par insertion de transgènes mutants ont pour même effet d’augmenter l’exclusion de 
cet exon. Ceci rend donc difficile la dissociation des rôles potentiellement distincts de la 
phosphorylation de S73 et de l’absence de l’exon 2B dans MITF. Ici, nous avons choisit 
d’étudier l’effet de l’absence de phosphorylation de MITF de façon endogène grâce à 
l’élaboration d’un contexte génétique qui empêche la reconnaissance de la jonction entre 
les exons 2A et 2B comme site potentiel d’épissage et force ainsi l’incorporation de 
l’exon 2B quelque soit la séquence du codon 73. Nous avons ainsi généré 3 nouveaux 
allèles ou l’exon 2B ne peut pas être exclus et comportant à la position 73 soit une Serine, 
soit un Aspartate mimant une phosphorylation constitutive, ou une Alanine. Nous avons 
ensuite comparé les phénotypes de ces 3 lignées de souris à la lignée originelle Mitfmi-S73A. 
Nous avons également croisé ces souris avec d’autres allèles de Mitf en présence ou non 
de la cassette Neo, ce qui permet, lorsqu’elle est présente, d’obtenir une réduction du 
niveau d’expression de Mitf et d’exacerber les différences entre les phénotypes. Nous 
avons ainsi démontré que l’allèle S-S73A non-phosphorylable, lorsque l’exon 2B est 
retenu, présente un gain d’activité par rapport à l’allèle témoin S-S73S. Nous suggérons 
que ce gain d’activité est réalisé grâce à un gain de stabilité de MITF, une augmentation 
Résultats 
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du nombre de melanocytes au cours du développement in vivo et grâce à une réduction de 
l’activité d’inhibition de la progression du cycle cellulaire, mesurée in vitro. 
Les travaux associés à cette étude sont décrits dans l’Article 5. 
 
As earlier described, exon 2B splicing is intrinsically linked to the sequence of the codon 
for residue-73. Therefore, in order to study the role of S73 phosphorylation 
independently of exon 2B exclusion, we chose a strategy to force the incorporation of 
exon 2B regardless of the codon at position 73. This was achieved by additional nucleic 
acid sequence modifications at the 5’ alternative splice site. Like other alternative sub-
exons, exon 2B can either be recognized as part of the following intron (Mitf intron 2 in 
that case), or as part of the preceding exon (exon 2A). One of the critical elements, 
which allows to switch between the two splice sites, lies in the sequence of the junction 
between exon 2A/2B. This sequence must match the 3’ exon/intron consensus 
sequence in order to allow the recognition of this site as a 3’ exon definition site. The 
introduction of mutations that would disrupt the recognition of this site by the splicing 
machinery would then prevent exon 2B exclusion. Hence, to test if, a re-engineered 
splice site, where exon 2B would be included in all Mitf transcripts, would have any 
phenotypic effects on melanocytes, we generated three Mitf knock-in alleles. All three 
alleles contain the 2A-2B exon junction mutations, and differ for residue 73, which either 
encodes, a non-phosphorylatable alanine (S73A), a constitutively phospho-mimetic 
aspartate (S73D) or a wild-type serine (S73S). 
We first demonstrate that the exclusion of exon 2B normally seen in the presence of a 
S73 codon mutation can be converted to a level of 100% of exon 2B incorporation by the 
introduction of the corresponding modifications in a minigene comprising exon 1M-3. 
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Having demonstrated that this is indeed the case, we generated the above mentioned 
mouse lines in order to study the role of M-MITF phosphorylation. 
We then tested the molecular and phenotypic consequences of each allele by 
themselves or in combination with several extant Mitf alleles and find that, perhaps 
surprisingly, the S73S (wild-type) allele acts as a hypomorph, while the S73A and to a 
lesser extent, S73D, act as a hypermorph. The simplest explanation for these findings is 
the fact that S73A protein accumulates to higher levels than S73S, likely because the 
lack of phosphorylation leads to an increased protein stability. 
Interestingly, the S73D protein also shows an increase in protein levels, though less than 
the S73A protein, likely reflecting the fact that a permanent negative charge at this 
position neither reflects the effect on degradation seen with S73S MITF nor the absence 
of phosphorylation of S73A MITF. 
The experimental work related to this study is described in Article 5.  
 
 
 
 
 
 
 
 
 
Article 5 
In vivo role of alternative splicing and serine 
phosphorylation of the microphthalmia-associated 
transcription factor MITF. 
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Abstract 
The basic-helix-loop-helix-leucine zipper transcription factor MITF plays major roles in 
the development and physiology of vertebrate melanocytes and melanoma cells. It is 
regulated by post-translational modifications, including phosphorylation at serine-73, 
which based on in vitro experiments imparts on MITF an increased transcriptional 
activity paired with a decreased stability. Serine-73 is encoded by an alternatively 
spliced exon, exon 2B, which, intriguingly, is preferentially skipped in mice carrying a 
targeted serine-73-to-alanine mutation. Here, we measured the relative abundance of 
exon 2B+ and exon 2B- RNAs in freshly isolated and FACS-sorted wild-type 
melanoblasts and melanocytes and generated a series of knock-in mice allowing forced 
incorporation of either alanine, aspartate, or wild-type serine at position 73. None of 
these knock-in alleles, however, creates a striking pigmentation phenotype on its own, 
but differences between them can be revealed either by a general reduction of Mitf 
transcript levels or in heteroallelic combinations with extant Mitf mutations. In fact, 
compared with straight serine-73 knock-in mice with their relative reduction of 2B+ Mitf, 
forced incorporation of alanine-73 leads to greater increases in MITF protein levels, 
melanoblast and melanocyte numbers, and extent of pigmentation in particular allelic 
combinations. These results underscore, in vivo, the importance of the link between 
alternative splicing and post-translational modifications and may bear on the recent 
observation that exon 2B skipping can be found in metastatic melanoma. 
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Alternative splicing and post-translational modifications are among the major 
mechanisms by which individual genes generate multiple protein products. In fact, 
modern sequencing technologies and proteomic analyses have shown that most if not all 
multi-exon pre-mRNAs give rise to alternatively spliced mature mRNAs (NILSEN and 
GRAVELEY 2010) and that posttranslational modifications modulate the activities of most 
eukaryotic proteins (MANN and JENSEN 2003). In a simple sense, then, the two 
mechanisms are linked as posttranslational modifications depend on the presence of the 
particular exons encoding the modifiable residues or proteolytic cleavage sites. Here, we 
present a mouse model that allows us to probe this link in vivo by separately targeting a 
splice site and a codon for a biologically relevant phosphoacceptor site in the gene 
encoding the pigment cell transcription factor MITF. In fact, pigmentation is particularly 
suitable for such studies as it provides for an easily visible and highly sensitive read-out 
of gene function. 
 MITF, which stands for microphthalmia-associated transcription factor, plays a 
crucial role in the development and function of melanin-bearing pigment cells in skin, eye 
and inner organs (ARNHEITER 2010; ARNHEITER et al. 2006; HODGKINSON et al. 1993). Its 
protein product is a basic helix-loop-helix-leucine zipper transcription factor that 
regulates target gene promoters by binding specific E box sequences as homodimers or 
heterodimers with the related proteins TCFEB, TCFE3 and TCFEC (STRUB et al. 2011). 
Mitf mutations have been found from zebrafish to man and their analyses have 
established that Mitf controls specification, proliferation, death, differentiation and stress 
responses of normal pigment cells and regulates migration, metastasis, and death of 
melanoma cells (ARNHEITER et al. 2006; HOEK and GODING 2010).  
 In vitro experiments have shown that phosphorylation of MITF serine-73 
increases the protein’s transcriptional activity about three-fold (HEMESATH et al. 1998) 
and that serine-73 phosphorylation alone or double serine-73/serine-409 
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phosphorylation lead to polyubiquitination and degradation of MITF (WU et al. 2000; XU 
et al. 2000). To address the question of whether serine-73 phosphorylation plays a role 
in vivo, we have previously generated targeted mice in which codon-73 was changed to 
one encoding alanine-73 which cannot be phosphorylated (BISMUTH et al. 2008). These 
mice had a normally pigmented coat and normal eyes, a finding that was later confirmed 
by using a transgenic bacterial artificial chromosome (BAC) rescue strategy with BACs 
engineered to encode alanine-73 alone or alanine-73 and alanine-409 together (BAUER 
et al. 2009). A complication of these experiments was the fact that the Mitf exon which 
encodes serine-73, exon 2, contains a 5’ alternative splice site that divides it into an 
exon 2A of 20 codons and an exon 2B of 56 codons, the latter including codon-73. This 
arrangement normally leads to a major transcript (at least 90% of total Mitf RNA in skin 
or heart) that contains the entire exon 2, and a minor one in which exon 2B, and hence 
codon-73, is missing although the open reading frame is maintained (BAUER et al. 2009; 
BISMUTH et al. 2008). Interestingly, the codon-73 mutation in both targeted mice and 
BAC transgenics is associated with a substantial decrease of the transcript containing 
exon 2B (only ~10% of total Mitf mRNA in the targeted mice and ~45% in the BAC 
rescue mice), and a concomitant increase of the transcript lacking exon 2B (BAUER et al. 
2009; BISMUTH et al. 2008). This splice change, which is likely due to the fact that codon-
73 is embedded in a splice enhancer sequence whose affinity for the serine/arginine rich 
splice regulator SRSF5 is reduced upon mutation (WANG et al. 2009), precluded 
meaningful conclusions on the specific role of serine-73. In order to separate the 
potential effects of mutations at residue 73 from the splice-dependent absence of this 
residue, we re-targeted Mitf in a way that renders the alternative 5’ splice site non-
functional and incorporates either a wild-type serine, a phosphomimetic aspartate, or an 
alanine at position 73. We find that although the new mutations cause no visible coat 
phenotypes on their own, they sensitize melanocytes to the phenotypic effects of 
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reductions in total Mitf levels and to the effects of extant Mitf alleles in compound 
heterozygotes. Intriguingly, when tested under such conditions, the targeted allele 
containing the wild-type serine behaves as a hypomorph while that containing the 
alanine behaves as a hypermorph. The results show that alternative splicing of exon 2B 
is indeed relevant in vivo, although in an unexpected manner and in a way that would be 
difficult to detect based solely on in vitro experiments. 
 
Material and Methods 
Melanoblast/melanocyte purification and RNA-Seq data 
FVB/N melanocytes were purified by FACS sorting from doxycycline-treated bi-
transgenic mice (iDct-GFP mice) that express H2B-GFP fusion proteins specifically in 
Dct-positive melanocytes, using previously published protocols (ZAIDI et al. 2011a; ZAIDI 
et al. 2011b; ZAIDI et al. 2011c). To purify melanoblasts from E15.5 and E17.5 C57BL/6 
iDct-GFP embryos and P1 pups, the dams were fed doxycycline-fortified chow for the 
entire duration of gestation until harvest. For P3 and P7 pups, doxycycline was injected 
intraperitoneally at 80µg/g body weight 24 hours before harvest. Total RNA was 
prepared from FACS-sorted melanoblasts/melanocytes according to standard Illumina 
RNA-Seq paired-end protocol and then sequenced on the Illumina GAIIx to 80 base 
pairs per read. For analysis of alternative exon 2B splicing, a set of possible splice sites 
was determined and assigned to the aligner, indicating that a given splice variant might 
exist. The sequences were aligned using Genomic Short-Read Nucleotide Alignment 
Program (WU and NACU 2010) to mouse genome assembly mm9. A custom Python 
script was then used to count introns that had one boundary at position 97944374 on 
chromosome 6 (5’ end of exon 3). The analysis revealed that only three splice sites were 
used, one at position 97943348, yielding 2B+ Mitf, one at position 97943180, yielding 
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2B- Mitf, and a single read for one at position 97879927, yielding Mitf with a junction 
between exon H and exon 3.  
Targeting constructs, minigenes and expression plasmids 
The 17.9 kb targeting construct described by Bismuth et al. (BISMUTH et al. 2008) was 
used as template to PCR-amplify a 1.2 kb EcoR1/HindIII-flanked fragment 
encompassing part of intron 1, exon2A/2B and part of intron2/Neo-loxP cassette. The 
PCR-amplified fragment was cloned into pcDNA 3.1 and used for PCR mutagenesis. In 
a first round, the exon 2A/2B junction was altered by changing 4 bases without changing 
the coding sequence. In a second round, the previously introduced ApaLI site was 
changed back to the wild-type sequence and codon A73 was either left intact or was 
changed into one encoding either aspartate or wild-type serine. Sequence-confirmed 
clones for each of the three different codons at residue 73 were digested with AflII and 
AgeI and used to replace the corresponding AflII/AgeI fragment in a 7.5 kb BamH1 
fragment representing the 3’ arm of the original construct. The resulting constructs were 
digested with BamH1 and ligated to a BamHI-linearized construct containing the 
thymidine kinase gene and the 5’ arm of the original construct, yielding three final re-
engineered targeting constructs. The correct orientation of the 7.5 kb BamHI fragment 
was verified by PCR with 2 primer pairs described in Supplemental Table 1. To test for 
the effect of the 5’ splice junction mutation, an Mitf minigene comprising exon 1M, intron 
1, exon 2A/B, intron 2 and exon 3 was subjected to PCR mutagenesis to alter the 5’ 
splice junctions and codon-73 as in the targeting contructs, using Quickchange site-
directed mutagenesis kit (Stratagene). For expression analysis, N-terminal estrogen-
receptor (ER)-coupled Mitf 6a+ pBABE vectors were obtained from Colin Goding 
(CARREIRA et al. 2005) and subjected to PCR mutagenesis to obtain MitfS73A (ER S73A) 
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and Mitf∆2B (ER 2B-) expression plasmids, using a primer set described in Supplemental 
Table 1. All constructs were sequence-verified. 
Mice 
Mice carrying the allele Mitftm1.2Arnh, containing a S73A mutation with or without a floxed 
neo-cassette in intron 2, have been described (BISMUTH et al. 2008). For the purpose of 
this study, Mitfmi-S73A mice from a separate targeting experiment were used and are 
designated Mitftm7Arnh (containing the neomycin resistance cassette) and Mitftm7.1Arnh 
(lacking the neomycin resistance cassette)(MGI:5050706). For targeting the exon 2A/2B 
5’ splice site in conjunction with mutations at serine-73, LC3 ES cells [genotype 
(C57BL/6Nx129S6)F1] were electroporated with 20 µg of the respective NotI linearized 
targeting constructs and grown under standard G418/FIAU selection protocols. After 
screening, targeted ES cells were injected into C57BL/6N blastocysts and chimeric mice 
were bred with C57BL/6J to test for germ line transmission and to establish Neo-
cassette-containing targeted lines. To remove the floxed Neo-cassette, mice were bred 
with C57BL/6•129S4-Prm1-Cre deleter mice. After removal of the neo-casette, mice 
were either intercrossed to obtain homozygous targeted mice or were crossed with mice 
carrying other mutant Mitf alleles. The official designation of these targeted mice are: 
Mitftm4Arnh (MGI:5050700) and Mitftm4.1Arnh (MGI:5050701) for the splice junction/S73 
allele; Mitftm5Arnh (MGI:5050702) and Mitftm5.1Arnh (MGI:5050703) for the splice 
junction/S73A allele; and Mitftm6Arnh (MGI:5050704) and Mitftm6.1Arnh (MGI:5050705) for the 
splice junction/S73D allele, each with or without the Neo-cassette, respectively. 
C57BL/6•129S2 Kittm1Alf (BERNEX et al. 1996) heterozygous males were bred with Mitfmi-
S73A∆neo and Mitfmi-S-S73A∆neo homozygous females. Double heterozygous offspring were 
then crossed with the corresponding Mitf homozygotes to establish E12.5, E15.5 
embryos and P1 pups homozygous for Mitf and heterozygous for Kittm1Alf. Xgal-labeling 
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was done as described (WEN et al. 2010). For generation of melanocyte lines, mice were 
crossed with B6•Cdkn2atm1Rdp mice to obtain double homozygous Mitf/Cdkn2a mutants. 
The bi-transgenic iDct-GFP mice (ZAIDI et al. 2011a) used for RNA-Seq were kept on a 
FVB/N background. 
Reverse transcription, RT-PCR and Real-time (q)RT-PCR, western blots 
Random primed cDNAs were made from 500 ng of total RNA extracted from heart or     
ng extracted from melanocyte lines using High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems) and RNAse inhibitor cocktail (Invitrogen). PCR and qPCR were 
performed as described (BHARTI et al. 2010), using primers described in Supplemental 
Table 1. For western blots, 600 µg of heart tissue or 120,000 cultured cells were 
separated by SDS-PAGE and blotted onto nitrocellulose membranes. The blots were 
exposed to appropriate antibodies and bands were revealed using SuperSignal West 
Pico Chemiluminiscent Substrate. Quantitation was done using a Biorad ChemiDoc 
XRS+ system. 
Genotyping and Southern analysis 
DNA extracted by standard procedures from tissue samples was analyzed by PCR, 
using primers indicated in Supplemental Table 1. For Southern blots, liver DNA was 
prepared, digested as indicated and probed using PCR-amplified probes as previously 
published (BISMUTH et al. 2008). 
Photography 
Photographs of knock-in mice and their intercrosses with other Mitf alleles were taken 
between 3 weeks and 2 months of age. 
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Cell lines stably expressing Mitf proteins 
pBABE-ER vectors allowing expression of HA-tagged exon 6A+ MITF fused with the 
estrogen responsive portion of the estrogen receptor were obtained from Colin Goding 
(CARREIRA et al. 2005). Virus was produced by co-transfection of pBABE vectors and 
pCL Ampho vectors in 293T cells, and ARPE-19 cells (spontaneously immortalized 
human retinal pigment epithelium cells) were infected and selected with puromycin 
(1µg/ml) without subsequent cloning. Stable cell lines were prepared allowing expression 
of only ER (ER- Ø) or MITF-ER with wild-type S73 (ER-WT), S73A (ER-S73A), or 2B- 
MITF (ER-2B-). For induction, cells were treated with 300 nM 4-hydroxy-tamoxifen (TM) 
for 48 hours. Total extracts were probed with 6A5 anti-MITF antibodies (BHARTI et al. 
2008).  
Flow cytometry 
For assaying MITF expression, ARPE19 cells were washed and fixed with 4% 
paraformaldehyde, permeabilized and incubated with mouse monoclonal antibody 6A5 
and R-phycoerythrin-goat anti-mouse IgG1 as second antibody. Flow cytometry was 
performed using a FACSVantage SE flow cytometer (Becton Dickinson) and the data 
processed using CellQuest software. The gating was determined empirically and applied 
in the same way to all experiments.  
 
Results  
Alternative splicing of exon 2B of Mitf in melanocytes 
Previous results have shown that heart and skin of wild-type mice express Mitf splice 
variants that specifically lack exon 2B (BAUER et al. 2009; BISMUTH et al. 2008; 
HALLSSON et al. 2000). To confirm these findings in freshly isolated embryonic and 
postnatal melanocytes, we purified the respective cells by FACS, using the recently 
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described bi-transgenic iDct-GFP mice that allow for tetracyclin-regulated expression of 
a histone H2B-GFP fusion protein in melanoblasts and melanocytes (ZAIDI et al. 2011a; 
ZAIDI et al. 2011b; ZAIDI et al. 2011c). For these experiments, we used wild-type 
embryos at E15.5, E17.5, and postnatal mice at P1, P3 and P7. RNA-Seq of sorted cells 
clearly showed the presence of Mitf RNA. As shown in Fig. 1A, detailed analyses 
revealed that although in all samples the majority of reads across the 5’ alternative splice 
junctions of exon 2 corresponded to the exon 2B-exon 3 sequence, a small subset 
corresponded to the exon 2A-exon 3 sequence. To further confirm these results, we 
subjected RNA from P1 and P3 FACS-sorted cells to real-time RT-PCR as described 
(BHARTI et al. 2008). The results showed a 2B-/(2B- + 2B+) ratio of between 1.85 and 
4.36%. These values were similar to those in passage 10 melanocytes obtained from P2 
mice that were wild-type at Mitf and homozygous for a Cdkn2a targeted null allele used 
to prevent cell senescence (SVIDERSKAYA et al. 2002) (Fig. 1B). In contrast, in 
corresponding melanocytes from P2 skin of Mitf-S73A mutated, Cdkn2a-/- mice (labeled 
S73A in Fig. 1B), the ratio was 90.75%. These results indicate that freshly isolated 
embryonic or postnatal melanocytes or cultured melanocytes express a small amount of 
Mitf mRNAs lacking exon 2B and that a serine-73 mutation substantially increases this 
alternatively spliced transcript.  
 
A targeted mutation in the exon 2A/2B junction of Mitf prevents exclusion of exon 
2B in vitro and in vivo 
As shown in Fig. 2A and Suppl. Fig. 1, the RNA sequence of the alternative 5’ splice 
site, CACCAG’GUAAAG, is close to the consensus splice sequence, 
C/AAG’GUA/GAGU. To ensure efficient inclusion of exon 2B despite codon-73 
mutations, we deliberately mutated this splice site in genomic DNA to yield RNAs with 
the sequence CAUCAA’GUUAAA. The mutation was expected to render the 5’ splice 
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junction non-functional without, however, changing the encoded aminoacid sequence. 
We first tested whether the mutation would function in the intended way in a minigene 
construct that comprised exon 1M-exon 3 of Mitf. Upon transfection into heterologous 
cells, this construct normally recapitulates the alternative exon 2B splicing and its 
dependence on the sequence of codon-73. When both the 5’ splice junction and codon-
73 were mutated, however, only exon 2B+ RNA and no aberrant splice products were 
produced in vitro (not shown). We then prepared 3 separate targeting constructs that 
carried the same splice mutation along with a codon for either wild-type serine, 
aspartate, or alanine (Fig. 2A; for details, see Materials and Methods). After 
electroporation into embryonic stem cells, three lines of targeted mice designated Mitfmi-
S-S73S, Mitfmi-S-S73A and Mitfmi-S-S73D (S-S for splice site and serine-73) were obtained and 
characterized by Southern blot analysis (Fig. 2B,C) and by sequencing (not shown). 
Together with Mitfmi-S73A mice, which do not carry the 5’ splice site mutation, we 
established eight separate lines, four of them containing a floxed neomycin resistance 
cassette in intron 2 (see Fig. 2A), and four corresponding ones in which this cassette 
was removed by breeding with Prm1-Cre deleter mice.  
 For RNA analyses, we first used heart tissue because heart expresses relatively 
high levels of Mitf RNA and, unlike melanocytes, is not altered in a major way by Mitf 
mutations. RT-PCR analyses showed the presence of both exon 2B+ and exon 2B- RNA 
in wild-type mice; the predominant lack of exon 2B in mice homozygous for the Mitfmi-
S73AΔneo allele; and the exclusive presence of exon 2B in hearts of mice homozygous for 
either of the three 5’ splice-mutant alleles [regular RT-PCR in Suppl. Fig. 2A, qRT-PCR 
(BHARTI et al. 2010) in Suppl. Fig. 2B]. Total levels of Mitf RNAs, averaged from 
quantitative RT-PCR analyses using primers for exon 6-7 and 8-9 (Suppl. Table 1), were 
similar to wild type in the mutants in which the neo cassette has been removed (Suppl. 
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Fig. 2C). In order to determine RNA levels in mice in which the neo cassette was left 
intact, we used primers specifically covering the mutated exon 2 region to avoid 
measuring aberrant RNAs potentially starting from the neo cassette. The results showed 
that when the neo cassette was present, Mitf RNAs containing part or all of exon 2 were 
reduced by ~50-75% (Suppl. Fig. 2D). Immunoprecipitation/immunoblotting assays of 
hearts of the different mutants indicated that Mitfmi-S73AΔneo mice produced MITF protein 
with a faster electrophoretic mobility, consistent with the predominant expression of 
MITF lacking exon 2B in such mice (Suppl. Fig. 2E). In contrast, the different S-S73 
mutants all produced predominantly full-length MITF protein, but their relative expression 
levels differed. Compared to Mitfmi-S-S73SΔneo mice, the levels were approximately 1.3 fold 
higher in Mitfmi-S-S73DΔneo and 1.6 fold higher in Mitfmi-S-S73AΔneo mice, suggesting that the 
particular residue at position 73 influences protein stability (Suppl. Fig. 2E).  
 To determine RNA and protein expression specifically in melanocytes, we then 
tested above described Mitf+/Mitf+;Cdkn2a-/- and Mitfmi-S73AΔneo/Mitfmi-S73AΔneo;Cdkn2a-/- 
melanocyte lines as well as a corresponding line derived from P2 skin of Mitfmi-S-
S73AΔneo/Mitfmi-S-S73AΔneo;Cdkn2a-/- mice. RT-PCR assays showed a predominent band 
representing the Mitf 2B+ transcript in wild type, a double band representing the Mitf 2B+ 
and Mitf 2B- transcripts in Mitfmi-S73AΔneo lines, and a single band representing the Mitf 
2B+ transcript in Mitfmi-S-S73AΔneo lines (Fig. 3A). As schematically depicted in Fig. 3B, 
MITF protein can undergo numerous post-translational modifications in melanocytes and 
other cell types, including phosphorylations, sumoylations and caspase cleavage. These 
modifications may lead to proteins with distinct electrophoretic mobilities on western 
blots. In fact, as shown in Fig. 3C, wild-type melanocytes showed the characteristic 
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double band of MITF protein representing S73-phosphorylated and S73-non-
phosphorylated, exon 2B+ protein. Mitfmi-S73AΔneo lines showed a more complex picture as 
based on electrophoretic mobilities, there was a band corresponding to non-
phosphorylated MITF 2B+ and one corresponding to MITF 2B-. In contrast to the relative 
amounts of the respective transcripts, however, the MITF 2B+ protein band was more 
prominent than the MITF 2B- protein band. This observation suggests that compared to 
the wild-type full-length protein, either non-phosphorylated full-length MITF is more 
stable or internally truncated MITF less stable, provided exon 2B+ and exon 2B- mRNA 
share equal translational efficiency. In addition, Mitfmi-S73AΔneo lines showed one band of 
lower and one of higher electrophoretic mobility (marked with arrows in Fig. 3C) that may 
represent differently modified or cleaved products. Mitfmi-S-S73AΔneo lines showed a single 
RT-PCR product corresponding to the Mitf 2B+ transcript and a simpler western blot 
signal with a prominent band corresponding to non-phosphorylated MITF 2B+ protein 
and one band each of higher and lower electrophoretic mobility (arrows), again 
potentially representing differently modified or cleaved products. Quantitation of the 
western blot bands revealed that Mitfmi-S73AΔneo and Mitfmi-S-S73AΔneo cells had higher MITF 
levels than the corresponding wild-type cells (Fig. 3C), consistent with the notion that 
lack of phosphorylation at residue 73 may increase accumulation of full-length MITF 
because of increased protein stability.  
 
Genetic dissection of pigmentation phenotypes associated with the targeted 
mutations 
To determine the phenotypic consequences of the above mutations, we performed 
extensive breeding tests. First, we generated mice containing the neomycin resistance 
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cassette that were either homozygous for the four targeted Mitf alleles or were 
compound heterozygotes with any of three extant Mitf alleles: Mitfmi-vga9, which is a null 
allele due to insertion of a transgene array in the M-Mitf promoter (HODGKINSON et al. 
1993); MitfMi-wh, a semidominant allele characterized by a Ileu212-to-Asn mutation in the 
DNA-binding basic domain (STEINGRÍMSSON et al. 1994); and Mitfmi, a semi-dominant 
allele characterized by the lack of an Arg in a row of four Arg in the basic domain 
(STEINGRÍMSSON et al. 1994). The targeted homozygotes showed normal eyes and 
normal pigmentation in coat, ears, and feet except for a white belly spot, which on 
average was largest in Mitfmi-S-S73SNeo but almost always absent in Mitfmi-S-S73ANeo mice 
(Fig. 4A-D). Similar phenotypic differences between the targeted alleles were seen in 
compound heterozygotes with Mitfmi-vga9. While Mitfmi-vga9/Mitf+ mice are normally 
pigmented (Fig. 4E) and Mitfmi-vga9/Mitfmi-vga9 mice totally white and microphthalmic, the 
compound heterozygotes showed various extents of white spotting whereby Mitfmi-S-
S73ANeo/Mitfmi-vga9 mice had the smallest areas of white coats; Mitfmi-S-S73SNeo/Mitfmi-vga9 mice 
were almost completely white; and Mitfmi-S73ANeo/Mitfmi-vga9 and Mitfmi-S-S73DNeo/Mitfmi-vga9 
mice were intermediate (Fig. 4F,G,I,J). In contrast, no such differences between the 
targeted alleles were seen in combination with MitfMi-wh as all mice had a fawn coat with 
white spots of similar sizes (Supplemental Figure 2A). Only rarely did we observe small 
black spots in these mice that may reflect somatic loss-of-function mutations in the 
dominant-negative MitfMi-wh allele (an example shown in Supplemental Fig. 2A for Mitfmi-S-
S73ANeo/MitfMi-wh). We also saw no major codon-73-dependent differences in combinations 
with Mitfmi as all mice were totally white except for small black spots that appeared in 
highest frequency and sizes in Mitfmi-S-S73ANeo/Mitfmi mice but were always absent in Mitfmi-
S-S73SNeo/Mitfmi mice (Supplemental Fig. 2B). These results indicate that in alleles 
containing the neomycin resistance cassette, the presence or absence of exon 2B and 
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the phosphorylatability or permanent negative charge of residue-73 are associated with 
phenotypic differences that are, however, only seen in particular allelic combinations.   
In a second round of breedings, we used mice lacking the neomycin cassette to 
generate targeted homozygotes or compound heterozygotes as above. As shown in Fig. 
4K-N, homozygotes were all normally pigmented regardless of the splice and serine-73 
mutations. In contrast, phenotypic differences between the different targeted Mitf alleles 
were seen in combination with MitfMi-wh (Fig. 4O-R). Compared with MitfMi-wh/Mitf+ 
littermates, both Mitfmi-S73AΔneo/MitfMi-wh and Mitfmi-S-S73AΔneo/MitfMi-wh mice had a 
considerably darker coat, yet they still carried white belly spots typical of the presence of 
the MitfMi-wh allele. However, the coat was only slightly darker in Mitfmi-S73DΔneo/MitfMi-wh 
mice, and Mitfmi-S73SΔneo/MitfMi-wh mice were phenotypically indistinguishable from MitfMi-
wh/Mitf+ mice (Fig. 4O-R). Because it was theoretically possible that the presence of 
MITF protein that cannot be phosphorylated at residue 73 might influence the 
phosphorylation status of the MITFMi-wh protein and so influence the stability and 
dominant-negative activity of the latter, we also performed 
immunoprecipitation/immunoblot assays of heart tissues of the different allelic 
combinations. As shown in Suppl. Fig. 2F, however, there was no clear indication for a 
change in phospho-MITFMi-wh as the bands in Mitfmi-S73AΔneo/MitfMi-wh hearts (lane 5) 
appeared as the sum of those seen in Mitfmi-S73AΔneo/Mitfmi-S73AΔneo (lane 3) and MitfMi-wh/ 
MitfMi-wh (lane 8) hearts. Furthermore, none of the targeted alleles showed any 
differences in combinations with Mitfmi-vga9 or Mitfmi (Supplemental Fig. 2C,D). These 
results again indicate that phenotypic differences between the different targeted alleles 
can be revealed only in particular allelic combinations.  
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Melanoblast and melanocyte accumulation is differently affected by Mitfmi-S73A and 
Mitfmi-S-S73A 
The darker coat associated with the presence of the serine-73-to-alanine mutated MITF 
protein in MitfMi-wh compound heterozygotes could be explained by the accumulation of a 
greater number of melanoblasts and melanocytes in the corresponding mice. The 
availability of Kittm1Alf, a Kit null allele characterized by the insertion of a bacterial lacZ 
gene in exon 1 of Kit, allowed us to specifically and reliably label melanoblasts during 
development. In fact, previous results have shown that the nuclear βGAL produced by 
Kittm1Alf is not affected by Mitf mutations, at least not in melanoblasts (HOU et al. 2000). It 
needs to be kept in mind, however, that Kittm1Alf/Kit+ mice have white feet, tail tips and 
belly spots as only two fully functional Kit alleles allow for completely normal melanoblast 
development. Hence, the use of Kittm1Alf gave us the added opportunity to compare the 
phenotypic effects of the different targeted Mitf alleles in conjunction with a separate 
mutation affecting melanogenesis. Intercrosses showed, however, that homozygosity for 
Mitfmi-S73A and Mitfmi-S-S73A did not grossly change the Kittm1Alf/Kit+ phenotype except that 
on average, the belly spots seemed slightly larger with both Mitf alleles. We then 
harvested corresponding E12.5 and E15.5 embryos as well as P1 skin and subjected the 
specimens to Xgal labeling (Fig. 5). At E12.5, in a representative area around the 
developing eye, Kittm1Alf/Kit+;Mitfmi-S-S73A/Mitfmi-S-S73A embryos showed similar numbers of 
Xgal-labeled cells as Kittm1Alf/Kit+;Mitfmi-S73A/Mitfmi-S73A embryos. At E15.5 and P1, 
however, representative areas showed slightly, but significantly higher numbers of 
labeled cells in Kittm1Alf/Kit+;Mitfmi-S-S73A/Mitfmi-S-S73A compared to Kittm1Alf/Kit+;Mitfmi-
S73A/Mitfmi-S73A mice. This was also reflected in the number of labeled cells in pigmented 
hair follicles in a representative dorsal area between the forelimbs. The results suggest 
that the absence of the entire exon 2B, and the selective absence of a phosphorylatable 
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residue at position 73, affect the accumulation of melanoblasts and melanocytes 
differentially. The findings are consistent with the facts that the presence of the S-S73A 
allele in some allelic combinations leads to decreased sizes of white spots (or increased 
numbers of pigmented spots) compared to mice carrying the S73A allele (see Fig. 4A,B; 
F,G; Suppl. Fig 2B). 
 Because Mitfmi-S73A is a complex allele, giving rise to both exon 2B- as well as 
exon 2B+ protein (see Fig. 3G), we finally assessed what the separate effects of each of 
these two isoforms might be in cells in culture. For this, we used ARPE19 cells, which 
are spontaneously immortalized human retinal pigment epithelial cells that are low in 
endogenous MITF and yet are derived from a pigmented cell type, and infected them 
with retroviral vectors expressing either (wild-type) MITF 2B+ (as derived from the Mitfmi-
S-S73S allele), MITFS73A or MITF∆2B proteins, each fused with the estrogen-responsive 
portion of the estrogen receptor (ER) (termed ER WT, ER S73A and ER 2B- in Fig. 6). In 
such cells, MITF proteins normally are found in the cytoplasm at relatively low levels but 
accumulate at high levels in nuclei after tamoxifen induction. In fact, western blots 
revealed the expected MITF bands and electrophoretic mobilities after tamoxifen 
induction (Fig. 6A). The cells were then subjected to flow cytometry, using two-color 
fluorescence labeling for MITF protein expression and total DNA content (DAPI) for cell 
cycle analysis. As shown in Fig. 6B, 48 hours of tamoxifen induction increased the 
percentage of gated cells showing above-threshold levels of MITF protein. Intriguingly, 
wild-type MITF-expressing cells showed distinct MITFlow and Mitfhigh populations, 
whereas MITFS73A and MITF∆2B expressing cells had a distinctly lower MITFlow 
population. This suggested that the MITFlow population was generated by a net reduction 
of MITF by degradation of the S73-phosphorylated form of MITF. As shown in Fig. 6C, 
tamoxifen induction of the different MITF isoforms had differential effects on DNA 
content of cells. While there was little change when the tag alone and no ectopic MITF 
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was present, wild-type MITFhigh cells showed a decrease in the percentage of cells in S 
phase and an increase in the percentage of cells in G0/G1 48 hours after tamoxifen 
induction. In contrast, the percentage of MITFS73Ahigh and MITF∆2B-high cells in S-phase 
was increased, rather than decreased, after tamoxifen induction, though less 
prominently with MITF∆2B compared to MITFS73A. This in vitro analysis with heterologous 
cells and overexpressed, cDNA-derived inducible proteins suggested that wild-type 
MITF has antiproliferative activities but that the lack of exon 2B, or the absence of 
phosphorylation at residue 73, have no such antiproliferative activity. The results confirm 
earlier findings with an S73A mutated protein analyzed in different cells (BISMUTH et al. 
2005) and are consistent with the in vivo genetic observations that the relative increased 
accumulation of non-phosphorylatable MITF protein leads to increased 
melanoblast/melanocyte numbers, increases in the size and extent of pigmentation in 
certain heteroallelic combinations, and increased ability to compensate a strong 
dominant-negative allele, MitfMi-wh.  
 
Discussion 
Numerous in vitro assays have shown that MITF is regulated by post-translational 
modifications, which in turn depend on the presence of the exons carrying the modifiable 
residues. Nevertheless, among the many spontaneous and induced Mitf mutations from 
zebrafish to man, few have been found so far to affect splicing or a specific post-
translationally modifiable residue. This is not surprising given the fact that, for instance, 
targeted mutations in the serine-73 phosphoacceptor site as described here, along with 
those used in BAC transgenic rescue strategies (BAUER et al. 2009), produce little if any 
phenotypes on their own. It is only in conjunction with additional perturbations, such as 
the reduction in overall Mitf RNA levels or the combination with other Mitf alleles, that we 
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start to see the effects of mutations in serine-73, or, in addition, the subtle differences 
between a serine-73 mutation and the lack of the entire exon carrying serine-73.  
Our analysis of the phenotypes produced by the targeted alleles benefited from 
the wide dynamic range of pigmentation and from the fact that the targeted mutations 
were produced in the endogenous gene rather than in BACs. Targeting the endogenous 
gene allows for a direct comparison between the different lines as their transcript levels 
are all similar to wild-type. In contrast, Mitf BAC transgenic lines show variable RNA 
expression levels (BAUER et al. 2009) likely due to the fact that the available BACs do 
not contain the entire 214 kb Mitf gene and so may lack the boundary elements 
necessary for sufficient insulation from neighboring sequences encountered at random 
transgene insertion sites. Comparable RNA expression levels were all the more 
important because the task was to evaluate the effects of mutations that may affect the 
stability of the mutated proteins. It has been shown in vitro that serine-73 mutated MITF 
has a similar activity on a test target gene promoter as non-phosphorylated wild-type 
MITF, but a lower activity when compared to phosphorylated wild-type MITF (HEMESATH 
et al. 1998). In subsequent in vitro experiments, it was reported that S73A singly 
mutated MITF or S73A/S409 doubly mutated MITF have an increased stability. Hence, it 
became important to determine whether there might be similar increases in the stability 
of mutated MITF protein in vivo, and whether a possible reduction in transcriptional 
activity was compensated for by increased protein stability.  
The simplest explanation for all genetic results presented in this paper is indeed 
an increased stability of the mutated proteins. First, we find that both in an unrelated 
tissue, the heart, and in melanocytes, S73A mutated MITF accumulates to higher levels 
than corresponding wild-type MITF. Interestingly, in heart, S73D mutated MITF 
accumulates to levels intermediate between those in S73A and S73S mutated MITF, 
reflecting the intermediate phenotype that the Mitfmi-S-S73D allele produces in some allelic 
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combinations. This suggests that a permanent negative charge at residue-73 neither 
reflects fully the properties of serine-73 phosphorylated MITF nor those of residue-73 
non-phosphoryated MITF. Second, homozygotes for the mutations with wild-type 
transcript levels are all fully pigmented. Third, the two mutations resulting in MITF that 
cannot be phosphorylated at residue 73 (Mitfmi-S-S73A∆Neo and Mitfmi-S73A∆Neo) are capable of 
partially compensating the effects of the strongly dominant-negative MitfMi-wh allele. 
Fourth, when the Mitf RNA expression levels of the neo-cassette-containing alleles were 
further reduced in compound heterozygotes with the null mutant Mitfmi-vga-9, MITFS73A-
expressing mice, with the lowest RNA levels, produced the most extensive pigmentation, 
and MITFS73S-expressing mice, with higher RNA levels, the least amount of 
pigmentation. Fifth, in vitro, both MITFS73A and MITF∆2B have milder anti-proliferative 
effects than corresponding wild-type MITF, or they may even stimulate cell proliferation 
given the non-limiting amounts of growth factors to which cultured cells are normally 
exposed. Nevertheless, despite this in vitro finding, the number of melanocytes found 
postnatally in vivo is not substantially different in mutants compared to wild type. This is 
likely due to the fact that only excess amounts of growth factors such as KIT ligand or 
endothelin-3 would allow for prolonged survival of supernumerary melanocytes in vivo.  
The above observations imply that increased accumulation of the mutated MITF 
proteins may not only compensate for the reduction of their activities observed in vitro, 
but may even over-compensate such activity reductions. This underscores the in vivo 
importance of post-translational modifications that would seem to allow for precise 
regulation of the activities of MITF. The results presented in this paper also imply that 
MITFS73A and MITF∆2B have slightly different effects in vivo. Although Mitfmi-S73A can 
produce both full-length and exon 2B-deleted MITF, and although the full-length 
MITFS73A protein may be relatively more stable than the internally truncated one, Mitfmi-
S73A and Mitfmi-S-S73A mice still differ slightly in melanoblast/melanocyte numbers when 
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they are counted during development and postnatally, or in extent of pigmentation in the 
adult if RNA levels are reduced below a threshold amount by presence of a neo cassette 
in combination with the Mitf null allele Mitfmi-vga9. Although subtle differences in the total 
levels of MITF may explain these variations, it is equally plausible that exon 2B has 
additional functions besides simply providing the substrate for serine-73 
phosphorylation. In fact, it is conceivable that wild type MITF, MITFS73A and MITF∆2B 
differentially stimulate their target genes. This may be important when considering allele-
specific genetic interactions of Mitfmi-bws, an Mitf allele with an exon 2B splice bias but low 
RNA levels and a wild type serine-73 (WEN et al. 2010). It may also be important to 
explain the recent finding that human MITF∆2B, when used to rescue pigmentation in 
zebrafish with a temperature-sensitive mutation in mitfa, leads to increased divisions of 
differentiated, pigmented cells (TAYLOR et al. 2011). Moreover, it may become important 
to explain the recent finding that a melanoma metastasis carries a somatic mutation at 
the downstream exon 2B splice junction that leads to elimination of exon 2B (CRONIN et 
al. 2009). Although alterations in MITF may be only one among many pathways whose 
changes allow for differentiated cells or melanoma cells to escape normal control of cell 
proliferation, it may well be that MITF splice alterations, genomically fixed or dynamically 
regulated, provide for both efficient and precise modulation of melanocyte or melanoma 
physiology.  
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Figure Legends 
Figure 1. Detection of Mitf isoforms in melanocytes in vivo. (A) GFP positive 
melanoblasts from bi-transgenic (iDct-GFP) embryos and postnatal pups of the indicated 
ages were isolated and subjected to sorting by FACS. Corresponding RNA-seq data 
were analyzed as described in Materials and Methods. The ratios of the reads across 
exon 2A/exon 3 and exon 2B/exon 3 [2B-/(2B- + 2B+)] as well as the total number of 
reads analyzed are shown. (B) The relative abundance of Mitf 2B+ and Mitf 2B- RNA 
prepared from in vivo isolated P1 and P3 melanocytes, expressing GFP and FACS-
sorted as for (A), was determined by qRT-PCR using the appropriate primer pairs 
(Suppl. Table 1). In addition, RNA from melanocyte cell lines derived from either 
B6•Cdkn2a-/-;Mitf+/Mitf+ and B6•Cdkn2a-/-;Mitfmi-S73A/Mitfmi-S73A P1 dorsal skins and 
cultured for 10 passages served as controls. The calculated percentages correspond to 
the ratio of 2B-/(2B- + 2B+). 
 
Figure 2. Generation of four knock-in Mitf alleles. (A) Schematic representation of the 
Mitf genomic structure and the mutations generated in Mitfmi-S73Aneo [previously described 
(BISMUTH et al. 2008) and re-targeted for the purpose of this study] and in the three 
novel splice alleles. Sequence modifications at the exon 2A-2B junction as well as at the 
S73 codon are highlighted in red, and the position of the neomycin resistance cassette in 
intron 2 is shown. (B,C) Differential restriction profile of the Mitf locus before and after 
targeting and Southern blot analysis of wild-type and one line each of homozygous 
targeted mice. DNA was digested as indicated and probed with the respective 5’ and 3’ 
probes shown in (B).  
 
Figure 3. Mitf exon 2B alternative splicing profile at the RNA and protein level in 
melanocyte lines. (A) RNA extracts were prepared from passage 10 Cdkn2a-/- 
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melanocyte lines from wild-type B6, Mitfmi-S73A∆Neo (S73A) and Mitfmi-S-S73A∆Neo (S-S73A) 
mice and subjected to RT-PCR. (B) Schematic diagram of select prost-translational 
modifications of MITF seen in melanocytes and other cell types. Indicated are 
phsophorylation, sumoylation and caspase cleavage sites, while sites for acetylation, 
ubiquitination and other modificatiions are not shown. (C) Western blots of protein 
extract of the cell lines used in (A), probed with 6A5 anti-MITF antibodies. The double 
band seen in the wild-type sample corresponds to phosphorylated and non-
phosphorylated exon 2B+ MITF. Mitfmi-S73A cells show both a minor band corresponding 
to 2B- MITF and a major band corresponding to 2B+ MITF, in addition to a band of 
higher molecular weight and one of lower molecular weight (arrows). Mitfmi-S-S73A cells 
show a predominant 2B+ MITF band and no 2B- MITF band. Also, there is a band of 
higher molecular weight and one of lower molecular weight (arrows). MITF quantification 
relative to the endogenous β-Tubulin is indicated below the gel. 
 
Figure 4. Phenotypes associated with the four knock-in alleles alone and in combination 
with extant Mitf alleles. (A-J) Controls and neo-cassette-containing lines. (A-D) White 
belly spots found in homozygotes of the indicated genotypes. Note that Mitfmi-S-S73A 
homozygotes show no belly spot, in contrast to the other lines. (E) Mitfmi-vga9 
heterozygotes show no pigmentary phenotype while (H) Mitfmi-vga9 homozygotes are 
completely white and microphthalmic. (F,G,I,J) Heteroallelic combinations with Mitfmi-vga9.. 
Note different degrees of white spotting with the different targeted alleles. (K-R) Lines 
lacking the neo cassette (∆Neo). (K-N) Regardless of the genotype, all homozygotes are 
normally pigmented and indistinguishable by visual inspection from wild-type B6 mice, 
except that Mitfmi-S73A∆Neo/Mitfmi-S73A∆Neo mice have a tail with generally lighter 
pigmentation compared to the other genotypes. (O-R) Heteroallelic combinations with 
MitfMi-wh. Note the darker pigmentation seen in combinations with either Mitfmi-S73A∆Neo or 
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Mitfmi-S-S73A∆Neo compared to combinations with Mitfmi-S-S73D∆Neo, which yield mice with a 
coat that was only slightly darker, and combinations with Mitfmi-S-S73S∆Neo, which yield mice 
that are indistinguishable from MitfMi-wh/Mitf+ heterozygotes. Each photograph in O-R 
represents littermates. 
  
Figure 5. Melanocyte numbers in developing embryos. Embryos homozygous for either 
Mitfmi-S73A∆Neo or Mitfmi-S-S73A∆Neo and heterozygous for Kittm1Alf were Xgal-labeled and blue 
cells counted in selected regions at E12.5, E15.5 and in P1 skin and P1 pigmented hair 
follicles. Numbers from 7-10 fields from at least three embryos are shown relative to 
those observed in Kittm1Alf/Kit+ control samples. Statistical significance (2 tailed unpaired 
t-test) is indicated (* p<0.1; ** p<0.01; *** p<0.001).  
 
Figure 6. Effects of the S73A mutation and exon 2B deletion on protein levels and DNA 
content in stable cell lines inducibly expressing MITF. ARPE-19 cells expressing either 
pBABE-ER (ER- Ø), MITF wild-type S73 (ER-WT), MITF S73A (ER-S73A), or MITF 2B- 
(ER-2B-) proteins were treated with 4-OH-tamoxifen (Tm) for 48h before collection, and 
total extracts were probed with 6A5 anti-MITF antibodies. Wild-type MITF expressing 
cells show the characteristic double band of S73-phosphorylated and non-
phosphorylated MITF protein, S73A-MITF expressing cells only one band corresponding 
to non-phosphorylated MITF, and 2B- MITF-expressing cells a single band 
corresponding to the 2B- isoform. (B,C) ER-MITF and ER-only (ER- Ø) expressing 
ARPE-19 cell lines were incubated with or without 4-OH-tamoxifen, harvested after 48 
hours, and labeled for MITF and DNA content, using DAPI. (B) Flow cytometric analysis 
displays the percentage of cells expressing relatively low (L) or high (H) MITF intensity 
and (C) their relative cell cycle stages based on DNA content. Gating was determined 
empirically and applied equally for all samples. 
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Supplemental Figure 1. Sequence changes at the 5’ alternative splice site and codon-
73. The exon 2A-2B junction closely matches the exon-intron consensus motif required 
for recognition by the spliceosome. Multiple nucleotide changes were made in order to 
alter this conserved motif while keeping the encoded protein sequence unchanged. In 
parallel, codon-73 was changed as indicated and the ApaL1 site present in Mitfmi-S73A 
was reverted to the wild-type sequence in the novel splice-mutant alleles.  
 
Supplemental Figure 2. (A) cDNA generated from hearts of wild-type and homozygous 
knock-in mice were amplified using a primer pair across exons 2A and 3. Wild-type B6 
cDNA (first lane) shows predominantly the 2B+ isoform while Mitfmi-S73A cDNA (second 
lane) shows predominantly the 2B- isoform and cDNAs of each of the splice mutant lines 
only the 2B+ isoform. Quantification by qRT-PCR, using appropriate mutant-specific 
primer pairs (see Supplemental Table 1) is shown in (B). (C) qRT-PCR of heart Mitf RNA 
from homozygotes carrying the indicated alleles after removal of the neo cassette. The 
results averaged from using primers spanning exon 6B-7 and 7-8 junctions are given 
and compared to those obtained from wild-type B6 and Mitfmi-S73A∆neo/Mitfmi-vga9 mice, the 
latter known to express no Mitf RNA from the Mitfmi-vga9 null allele. The measurements 
showed no statistically significant changes in Mitf expression levels in the knock-in mice 
compared to wild type. (D) Effect of the neo cassette on Mitf expression in heart. The 
expression levels of Mitf 2B- in Mitfmi-S73ANeo mice and Mitf 2B+ in Mitfmi-S-S73ANeo, Mitfmi-S-
S73DNeo and Mitfmi-S-S73SNeo mice (Neo) was compared to those of the corresponding mice 
lacking the neo cassette (∆Neo). The results show a reduction of 50% to 75% of Mitf 
expression in Neo-containing alleles. (E) MITF protein expression in heart tissue. Whole 
protein extracts were immunoprecipitated with a rabbit-anit-MITF serum from wild-type, 
Mitfmi-vga9/Mitfmi-vga9 and ∆Neo knock-in mice, subjected to SDS-polyacrylamide gel 
electrophoresis, and probed with 6A5 antibodies, which recognize the C-terminal part of 
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MITF protein. Mitfmi-S73A hearts show a band corresponding to exon 2B- MITF in addition 
to possible degradation products and a background band representing IgG (arrows). 
Heart extracts from mice homozygous for the 3’ splice mutation each show a major band 
corresponding to exon 2B+ MITF. Their expression levels relative to the internal β-
Tubulin control and S-S73S as reference are shown below the gel. The S73A sample 
was not quantified because of the overlap of some MITF isoforms with the background 
IgG band. (F) Western blots of heart extracts of various mutants and their combinations. 
Protein extracts were prepared an d processed as for (E). Alleles and allelic 
combinations are as indicated. Note MITF 2B+ phospho and non-phospho form in wild 
type (lane 1), absence of MITF in Mitfmi-vga-9 homozygotes (lane 2), and absence of MITF 
2B+ phospho form in Mitfmi-S73A∆neo homozygotes. Arrows indicate a band corresponding 
to IgG heavy chain.  
 
Supplemental Figure 3. Additional phenotypes associated with heteroallelic 
combinations between the targeted and extant Mitf alleles. The genotypes of the 
depicted mice are indicated. Note that in combinations with MitfMi-wh, all four targeted 
alleles containing the Neo cassette produce a similar lightly tanned coat and variably 
sized white belly spots (A). In combination with Mitfmi, the mice become largely white 
with small black spots that are most frequent with Mitfmi-S-S73Aneo and totally absent in 
Mitfmi-S-S73Sneo (B). (C,D) No phenotypic distinctions are seen in heteroallelic combinations 
with Mitfmi or Mitfmi-vga9 once the neo cassette has been removed, except for Mitfmi-
S73A∆Neo/Mitfmi, Mitfmi-S-S73S∆Neo/Mitfmi, and Mitfmi-S-S73S∆Neo/Mitfmi-vga9 mice, which displayed 
variable, though more extensive depigmentation of the tail tip compared to normal 
C57BL/6 mice. 
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Wild Type :  CACCAG GTAAAG-----AGCGCACCCAACAGCCCT
S73A :           CACCAG GTAAAG-----AGTGCACCCAACGCCCCT
S-S73A:        CATCAA GTTAAA-----AGCGCACCCAACGCCCCT
S-S73D:        CATCAA GTTAAA-----AGCGCACCCAACGACCCT
S-S73S:         CATCAA GTTAAA-----AGCGCACCCAACAGCCCT
Ex2A Ex2B S73ApaLI
Consensus :       A/CAG GURAGU  
Wild Type Sequence:  CACCAG GUAAAG  
Mutated Sequence: CAUCAA GUUAAA  
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Supplemental Table 1: List of primers used
Primers for mutagenesis of Mitfmi-S-S73 alleles 
and pBABE constructs
5’-CAGCAAGCTCAGAGGCATCAAGTTAAACAGTACCTTTCTACC-3’  F
5’-GGTAGAAAGGTACTGTTTAACTTGATGCCTCTGAGCTTGCTG-3’  R
Exon 2A-2B junction
mutation
5’-CCAGTGCCGGGGAGCAGCGCACCCAACAGCCCTATGGCTATGC-3’  F
5’-GCATAGCCATAGGGCTGTTGGGTGCGCTGCTCCCCGGCACTGG-3’  R
5’-CCAGTGCCGGGGAGCAGCGCACCCAACGCCCCTATGGCTATGC-3’  F
5’-GCATAGCCATAGGGGCGTTGGGTGCGCTGCTCCCCGGCACTGG-3’  R
5’-CCAGTGCCGGGGAGCAGCGCACCCAACGACCCTATGGCTATGC-3’  F
5’-GCATAGCCATAGGGTCGTTGGGTGCGCTGCTCCCCGGCACTGG-3’  R
5’-CAGCAAGCTCAGAGGCACCAGGCATTTTATAAGTTTGAG-3’  F
5’-CTCAAACTTATAAAATGCCTGGTGCCTCTGAGCTTGCTG-3’  R
S73S codon mutation 
S73A codon mutation 
S73D codon mutation 
∆2B mutation 
Primers for Mitf sequence verification and cloning
5’-AGCACAATGGCCAGTACCTT-3’ F
5’-TTGGTGACAATGACCAGGTG-3’ R
Genomic sequencing from 
M-Mitf Intron 1 to Intron 2
5’-TGCTGGAAATGCTAGAATACAGTC-3’ F
5’-TAGCTCCTTAATGCGGTCGT-3’     R
cDNA sequencing from 
M-Mitf exons 1M to 7
5’-CATTGGCTAAAGAGAGGCAGA-3’ F
5’-CTAGCCTGCATCTCCAGCTC-3’  R
cDNA sequencing from 
M-Mitf exons 6B to 9
Primers for qRT-PCR
5’-AAGCTCAGAGGCACCAGGTAAAG-3’ F
5’-ATGGTGAGCTCAGGACTTGG-3’    R
5’-GCTCAGAGGCACCAGGCATTTT-3’ F
5’-GACGCTCGAGAGTGCGTGTT-3’   R
5’-GCAAGCTCAGAGGCATCAAGTTAAA-3’ F
5’-ATGGTGAGCTCAGGACTTGG-3’      R
5’-CAAGCTCAGAGGCATCAAGCATTTT-3’ F
5’-GACGCTCGAGAGTGCGTGTT-3’      R
5’-CATTGGCTAAAGAGAGGCAGA-3’ F
5’-TAGCTCCTTAATGCGGTCGT-3’  R
qPCR Mitf 2B+
qPCR Mitf 2B-
qPCR Mitf 2B+ on mutated
Exon2A-2B junction
qPCR Mitf 2B- on mutated
Exon2A-2B junction
qPCR Mitf 6B - 7
5’-CCCCAAGTCAAATGATCCAG-3’ F
5’-GCAACTTCCGGATGTAGTCC-3’ R
5’-GGACCTTGAAAACCGACAGAAG-3’ F
5’-CTAGCCTGCATCTCCAGCTC-3’   R
qPCR Mitf 7 - 8
qPCR Mitf 8 - 9
5’-CAGGGCTCAGAGGCACTACT-3’ F
5’-GCTCCCTCCCTGCAATACTT-3’ R qPCR USF1
Specific purpose
Debbache et al.
5’-GGGCGGCAAATTGTTTTATAAAGC-3’ F
5’-GAAGTCAGCAAATGGTGGTGG-3’    R
5’-TGCTTTAGGTAAGAAAGGACCAAG-3’ F
5’-CGGCTCGTATGTTGTGTGGAA-3’  R
5’ BamHI fragment
3’ BamHI fragment
5’-ACGTGAATTCTGATTTAAACATGGCAATATTTCTG-3’ F
5’-ACGTAAGCTTGGGGGAACTTCCTGACTAGG-3’      R
EcoRI-HindIII Mitf 
PCR cloning
Page 1
Primers for genotyping and Southern probes
5’-GTGCAGACCCACCTGGAAAAC-3’ F
5’-ACTCATCTAAGGACGGTGAT-3’  R
Presence of LoxP site
Removal of Neo cassette
5’-CACCATGATATTCGGCAAGCAGGC-3’ F
5’-TGACTGGGCACAACAGACAATCGG-3’ R Presence of Neo cassette
5’-ATGACAGGCCCTTTCTAGT-3’ F
5’-ACATGCAGTTCATGTGAG-3’  R
5’-GTAAGCGCAGCCTGCTCAG-3’  F
5’-TCTTGACCTGAAATCGCAGC-3’ R
5’ probe generation
3’ probe generation
Specific purpose
Page 2 Debbache et al.
Supplemental Table 1: List of primers used (ct)
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6 – La caractérisation d’un nouvel allèle du gène Mitf associé à un gain de 
d’activité. 
 
Bien que les cribles de mutants suppresseurs aient souvent produit des données 
intéressantes dans la compréhension de la fonction de certains gènes chez plusieurs 
organismes, leur utilisation chez la souris reste restreinte. Dans cette étude nous 
décrivons l’isolation d’une mutation intra-génique de l’allèle « spotted » Mitfmi-sp du 
facteur de transcription murin Mitf. Ce nouvel allèle corrige largement les phénotypes 
pigmentaires associés à la présence combinée de l’allèle Mitfmi-sp et d’autres allèles de 
Mitf. La mutation localisée dans l’allèle Mitfmi-sp entraine l’absence de l’exon alternatif 
6A qui code pour 6 acides aminés proche du domaine basique de fixation a l’ADN. Le 
nouvel allèle nommé « spotless » ou Mitfmi-sl conserve le défaut d’épissage alternatif de 
l’exon 6A mais dispose d’un site de terminaison de la traduction prématuré à l’acide 
amine 316. Ce codon STOP entraine une perte de 104 acide aminés de la partie Carboxy-
terminale de MITF qui contient plusieurs sites de régulation post-traductionnelle de la 
protéine dont la K316 et S409. Même si nous ne trouvons pas de différences concernant 
la stabilité de la protéine ou l’affinité de fixation à l’ADN entre les protéines 
correspondantes, des expériences de gène rapporteur montrent une augmentation de 
l’activité transcriptionnelle de la protéine MITFmi-sl ainsi qu’une augmentation de la 
stabilité leurs homodimers. Cependant, aucune différence n’a été observée en ce qui 
concerne le développement des mélanocytes entre les souris Mitfmi-sp et Mitfmi-sl 
homozygotes, que ce soit en terme de prolifération cellulaire ou du nombre total de 
mélanocytes, bien que la pigmentation postnatale de ces derniers soit différée dans les 
Résultats 
 48 
souris Mitfmi-sl. Ces résultats indiquent que la partie carboxy-terminale de MITF n’est pas 
essentielle à sa fonctionnalité, et qu’au contraire elle pourrait avoir un rôle négatif dans la 
régulation de son activité. 
Les résultats expérimentaux liés à cette étude sont présentés dans l’Article 6. 
 
 
The following expriments describe the characterization of a new allele identified in a N-
ethyl-N-nitrosurea (ENU) mutagenesis screen on a Mitfmi-sp/Mitfmi-sp sensitized 
background. The aim of the screen was to discover new pigmentation gene modifiers 
that would either enhance or rescue the phenotype observed in Mitfmi-sp/ Mitfmi-ew mice. 
In this study, we describe the molecular analysis of one particular mutant allele, which 
results in the correction of the pigmentation defect of Mitfmi-sp when crossed with null or 
dominant-negative Mitf mutants. Intriguingly, this new modifier allele was found to be 
genetically linked to the Mitf locus, and by further sequencing, it happened to be a 
additional modification on the mutant Mitfmi-sp allele. The new allele, named Mitfmi-sl 
(spotless), results in the truncation of MITF protein due to the appearance of an early 
stop codon at the position 316. 
While the Mitfmi-sl allele displays a gain-of-function when crossed with other Mitf mutants 
compared to Mitfmi-sp, Mitfmi-sl/Mitfmi-sl homozygotes display a coat color dilution, turning 
them from black to brownish. In this study, we present the analysis of this complex and 
unique Mitf allele and we attempt to explain both molecularly and developmentally the 
rescue of the pigmentation phenotype observed when crossed with other mutant Mitf 
alleles. 
The details of this research study are described in the following Article 6. 
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An induced suppressor mutation at the microphthalmia 
locus in the mouse reveals novel insights into bHLH-LZ 
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The analysis of mutations which suppress or compensate the effects of other 
mutations has revealed important insights into gene function in many organisms. 
Here we report the isolation of an intragenic mutation in the Mitfmi-spotted (Mitfmi-sp) 
allele of the mouse bHLHZip transcription factor gene Mitf, which largely corrects 
the phenotypic enhancement observed when this allele is combined with other Mitf 
mutations. The Mitfmi-sp mutation leads to the absence of the alternatively spliced 
exon 6A, which encodes 6 residues close to the DNA-binding basic domain of MITF. 
The novel suppressor mutation, termed spotless or Mitfmi-sl, retains this splice 
alteration but introduces a stop codon at amino acid 316, leading to the loss of 104 
residues at the carboxyl terminus of MITF. Although we find no differences in 
protein stability or DNA binding between the corresponding proteins, reporter 
assays show increased transcription activation potential of the MITFmi-sl protein, 
and the stability of MITFmi-sl homodimers seems to be increased. Nevertheless, 
developmental studies show no differences between Mitfmi-sp and Mitfmi-sl 
homozygotes in cell proliferation or melanocyte numbers although the postnatal 
onset of pigmentation is delayed in Mitfmi-sl homozygotes. Our data indicate that the 
carboxyl-end of MITF is not essential for the function of Mitf in melanocytes and 
may rather play a negative role. We conclude that searching for suppressor 
mutations in the mouse is feasible and provides a powerful tool for generating 
unexpected insights into gene function. 
 
The analysis of suppressor mutations, many of them identified by suppressor screens, has 
provided many insights into gene function, gene interactions and genetic pathways in 
organisms ranging from bacteria to Drosophila. In mice, however, few suppressor screens 
have been performed, but the analysis of spontaneous suppressor mutations such as the 
dilute-suppressor suggest that such mutations may lead to important mechanistic insights 
also in this species. The dilute-suppressor is an allele of the gene Mreg (Mregdsu) that acts 
on Myo5a, whose mutations affect coat pigmentation (1). In fact, alterations in coat 
pigmentation provide for an ideal phenotype when screening for suppressors because 
more than 150 genes affecting pigmentation have been cloned already, coat pigmentation 
allows for a readily visible and highly sensitive read-out of gene function, and alterations 
Steingrímsson et al. Mitf suppressor 
 
 3 
in pigmentation are usually compatible with normal life and breeding. Here, we describe 
experiments in which we screened for suppression of a mutation in the pigment gene 
Mitf. 
Mutations at the mouse microphthalmia locus (Mitf) affect the development of 
several different cell types including neural crest-derived melanocytes, pigmented 
epithelial cells of the eye, mast cells, and osteoclasts.  The many mutations found at the 
locus over the last 60 years have different phenotypic effects and can be arranged in an 
allelic series.  The original and most severe allele, Mitfmi, affects all of the above cell 
types and results in death at 3-4 weeks of age while the mildest allele, Mitfmi-spotted (Mitfmi-
sp), creates no visible phenotype even when homozygous. Nevertheless, this latter allele is 
named “mi-spotted” because it induces or enhances a white spotting phenotype when 
combined with other mutations at the locus (reviewed by (2, 3).  Some of these other Mitf 
alleles are inherited semidominantly and show white spotting on their own when 
heterozygous with wild type, but their white spotting is enhanced in compound 
heterozygotes with Mitfmi-sp. Most Mitf alleles, however, are recessive and do not exhibit 
white spotting when heterozygous, and yet when combined with Mitfmi-sp, white spotting 
becomes visible and can indeed be quite extensive (reviewed in (3). 
The MITF protein is a member of the MYC family of basic-Helix-Loop-Helix-
leucine zipper (bHLH-Zip) transcription factors and is closely related to the TCFE3, 
TCFEB and TCFEC proteins (formerly known as TFE3, TFEB and TFEC proteins) (4, 
5).  The basic domain is the DNA binding domain of the protein while the HLH and Zip 
domains are responsible for dimerization.  Other domains in the MITF protein include 
distinct activation domains, several conserved domains of unknown function and many 
sites for posttranslational modifications including phosphorylation, sumoylation, and 
caspase cleavage (6-13). The MITF protein can bind DNA as homodimers or 
heterodimers with other TFE family members [Hemesath, 1994]. It is a nuclear protein 
(14) which regulates the expression of genes involved in cell specification, differentiation 
and function, cell survival, and cell cycle regulation (15-17). In melanoma cells, MITF 
plays a critical role as a lineage-survival oncogene (18) and may act as a molecular 
switch that determines whether cells proliferate or become quiescent, thus allowing 
migration and formation of metastasis (19). Genome-wide analysis suggests that MITF is 
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indeed involved in DNA replication and genome stability in melanoma cells, and ChIP-
sequencing studies show that MITF binds predominantly to two related E-box sequences, 
CACGTG and CATGTG (20). Given its multiple roles, MITF can be considered a master 
regulator of both normal melanin-bearing pigment cells as well as their malignant 
derivatives. 
The molecular defects associated with most of the Mitf-alleles in mice and other 
vertebrates have been determined and their biochemical properties analyzed (21).  The 
Mitfmi-sp mutation is characterized by an extra cytosine in the alternatively spliced 18 bp 
exon 6A that encodes 6 amino acids just upstream of the basic domain. The extra base 
may affect the splicing reaction directly, leading to a decrease in mRNAs containing the 
6A exon. It may also subject RNAs still containing exon 6A to non-sense-mediated 
decay, as the mutation leads to a premature stop codon in the adjacent exon 6B. In 
contrast to wild-type mice where the 6A+ and the 6A- RNAs are made in approximately 
equal proportion in most cell types, the 6A+ version is missing in Mitfmi-sp homozygotes 
and, as we show here, the overall Mitf mRNA levels are reduced. The corresponding 
MITF+ and MITF- (MITFmi-sp) proteins have similar DNA binding properties, but the 
DNA binding stability of the latter protein is slightly reduced (22). The combination of 
reduced mRNA levels and reduced DNA binding may explain why the pigment enzyme 
encoded by the Mitf target gene Tyrosinase and the survival of melanocytes are 
somewhat impaired in Mitfmi-sp homozygotes (23, 24). These negative effects may be 
counteracted in part by the fact that, based on ectopic expression in heterologous cells in 
vitro, the MITF+ protein inhibits DNA synthesis whereas the MITF- protein has only 
mild if any effects (25). Interestingly, in melanoma cells, the 6A+/6A- ratio is regulated 
by the MAP kinase pathway, and a subset of melanoma samples shows a decreased ratio 
of 6A+/6A- RNAs (26). 
Besides Mitfmi-sp, there is a second allele, MitfMi-White (MitfMi-Wh), that underscores the 
importance of exon 6A. This allele is inherited semidominantly and results in coat color 
dilution and a belly spot in heterozygotes (2, 3, 27).  It is characterized by a point 
mutation changing residue 212 from isoleucine to asparagine (21). This position lies in 
the middle of the DNA-binding basic region of the protein and is conserved in the three 
TCFE (formerly known as TFE) family members.  Biochemical analysis using proteins 
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truncated at both the amino- and carboxyl termini showed that neither version of the 
MITFMi-Wh protein, containing or lacking the 6 residues, bind DNA as homodimers, 
suggesting that the MitfMi-wh mutation has dramatic effects on DNA binding.  However, as 
dimers with wild-type MITF or the wild-type TCFE3, the MITFMi-Wh+ protein was shown 
to bind DNA at normal levels (22).  Based on these studies, DNA binding of the MITFMi-
Wh protein depends on the presence of both the alternative 6 residues and a wild-type 
dimerization partner. Nevertheless, an explanation for why the 6 residues are important in 
this context may require detailed structural analyses. Interestingly, the combination of 
MitfMi-wh with Mitfmi-sp results in mice that do not only show an enhanced white spotting 
compared to MitfMi-wh/Mitf+ heterozygotes but also a pale tan color as opposed to the mild 
dilution seen with MitfMi-wh/Mitf+ heterozygotes. This suggests that these alleles engage in 
complex interactions that affect melanocyte development as well as differentiation.   
The variety of coat pigmentation alterations obtained with Mitfmi-sp made this allele 
ideal for an N-ethyl-N-nitrosurea (ENU) mutagenesis screen. Such a screen would not 
only allow identification of mutations that enhance the phenotype of compound 
heterozygotes but also of mutations that alleviate it. Using this approach we expected to 
find mutations in novel genes participating in the molecular pathways through which Mitf 
regulates pigment cell development and melanogenesis. In fact, we were able to isolate a 
suppressor mutation, but intriguingly, it does not represent an allele of a different gene 
but is a derivative of the Mitfmi-sp allele itself, perhaps further highlighting the central role 
that Mitf plays in melanocyte biology. 
  
Results and Discussion 
Generation and analysis of an Mitf suppressor mutation. We designed a simple F1 
mutagenesis screen for dominant coat color changes of the mouse Mitf mutation  After 
testing for tolerance to the mutagen and for male and female fertility, the Mitfmi-sp and 
Mitfmi-eyeless white (Mitfmi-ew) mutations were chosen for the mutagenesis experiment.  While 
Mitfmi-sp homozygotes have no visible coat color phenotype, animals homozygous for the 
Mitfmi-ew mutation are white, severely microphthalmic and exhibit mild hyperosteosis (28) 
(Supplementary Table 1).  Compound heterozygotes for these two mutations have a "salt-
and-pepper" body color with white head, belly and feet (Fig. 1A).  For the experiment, 
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homozygous C57BL/6 (B6)-Mitfmi-sp males were treated four times at one week intervals 
with 100 mg/kg ENU.  After a 6-8 week recovery time, the males were mated to NAW-
Mitfmi-ew/Mitfmi-ew females and the resulting F1s, which all should show the identical "salt-
and-pepper" body color with white head, belly and feet, were screened for coat 
pigmentation changes.  Numerous B6-Mitfmi-sp/Mitfmi-sp males were treated with ENU and 
mated to 63 NAW-Mitfmi-ew/Mitfmi-ew females of which only 44% bred, resulting in the 
generation of a total of 470 offspring.  In one of the matings, a deviant female, marked by 
a * to indicate the presence of a mutagenized chromosome, showed a considerably darker 
coat (near-black coat with pale ears, tails and toes) compared to littermates  (Fig. 1A).   
When this female with the genotype Mitfmi-ew/Mitfmi-sp * was bred to a B6-Mitfmi-
ew/Mitfmi-ew male, two classes of offspring resulted: white microphthalmic mice of the 
genotype Mitfmi-ew/Mitfmi-ew and mice with the same phenotype as the mother: near-black 
coat with pale ears, tails and toes and the genotype Mitfmi-ew/Mitfmi-sp * (Supplemental Fig. 
1A).  Again, these animals were considerably more pigmented than the corresponding 
B6-Mitfmi-sp/Mitfmi-ew mice.  This suggested that the mutation altering the Mitf phenotype 
is dominant, at least with respect to the combination of these two alleles.  Also, because 
the above crosses did not yield mice with the phenotype expected for Mitfmi-ew/Mitfmi-sp 
mice, the novel suppressor mutation is likely closely linked with Mitfmi-sp, or lies within 
the gene itself, rather than on a different chromosome. Furthermore, crossing the near-
black mice to C57BL/6J or B6-Mitfmi-sp animals only resulted in black offspring showing 
that the new suppressor does not alter the heterozygous phenotypes of these alleles.   
When the near-black Mitfmi-ew/Mitfmi-sp * mice were mated to MitfMi-wh/MitfMi-wh 
homozygotes, there were again two classes of offspring: white mice with normal eye size 
(Mitfmi-ew/MitfMi-wh heterozygotes) and “steel”-colored mice with pale ears, tail, toes and a 
belly spot (MitfMi-wh/Mitfmi-sp * animals, Fig. 1B).  The coat color of the latter animals is 
much darker than that of the corresponding MitfMi-wh/Mitfmi-sp animals which are light tan 
with white spots (24) (Fig. 1B). In fact, the color is even darker when compared to MitfMi-
wh/Mitf+ mice, suggesting that the new mutant represents a gain-of-function compared to 
wild type.  Similar effects were also seen when animals carrying the new Mitfmi-sp * 
mutation were crossed to the dominant-negative Mitfmi (Fig 1C), MitfMi-or and MitfMi-b 
mutations (Supplemental Fig. 1B-D).  In all these cases, the coat was more pigmented 
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than when the respective mutations were crossed to the original Mitfmi-sp mutation. The 
effect was most dramatic when comparing the Mitfmi/Mitfmi-sp * and Mitfmi/Mitfmi-sp 
compound heterozygotes (Fig. 1C).  These observations showed that the suppressing 
effects of the new mutation were not restricted to the Mitfmi-ew allele and were seen 
regardless of genetic background (compare Fig. 1A to Supplemental Fig. 1A and 
Supplemental Figs. 1B to 1C).   
Interestingly, the new mutation also improves the phenotype of a loss-of-function 
mutation in Mitf. The Mitfmi-vga9 mutation is caused by a transgene insertion into the Mitf 
regulatory region which eliminates expression of the Mitf gene and results in a severe eye 
and coat color phenotype (4, 29).  When animals homozygous for the new suppressor 
mutation were crossed to B6-Mitfmi-vga9/Mitfmi-vga9 animals, the resulting progeny were 
black with a small belly spot, in contrast to B6-Mitfmi-vga9/Mitfmi-sp mice which show 
extensive white spotting (Fig. 1E, F).  The fact that the Mitfmi-vga9/Mitfmi-sp * animals 
exhibit near-normal pigmentation suggests that the Mitfmi-sp * mutation can restore 
pigmentation to areas which otherwise would be unpigmented, suggesting that the 
mutation restores the effects of Mitf during melanocyte development. The new mutation 
does not affect the coat color of the recessive Mitfmi-rw allele as compared to Mitfmi-
rw/Mitfmi-sp animals (Fig. 1H), reflecting the fact that the latter animals are already black 
and no further improvement in coat color is possible.  Similarly, no effects were observed 
on eye size or bone development in any of the combinations since both phenotypes are 
normal in Mitfmi-sp homozygotes or their compound heterozygotes.   
Intercrosses of B6-Mitf+/Mitfmi-sp * heterozygotes produced two classes of 
offspring: normal non-agouti (black) mice and mice with a diluted “brownish” coat color, 
in a 3 to 1 ratio.  Genotyping showed that the “brownish” animals were homozygous for 
the Mitfmi-sp mutation (compare Figs. 1G to 1H).  Thus, intriguingly, the new mutation 
suppresses the spotting phenotype of most combinations of Mitf alleles but causes the 
Mitfmi-sp mutation to express a neomorphic function.  
 
Molecular analysis of the new mutation. From the various crosses described above it 
was clear that the new mutation is either tightly linked to Mitf on chromosome 6, or is an 
intragenic mutation.  We therefore performed RT-PCR and sequencing studies of the Mitf 
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gene in total RNA isolated from homozygous Mitfmi-sp * heart and kidney.  Consistent 
with the induced origin of the mutation, sequencing of the cDNA revealed the previously 
characterized Mitfmi-sp mutation, namely the lack of the 18 bp alternative exon (21).  In 
addition, an A to T transversion was detected at nucleotide 1075 of the cDNA (4) 
resulting in a Lys316Stop mutation and a predicted premature truncation of the protein 
(Fig. 2A). The presence of the Stop codon was confirmed by genomic sequencing of the 
last Mitf exon, exon 9, which encodes Lys316. Thus, the new mutation is an intragenic 
re-mutation at the Mitfmi-sp allele.  We have termed the new mutation Mitfmi-spotless (Mitfmi-
sl) in order to distinguish it from the Mitfmi-sp mutation on which it arose.  Accordingly, 
the mutant MITFmi-sl protein contains the bHLHZip domain, the amino-terminal 
activation domain and the Ser73 phosphorylation site but is missing 104 residues of the 
carboxyl end, including a SUMOylation site (Lys 316) (11), a caspase cleavage site (Asp 
345) (8), a phosphorylation site implicated in the MAP kinase signal transduction 
pathway (Ser 409) (13)), and a putative transcription activation domain (12). To confirm 
that the carboxyl-end of MITF indeed is missing from the Mitfmi-sl mutant, we labeled 
melanocyte cultures and eye sections from Mitfmi-sl and Mitfmi-sp mutants with the 
monoclonal antibody 6A5, which reacts with the carboxyl terminus of MITF (30). As 
shown in Fig. 2B, the antibody did not give a signal in Mitfmi-sl cells or eye sections 
whereas Mitfmi-sp cells and sections exhibited clear nuclear staining; eye sections from 
both genotypes were stained with a polyclonal rabbit anti-MITF antibody. The results 
indicated that the MITF protein is present in Mitfmi-sl mutants but lacks the carboxyl-end. 
Further proof that MITFmi-sp and MITFmi-sl proteins accumulate in the nuclei of cells came 
from experiments in which we transfected cells with corresponding GFP fusion 
constructs or labeled the expressed proteins directly with the C5 anti-MITF antibody 
(Suppl. Fig. 2). Nevertheless, as these assays would not be able to detect minor 
differences in the efficiencies of nuclear translocation, potential differences in nuclear 
accumulation cannot be entirely excluded to explain the mutant phenotype. 
 
Mitfmi-sl/Mitfmi-sl homozygotes show normal melanoblast development but delayed 
onset of pigmentation. Conceivably, the above suppressor phenotype might be explained 
by increased proliferation of melanoblasts or melanocytes induced by the MITFmi-sl 
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protein. To investigate this possibility, we first tested BrdU incorporation in HEK293 
cells expressing MITFmi-sp or MITFmi-sl proteins from corresponding expression vectors.  
However, these assays revealed no significant difference in BrdU incorporation between 
the two different mutations (69 ± 2% BrdU positivity in MITFmi-sp -expressing cells 
versus 71± 2 % BrdU positivity in MITFmi-sl -expressing cells).  To count melanoblast 
numbers during development in vivo, we generated Mitfmi-sp and Mitfmi-sl homozygous 
embryos carrying a melanoblast marker transgene, Dct-LacZ (31). In wild type C57BL/6 
embryos, the Dct-LacZ marker (as determined by blue cells after Xgal staining) showed, 
as expected, an increase of labeled cells with developmental time. Similar increases were 
seen in Mitfmi-sp and Mitfmi-sl homozygotes, although the total number of labeled cells 
seemed on average reduced compared to wild type. Possibly because of varying degrees 
of transgene silencing, however, there was a great variability in staining from embryo to 
embryo. Therefore, we switched to a different marker, Kit-LacZ, in which we expected 
less variability because the LacZ gene was inserted by targeted mutagenesis into the 
endogenous Kit gene (32). As Kit was rendered non-functional by targeting and Kit is 
involved in the regulation of melanocyte development, Kit-LacZ heterozygotes have a 
reduced number of melanocytes, phenotypically manifested as white feet and tail tips, 
and, in our colony, a white belly spot. Hence, by introducing Kit-LacZ into Mitfmi-sp and 
Mitfmi-sl mice, we also could evaluate whether the suppressor mutant was able to suppress 
white spotting created by the Kit mutation. In fact, the white spotting associated with Kit-
LacZ heterozygosity was not influenced by the presence of either Mitf allele, suggesting 
that the suppressor mutation acts only on Mitf itself (data not shown). The analysis of X-
gal staining in the respective embryos is shown in Fig. 3A,B. At 12.5 days, the mutant 
embryos have fewer melanocytes than wild type.  However, no differences were observed 
between Mitfmi-sp and Mitfmi-sl.  At 15.5 days, no difference was seen when the cells were 
counted in the hind-limb region whereas a region around the ear showed that Mitfmi-sp and 
Mitfmi-sl had more melanocytes than wild type and Mitfmi-sl had the highest levels.  This 
suggests that generally, the numbers of melanocytes are the same in the two mutations 
although there may be region-specific differences.   
In order to determine if the phenotypic suppression of Mitfmi-sl is due to effects on 
developmental timing, the appearance of pigmentation was traced both in neural crest 
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cultures established at E9.5 and in newborn Mitfmi-sp and Mitfmi-sl mice. In Mitfmi-sp 
cultures, the first pigmented melanocytes appear at day 10 of culture (N=38) and their 
number increases steadily through day 17 (N=372) (Supplemental Fig. 3A ). In Mitfmi-sl 
cultures, the first pigmented melanocytes appear at day 14, i.e. 3 days later than in Mitfmi-
sp cultures, and their average number is lower (N=95) (Supplemental Fig. 3A).  
Nevertheless, in both Mitfmi-sp and Mitfmi-sl cultures, melanoblasts can be detected by 
expression of the MITF protein as early as day 1 of culture (Supplemental Fig. 3, inset, 
for day 3 of culture), suggesting that the delay in pigmentation is not due to a delay in 
melanoblast appearance.  Comparing pups of the two genotypes shows that pigmentation 
appears later in Mitfmi-sl mice than in Mitfmi-sp animals, particularly striking at postnatal 
day 2 and 3 (Supplemental Fig. 3B). However, this difference is only seen when the mice 
are homozygous for these alleles and not when they are combined, for instance, with 
Mitfmi-vga9 (Supplemental Fig. 3C, comapre mice labeled #1 and #3). Hence, it is 
conceivable that delayed onset of pigmentation reflects the appearance of the “brownish” 
color which also requires homozygosity for Mitfmi-sl. In any event, the above results 
suggest that the delayed onset of pigmentation in Mitfmi-sl cultures and pups is not due to 
an extended period of cell proliferation that would delay the beginning of differentiation.  
 
RNA expression and protein stability. In order to determine expression levels of the 
Mitf gene in the mutants, we first quantitated Mitf RNA expression in the heart, an organ 
that is not overtly affected in any of the extant Mitf mutants. Quantitative RT-PCR (33) 
showed that expression of Mitf RNA is reduced to 65.7% in Mitfmi-sp hearts compared to 
wild-type controls but remains at wild-type levels (115.8%) in Mitfmi-sl hearts. Similar 
observations were made when RNA obtained from skin was quantitated (Fig. 4A). 
Indeed, increased Mitf RNA expression or stability would explain the phenotypic 
suppression observed with the Mitfmi-sl mutation. The results may indicate either that 
MITF regulates its own expression, with MITFmi-sl protein being a more potent activator 
than MITFmi-sp, or that MITFmi-sl may bias the exon 6A splice reaction such that less of 
the Mitf RNA is removed by non-sense mediated degradation.  
The MAPK signalling pathway has been shown to lead to phosphorylation of Ser73 
and Ser409 of MITF, resulting in increased transcription activation potential and reduced 
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protein stability (13).  The MITFmi-sl mutant protein is missing the Ser409 
phosphorylation site and might therefore be more stable, thus explaining the more normal 
phenotype observed in compound heterozygotes.  Protein kinetic studies were therefore 
performed in transfected Cos cells to test if the Mitfmi-sl mutation differentially affects the 
stability of the corresponding proteins.  The results show that whereas there is less 
MITFmi-sl protein expressed in the cells to begin with, its stability is not affected by the 
deletion mutation or by the absence of the 6 amino acid insert sequence (Fig. 4B). This is 
consistent with the above observation that reduced MAPK activity as seen in Kit-
LacZ/Kit+ mice does not alter the Mitfmi-sl phenotype and with previous results that 
showed that transgenic Mitf BACs with a Ser409Ala mutation can fully rescue the 
phenotype of Mitfmi-vga9/Mitfmi-vga9 mice (34). 
 
DNA binding and transcription activation. The DNA binding abilities of the MITFmi-sl, 
MITFmi-sp and MITF+ proteins were determined using electrophoretic mobility shift assays 
(EMSA).  Previous DNA binding studies have shown that the MITFmi-sp and MITF+ 
proteins bind DNA with similar steady state affinities (22).  Our EMSA results are in 
agreement with this (Fig. 4C, lane 2, 6).  Consistent with its smaller size the MITFmi-sl 
protein results in a band that moves faster in the gel than the wild-type and MITFmi-sp 
proteins; this band is also more diffuse (Figure 4C, compare lanes 2, 6 and 10).  In order 
to determine if dimerization ability was affected, the three proteins were co-translated 
with the dominant negative MITFmi protein before performing the EMSA.  This mutant 
protein carries a deletion of one of three arginines in the DNA binding domain (21), is 
unable to bind DNA but can still dimerize with its partners and thus interfere with their 
DNA-binding (22).  Co-translating this protein with the wild type, MITFmi-sp and MITFmi-sl 
proteins and then performing gel shift experiments shows that increasing amounts of the 
MITFmi protein interfere with the DNA binding of all three proteins.  However, 
quantitation of the bands revealed that MITFmi is twice as effective at interfering with the 
wild type protein (MITF+) than with either of the mutant proteins, suggesting that the 
lack of exon 6A confers reduced dimerization abilities (Fig. 4C).  Nevertheless, 
according to this analysis, the C-terminal truncation has no additional effects.  A slightly 
different picture emerges when the proteins were translated separately and mixed before 
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the EMSA.  Again, the MITFmi protein is more effective at interfering with binding of the 
wild type protein than with the MITFmi-sp and MITFmi-sl proteins. In this case, however, it 
is even less effective at interfering with the MITFmi-sl protein (Fig. 4D) than with MITFmi-
sp.  This suggests that, once formed, the MITFmi-sl dimers are more stable than either the 
wild type or MITFmi-sp dimers and thus less prone to interference by the MITFmi protein.  
More stable MITFmi-sl dimers might explain the suppressor phenotype. 
In order to test the transcription activation potential of the MITFmi-sl mutant protein, 
co-transfection assays were performed.  When transfected into 293T cells, the Mitfmi-sp 
protein is a less potent transcription activator than MITF+ on all promoters tested.  
However, the MITFmi-sl protein was a more potent transactivator than the MITFmi-sp 
protein on the tyrosinase promoter as well as on all other promoters tested and was in all 
cases similar to the wild type protein (Fig. 5).   Similar results were obtained in 501mel 
melanoma cells.  This is consistent with the suppressor phenotype as increased activity of 
the MITFmi-sl protein might improve the phenotype in compound heterozygotes. This is 
also consistent with the increased expression of the Mitf gene in heart of Mitfmi-sl mutant 
animals, again suggesting that MITF regulates its own expression. It has also been shown 
that the carboxyl end of MITF is important for maintaining transcription activation of the 
tyrosinase promoter (12).  These results suggested the presence of an important 
transcription activation domain between amino acids 293 and 324. As the MITFmi-sl 
protein is truncated at residue 316, yet maintains transcription activation ability, the 
domain important for transcription activation must lie between residues 293 and 316. 
Alternatively, the 6 amino acids lacking in the MITFmi-sp and MITFmi-sl proteins may 
contain an activation domain that depends on the carboxyl-end of MITF such that in the 
absence of both, other activation domains dominate, leading to increased activation. 
Nevertheless, it needs to be kept in mind that all experiments of Takeda et al. (2000) were 
performed using MITF which contains the 6 amino acids and a reporter containing a 
larger segment of the tyrosinase promoter than was used here.   
 
Conclusions. We have generated a novel intragenic suppressor mutation at the Mitf locus 
in the mouse, characterized the molecular lesion involved and the biochemical effects in 
vitro.  The mutation is a re-mutation at the Mitf locus which results in a truncation of the 
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already mutated Mitfmi-sp protein.  In the homozygous condition, the Mitfmi-sl mutation 
results in a brownish coat color, suggesting a neomorphic action as compared to the 
Mitfmi-sp mutation on which it arose which leads to a normal black coat.  However, in 
compound heterozygous conditions with other Mitf mutations, including severe mutations 
at the locus such as Mitfmi, MitfMi-or, MitfMi-wh, Mitfmi-ew and the loss-of-function mutation 
Mitfmi-vga9, the Mitfmi-sl mutation improves the phenotype as compared to the same alleles 
combined with the original Mitfmi-sp mutation. A molecular explanation of this mutation 
needs to consider its contradictory genetic behaviour. Some of our data is consistent with 
the altered pigmentation observed in homozygotes. For example, developmental analysis 
shows a delay in pigmentation.  However, other data is consistent with the suppressor 
phenotype, including the increased expression of the Mitf gene in Mitfmi-sl hearts, the 
increased ability of MITFmi-sl to activate expression and the increased stability of dimers 
formed by the MITFmi-sl protein. Recently, two independent reports showed association 
of mutations in the human MITF gene with melanoma [Bertolotto, 2011; Brown, 2011].  
The mutation involved is an E318K mutation that affects sumoylation of the protein and 
leads to increased transcription activation potential, thus leading to oncogenic ability.  
This is consistent with the results observed with the MITFmi-sl protein which lacks the 
sumoylation site and has increased transcription activation ability.  This mouse may 
therefore be useful as a model for MITF-mediated melanoma. 
Our analysis suggests that the Mitfmi-sl mutation may affect several different aspects 
of MITF function.  The effects of the Mitfmi-sl mutation, although clearly visible in the 
mouse, would not have been predicted a priori based on DNA or protein sequence.  We 
therefore conclude that generating suppressor mutations in the mouse is an interesting 
and feasible option for studying gene function and may reveal unexpected aspects of 
protein function or regulation, leading to novel insights into protein activity in the living 
organism.   
 
Methods 
Mouse strains used, mutagenesis and genotyping. The following Mitf mutants were 
used in this study: C57BL/6J-Mitfmi-sp, C57BL/6J-Mitfmi-eyeless white (Mitfmi-ew), NAW-Mitfmi-
eyeless white (Mitfmi-ew), C57BL/6J-MitfMi-Wh, C57BL/6J-Mitfmi-red-eyed white (Mitfmi-rw), C57BL/6J-
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Mitfmicrophthalmia, 82UT-Mitfmi-Oak ridge (MitfMi-Or), C57BL/6J-Mitfmi-oak ridge (MitfMi-or), 82UT-
Mitfmi-brownish (Mitfmi-b) and a [C3H/C57BL/6J]-Mitfmi-vga-9 strain (Table 1).  These strains are 
maintained at the NCI in Frederick, MD and at the NINDS, NIH in Bethesda, MD.  The 
mice were mated systematically in order to generate the different allelic combinations.  In 
order to screen for Mitf suppressor mutations, homozygous B6-Mitfmi-sp males were 
treated four times at one week intervals with 100 mg/kg ethylnitrosourea (ENU).  After a 
6-8 week recovery period, the males were mated to NAW-Mitfmi-ew/Mitfmi-ew females and 
the resulting offspring, which all should show an identical phenotype, screened for more 
normally pigmented deviates.  DNA-HPLC was used to confirm the presence of the 
Mitfmi-sp mutation. The Kit-LacZ mice, involving C57BL/6J, C3H/HeJ and 129/Sv, were 
originally obtained from Jean-Jacques Panthier. 
 
RT-PCR and sequencing. Total RNA was isolated from hearts of wild type and mutant 
mice using the RNAwiz kit from Ambion.  The RNA was reverse transcribed by 
SuperScript reverse transcriptase (Invitrogen) and the resulting cDNA phenol/chloroform 
extracted.  Alternatively, RNA was isolated using the Macherey Nagel RNAII kit.  The 
entire Mitf cDNA was amplified by PCR using overlapping primers and the resulting 
PCR products sequenced directly using Big Dye Terminator Cycle Sequencing kit (ABI) 
and the ABI 377 sequencer.  The results were confirmed by sequencing additional 
animals as well as several controls animals, on which the mutation was induced, in order 
to confirm the alterations. 
 
Generation of plasmid constructs. The wild type and  mutant expression clones were all 
generated in pcDNA3, by subcloning and/or in vitro mutagenesis.  In order to determine 
nuclear localization experiments, fusion proteins were generated where wild type and 
mutant versions of the Mitf gene were fused to Green Fluorescent Protein (GFP).  All the 
constructs were sequence verified.   
 
Co-transfection experiments 
Co-transfection experiments were performed in 293T cells maintained in Dulbecco´s 
modified Eagle medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS), 2 
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mM L-glutamine and penicillin/streptomycin (50 U/mL).  Cells were grown at 37°C in a 
humidified atmosphere of 5% CO2.  Cells were split on Nunc 12-well plates 24 hours 
prior to transfection such that cells were ~50-60% confluent at the time of DNA addition. 
At harvest, the cells were washed with ice cold PBS and lysed with passive lysis buffer 
(PLB) from the Dual Luciferase assay Kit (Promega).  Then a part of the cell lysaste was 
used to evaluate luciferase activity; all reactions were preformed according to 
manufacturer's suggestions. 
 
DNA binding studies. Electrophoretic Mobility Shift Assays were performed using 
proteins expressed in the TNT T7 Coupled Reticulocyte Lysate System (Promega, WI), 
according to the manufacturer´s recommendation.  DNA binding reactions were 
performed in 10 mM Hepes (pH 7.9), 50 mM NaCl, 5 mM MgCl2, 0.1 mM EDTA, 2 mM 
dithiothreitol (DTT), 5% ethylene glycol and 5% glycerol.  The buffer was mixed in 2X 
concentration and was diluted to 1X concentration in the binding reaction which was 
composed of 10 µL of 2X binding buffer, 2.5 µL of TNT translated Mitf protein, 1.4 ng 
of labeled probe, 4 µg of bovine serum albumin (BSA) (35) and water adjusting the 
reaction volume to 20 µL.  For supershifts, 0.5 µL of C5-Mitf antibody was added to the 
reaction.  The samples were incubated on ice for 30 minutes to allow binding to proceed.  
The resulting DNA-protein complexes were resolved on 6% non-denaturing 
polyacrylamide gels, placed on a storage phosphor screen and then scanned on a Typhoon 
Phosphor Imager 8610 (Molecular Dynamics) for analysis. 
 
Protein kinetic studies. COS cells were transfected with constructs expressing the Mitf+, 
Miftmi-sp, and Mitfmi-sl proteins (in pCDNA3) and grown in DMEM plus 10% fetal bovine 
serum.  The cells were then treated with 100 nM TPA (Sigma) and 15µg/ml 
cyclohexamide (Sigma) and incubated for 0, 1, 2 and 3 hrs before harvesting.  The cells 
were then lysed in SDS buffer and the expression of the Mitf proteins determined by 
Western-blotting using the C5 monoclonal Mitf antibody (36). 
 
Neural crest cells cultures and staining. Neural crest cells were prepared from Mitfmi-sp/ 
Mitfmi-sp and Mitfmi-sl/ Mitfmi-sl embryos following the protocol previously described (37).  
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The cultures were observed daily for the appearance of pigmented melanocytes.  The 
number of pigmented melanocytes was counted for each mutant in 4 independent 
cultures.  The presence of MITF positive cells was detected by immunofluorescence 
using anti-microphthalmia C5 antibody (Neomarkers) and anti-mouse-FITC secondary 
antibody (Sigma). 
 
Proliferation assay. HEK 293 cells were transfected with Mitfmi-sp or Mitfmi-sl cDNA and 
18 hours after transfection, the cells were incubated in 10 µM BrdU (Sigma) for 30 min 
at 37 °C.  The cells were then fixed in 4% paraformaldehyde and processed for MITF 
staining using anti-microphthalmia C5 antibody (Neomarkers) and rat-absorbed anti-
mouse-FITC antibody (Southern Biotech) after post-fixation in 4% paraformaldehyde.  
BrdU labeling was performed using rat anti-BrdU (Accurate Chemical) and mouse 
absorbed anti-rat TRITC (Southern Biotech).  One hundred cells were counted per 
transfection, whereby each transfection was done in triplicate, in 3 independent 
experiments. 
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Figure legends 
 
Figure 1. Phenotypic behavior of the induced Mitfmi-sp* suppressor mutation.  (A) 
NAW-Mitfmi-ew/B6-Mitfmi-sp and NAW-Mitfmi-ew/B6-Mitfmi-sp* compound heterozygotes.  
(B)  B6-MitfMi-Wh/B6-Mitfmi-sp* and B6-MitfMi-Wh/B6-Mitfmi-sp compound heterozygotes.  
(C) B6-Mitfmi-sp/B6-Mitfmi and B6-Mitfmi-sp*/B6-Mitfmi compound heterozygotes.  Notice 
the dramatic suppression of the phenotype from near-white to black coat color. (D)  B6-
Mitfmi-sp/B6-Mitfmi-rw and B6-Mitfmi-sp*/B6-Mitfmi-rw animals.  (E) B6-Mitfmi-sp*/B6-Mitfmi-
vga9. (F)  B6-Mitfmi-sp/B6-Mitfmi-vga9.  (G) B6-Mitfmi-sp/Mitfmi-sp.  (H)  B6-Mitfmi-sp*/Mitfmi-sp*.   
 
Figure 2. The molecular alteration associated with the Mitfmi-sl  suppressor mutation.  
(A) The Mitfmi-sl mutation is a A to T transversion at nucleotide 1075, replacing Lys316 
with a stop codon, resulting in the absence of a large portion of the carboxyl end of the 
protein. Like the Mitfmi-sp mutation, the Mitfmi-sl RNA is also missing the alternative 18 bp 
exon encoding a 6 amino acid alternatively spliced insert sequence.  (B) The 6A5 
monoclonal antibody, which recognizes the C-end of MITF, shows that Mitfmi-sl tissues 
and cells express a truncated form of MITF.  The polyclonal rabbit anti-MITF antibody 
recognizes the MITF protein in both Mitfmi-sp and Mitfmi-sl tissues. 
 
Figure 3. Melanocyte numbers in developing embryos.  The Kit-LacZ transgene was 
crossed into Mitfmi-sl and Mitfmi-sp mice and the number of melanocytes, as determined by 
the presence of blue cells, determined in selected regions in 12.5 and 15.5 day old 
embryos (indicated by red boxes).  Statistically significant differences (Student’s t-test) 
are indicated by **.  
 
Figure 4. RNA expression levels and MITF protein stability and DNA binding 
ability. (A) Relative RNA expression levels in wild type, Mitfmi-sp and Mitfmi-sl heart and 
skin, as detrmined by qRT-PCR. (B) Stability of the MITF, MITFmi-sp or MITFmi-sl 
proteins.  In order to determine effects on stability, Cos cells were transfected with 
expression constructs containing wild type MITF, MITFmi-sp and MITFmi-sl proteins.  The 
cells were then stimulated with TPA in the presence of cyclohexamide and the amount of 
Steingrímsson et al. Mitf suppressor 
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MITF protein after 0, 1, 2 and 3 hrs compared by Western blotting using the monoclonal 
C5 anti-MITF antibody.  Anti-tubulin antibodies were used as a control. (C,D) 
Electrophoretic mobility shift assays were performed using the M-box sequence as a 
probe.  (C) Wild-type, MITFmi-sp and MITFmi-sl proteins were expressed using the TNT 
system alone (lanes 1, 2, 6, 10 and 11) or co-expressed with the dominant negative 
MITFmi protein (lanes 3-5, 7-9 and 12-14) and then incubated with the labelled probe.  
The binding is specific since the presence of the C5 monoclonal MITF antibody results in 
a supershift (Ab).  (D) The same experiment as in (C), except the proteins were translated 
separately and then incubated for half an hour in presence of DNA to allow 
heterodimerization before performing the mobility shift experiment. 
 
Figure 5. Promoter-specific differences in transcription activation ability.  
Cotransfection studies comparing the transcription activation potential of the wild-type 
MITF, MITFmi-sp, MITFmi-sl and MITFmi-ew proteins from two different promoters.  
(A)The MITFmi-sp and MITFmi-sl proteins are both less effective at activating transcription 
from the tyrosinase promoter than the wild type MITF protein.  The MITFmi-sl protein is 
less active from this promoter than the MITFmi-sp protein. The MITFmi-ew protein is 
lacking the basic domain and therefore cannot bind DNA or activate gene expression.  
(B) The MITFmi-sl protein is a better transactivator than the MITFmi-sp protein from the 
synthetic 4x M-box promoter.  In fact, it is as effective as the wild type MITF protein in 
activating this promoter. 
Steingrímsson et al. Mitf suppressor 
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Supplementary Figures 
 
Supplementary Figure 1. Phenotypic behavior of the induced Mitfmi-sp* suppressor 
mutation. (A) B6-Mitfmi-ew/B6-Mitfmi-sp and B6-Mitfmi-ew/B6-Mitfmi-sp* compound 
heterozygotes. (B) 82UT-MitfMi-Or/B6-Mitfmi-sp* and 82UT-MitfMi-Or/B6-Mitfmi-sp 
compound heterozygotes. (C) B6-Mitfmi-sp*/B6-MitfMi-Or and B6-Mitfmi-sp/B6-MitfMi-Or 
compound heterozygotes. (D) B6-Mitfmi-sp*/B6-MitfMi-b and B6-Mitfmi-sp/B6-MitfMi-b 
animals.   
 
Supplementary Figure 2. The mutations do not affect nuclear localization of MITF.  
The nuclear localization of the MITF, MITFmi-sp, MITFmi-sl and MITFmi-ew proteins were 
determined using two different methods.  First, by fusing the respective MITF proteins to 
GFP, transforming the constructs into 293T cells and then tracing the location of the GFP 
protein (top panel), the protein was exclusively seen in the nucleus (counterstaining by 
TOPRO).  Second, constructs expressing the different versions of MITF (not as GFP 
fusions) were transformed into 293T cells and the cells stained with the C5 antibody to 
detect the presence of MITF.  The nuclear localization of the MITFmi-ew proteins 
contradicts the results of (14) who showed this protein to be both cytoplasmic and 
nuclear.  This difference may be due to the fact that the protein is overexpressed in our 
system. 
 
Supplementary Figure 3. The Mitfmi-sl mutation results in delayed pigmentation.  (A) 
Melanocytes differentiating from neural crest cultures from Mitfmi-sl and Mitfmi-sp animals 
show that pigmentation is severely delayed in Mitfmi-sl homozygotes as compared to 
Mitfmi-sp homozygotes. Nevertheless, melanoblasts are present as evidenced by anti-MITF 
antibody staining (inset). (B) Homozygous Mitfmi-sl newborns show delayed onset of 
pigmentation as compared to Mitfmi-sp homozygotes, particularly clearly visible at 
postnatal day 2 and 3. (C) No difference in onset of pigmentation in compound 
heterozygous condition with Mitfmi-vga9. Compare mice labeled #1 (Mitfmi-sp/Mitfmi-vga9) 
with mcie labeled #3 (Mitfmi-sl/Mitfmi-vga9).  
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Table 1.  The Mitf mutants used in this study 
   Phenotype*   
  Mode of    
Allele Symbol induction Heterozygote Homozygote Lesion 
 
micropthalmia 
 
Mitfmi 
 
X-irradiation 
 
Iris pigment less than in wild type; 
occasional spots on belly, head or tail 
 
White coat, eyes small and red; deficiency 
of mast cells, incisors fail to erupt, 
osteopetrosis; inner ear defects 
 
3 bp deletion in basic 
domain 
 
oak ridge 
 
Mitfmi-or 
 
gamma-
irradiation 
 
Pale ears and tail; belly streak or head 
spot 
 
White coat, eyes small and red; incisors fail 
to erupt, osteopetrosis 
 
R216K 
 
white 
 
MitfMi-Wh 
 
spontaneous  
or X-irradiation 
 
Coat color lighter than dilute (d/d); 
eyes dark ruby; spots on feet, tail and 
belly 
 
White coat; eyes small and slightly 
pigmented; inner ear defects 
 
I212N 
 
brownish 
 
MitfMi-b 
 
spontaneous 
 
Fur diluted brownish with pale ears 
and tail 
 
White coat, reduced eye pigment, eyes of 
normal size 
 
G244E 
 
eyeless-white 
 
Mitfmi-ew 
 
spontaneous 
 
Normal 
 
White coat, eyes almost absent, eyelids 
never open 
 
25 amino acid deletion 
(splicing) 
 
VGA-9 
 
Mitfmi-vga9 
 
transgene 
insertion 
 
Normal 
 
White coat, eyes red and small; inner ear 
defects 
 
transgene insertion and 
882 bp deletion 
 
red-eyed white 
 
Mitfmi-rw 
 
spontaneous 
 
Normal 
 
White with pigmented spot on head and 
rump; eyes small and red 
 
Upstream genomic deletion 
 
spotted 
 
Mitfmi-sp 
 
spontaneous 
 
Normal (reduced tyrosinase activity in 
skin) 
 
Normal (reduced tyrosinase activity in skin).  
MitfMi-Wh/Mitfmi-sp animals are light yellow 
with white spots on coat; eyes are 
pigmented 
 
Additional cytosine in 
polypyrimidine tract; 18 bp 
exon missing 
 
Spotless 
 
Mitfmi-sl 
 
ENU 
 
Normal 
 
“Brownish” coat color.  Compound 
heterozygotes with other Mitf mutations 
show a more normal coat color than is seen 
with Mitfmi-sp mice. 
 
Additional cytosine in 
polypyrimidine tract; 18 bp 
exon missing.  In addition, 
Lys316STOP 
*  The phenotypes of the mutant alleles have been described by different researchers 
and to different extents.  Features described for all the mutants are coat and eye color,  
eye size and tooth and bone defects. 
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Discussion 
 
 
 
The Mitf transcription factor gene is a highly, if not the most important gene for 
the pigment cell lineage. It controls biological features as diverse as proliferation, 
differentiation, migration, and survival and so has been called the master regulator of 
melanocyte biology. Alterations of MITF activities are very often associated with 
abnormalities of development and maintenance of this cell type, as well as of melanocytic 
cancers. Therefore, tight regulations of Mitf levels, target gene activation and target gene 
specificity are crucial factors in the maintenance of melanocyte homeostasis in the skin. 
The net activity of MITF is the result of the integration of transcription activation of Mitf 
isoform specific promoters, alternative splicing, Mitf mRNA stability, translation 
initiation, post-translational modification, MITF protein degradation, and MITF DNA 
binding activation. For this reason, we developed several methods to quantify distribution 
of Mitf isoforms both in vivo and in vitro. 
The MAPK signaling pathway is vital to melanocytes and its constitutive activation in 
one of the essential steps towards melanoma genesis. Intriguingly, it is also known to be 
associated with most of the regulatory processes of MITF activity, such as M-Mitf 
transcriptional activation, Mitf exon 6A alternative splicing, and the regulation of MITF 
stability. By using several genetic approaches, we show that the role of MITF 
phosphorylation at the Ser73 position is a critical modulator MITF activity. In vitro, 
MITF S73 phosphorylation was found to lead to a gain of transcriptional activity as well 
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as to a reduction of MITF stability in conjunction with MITF S409 phosphorylation, 
(Hemesath et al., 1998; Wu et al., 2000). Furthermore, the absence of phosphorylation at 
both S73 and S409 sites resulted in a protein that was transcriptionally inactive. While 
the phenotype of the Mitfmi-S73A knock-in mice clearly indicated that MITF S73 
phosphorylation is not required for the normal development of melanocytes (Bismuth et 
al., 2008), the molecular analysis of this mutant mouse revealed that the absence of a 
overt phenotype might be the consequence of the absence of exon 2B rather than the 
prevention of S73 phosphorylation. The phenotypes resulting from mouse lines 
expressing mutant Mitf BAC transgenes confirmed, first, that exon 2B is not required for 
the normal development of melanocytes and, second, that the alteration of the Ser73 
codon was leading to increased exclusion of exon 2B from Mitf messages (Bauer et al., 
2009). Furthermore, this transgenic study showed that the mutation of both S73 and S409 
into alanines was still able to rescue the Mitfmi-vga9 phenotype. However, in that particular 
case, it is difficult to assess whether the rescue can be attributed to MITF S73/409A 
protein or whether the exclusion of exon 2B may help in the rescue effect by increasing 
the amount of MITF 2B- S409A protein. In addition, the inherent variabilities of Mitf 
levels between different lines are of concern and may not allow a full assessment of the 
role of phosphorylation in MITF activity regulation. This led us to use a different 
mutagenesis strategy, allowing us to dissociate the Ser73 mutation from exon 2B 
alternative splicing. Hence, we generated three Mitf knock-in alleles, Mitfmi-S-S73A, Mitfmi-S-
S73D and Mitfmi-S-S73S by targeting both the 5’ alternative splice site and the codon for 
residue-73. The phenotypic analysis of these Mitf S73 mutants in combination with 
additional Mitf mutant alleles demonstrated a gain-of-function of the non-
Discussion 
 51 
phosphorylatable MITF 2B+ isoform. We attribute this gain of function to a significant 
increase in protein stability. The specific activity of the protein was, however, not 
determined and would require additional micro array experiments with respect to in vivo 
expression profiling and chromatin binding. 
In a study not directly related to the question of exon 2B splicing and phosphorylation, 
we also presented the molecular and phenotypic characterizations of a gain of function 
modifier allele obtained by ENU mutagenesis on a Mitf pre-sensitized background. This 
new mutant allele happened to be an additional alteration of the Mitf mutant allele Mitfmi-
sp. The resulting MITF protein truncation leads to a rescue of the spotted phenotype that 
is produced when Mitfmi-sp mice are crossed with mice carrying other Mitf mutations. This 
suppressor phenotype is linked to an apparent upregulation of transcriptional activity of 
MITFsl.  
The integration of the results obtained in the above-described studies rises 3 main 
discussion topics: 
1) The physiological consequences of the lack of Mitf exon 2B 
2) The discrepancies between in vitro and in vivo experiments 
3) Mitf gain-of-function and melanoma  
 
1) The physiological consequences of the lack of Mitf exon 2B 
 
As described earlier, Mitf is subject to alternative splicing at exon 2B that gives 
rise to 2 isoforms, MITF 2B+ and MITF 2B(-). MITF 2B- lacks 56 amino acids. This 
serine/proline-rich sequence is thought to play a role in the CBP/P300 interaction but no 
Discussion 
 52 
co-immunoprecipitation assay has been demonstrated to indicate that MITF 2B- protein 
is, indeed, unable to bind CBP/P300. Within this sequence also lies the critical S73 
phosphorylation site that we have been studying here. Hence MITF 2B- lacks this critical 
regulation site and can therefore not be phosphorylated at this position. By modulating 
the level of exon 2B incorporation in Mitf transcripts, cells can therefore regulate the 
amount of phosphorylatable MITF. The importance of exon 2B and/or S73 
phosphorylation has been further supported by several studies, indicating that MITF 2B- 
plays a fundamentally different role with respect to proliferation in melanocytes (Cronin 
et al., 2009; Taylor et al., 2011). In a melanoma sample screen looking for tumor-specific 
genomic alterations, Y. Samuels’ group identified several somatic mutations in MITF that 
affected the coding sequence. While no mutation was found to affect S73 
phosphorylation itself, one of them, called MITF4T∆2B, leads to the exclusion of exon 
2B in a melanoma metastasis sample. Reporter assays were performed to assess the 
activity of this mutant MITF protein among the others and led the authors to conclude 
that MITF 2B- was more active on certain target genes. Although the expression of MITF 
2B- leads to an increase in luciferase induction, based on the western blot results, the 
amount of MITF 2B- protein reported relative to the loading control was much higher 
compared to wild-type MITF (Cronin et al., 2009). This would still support an increased 
transcription activation linked to the expression of MITF 2B(-), but not through an 
increase of the specific activity of MITF. The interesting differential activation of genes 
controlling differentiation processes compared to cell proliferation subsequently caught 
the interest of Patton’s group. This MITF4T∆2B mutant was used in rescue experiments 
on Mitf null zebrafish in order to determine its in vivo implication for development. The 
Discussion 
 53 
results show that MITF 2B- protein is able to rescue pigmented cells more efficiently 
than wild-type MITF. In addition, MITF 2B- expressing pigmented melanocytes are still 
able to perform several division cycles while the wild-type MITF expressing cells stop 
dividing when they become pigmented (Taylor et al., 2011). Similar results have been 
observed in vitro where MITF 2B- transfected cells incorporate more BrdU than MITF 
2B+ transfected cells. A higher proliferation rate was also observed in NCC derived from 
Mitfmi-S73A mutant mice compared to wild-type explants (Bismuth, PhD Thesis). While 
more cell divisions are observed in seemingly differentiated melanocytes, it is interesting 
that no increased pigmentation due to the presence of comparatively higher numbers of 
melanocytes, was observed in zebrafish or mouse. This suggests that independently of 
their differential growth rate, MITF 2B- expressing pigmented cells do not overcome the 
dependence on extracellular growth factors. It is important to note that in the zebrafish 
developmental study, dividing pigmented cells were considered as differentiated 
melanocytes (Taylor et al., 2011). While it is true that pigmentation is the primary goal of 
a differentiating melanoblasts, pigmentation is not the only parameter of differentiation. 
For instance, Tyrosinase negative melanocytes are unable to produce melanin but, apart 
from the lack of pigment, are otherwise most similar to wild type melanocytes. Hence, 
additional morphological and molecular markers should be taken into consideration to 
state that these proliferating cells were indeed differentiated and were not just early 
pigmented precursor cells.  
With regards to our mouse models, the initial Mitfmi-S73A knock-in mutant turned out to be 
a rather complicated genetic entity. We demonstrated that the mutation of the S73 codon 
reduces the binding affinity for SRp40, which subsequently leads to the exclusion of exon 
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2B in the majority of Mitf mRNA. It is, however, important to note that despite this Mitf 
alternative splicing defect, resulting in 95% Mitf 2B- and only 5% Mitf 2B+ at the 
mRNA level, the respective protein isoform do not seem to faithfully reflect the ratios of 
the mRNA. Endogenous MITF expression from heart tissue as well as primary 
melanocyte cultures from Mitfmi-S73A mutant mice show that MITF 2B+ represent between 
30 to 50% of total MITF protein. The discrepancies between RNA and protein ratios is 
conceivably due to the fact that MITF 2B+ and MITF 2B- have different stabilities. In 
this genetic context, both MITF 2B+ S73A and MITF 2B- proteins cannot be 
phosphorylated. The significant amount of MITF 2B+ S73A protein seen in Mitfmi-S73A 
mice could be an explanation for the phenotypic similarities observed between mice 
carrying the S73A and S-S73A alleles. The additional amount of full-length protein 
found in Mitfmi-S-S73A mice, which cannot include exon 2B, might then be a plausible 
explanation for the slight gain in pigmentation observed by comparing Mitfmi-S73A and 
Mitfmi-S-S73A mice mice. In order to identify specific target genes subject to regulation by 
MITF 2B+ and MITF 2B(-), microarray gene expression analysis could be performed 
from either skin-derived sorted melanocytes or transgenic mouse-derived melanocyte cell 
lines cultured in vitro. While the first approach seems to be the most accurate with 
respect to expression profiling of melanocytes in their native environment, it also has 
several technical disadvantages. First of all, iDct-GFP bi-transgenic mice would need to 
be intercrossed with the Mitf mutant mice (Zaidi et al., 2011). Secondly, the GFP-sorted 
cell population obtained from these animals is heterogeneous as it consists of three 
subpopulations, undifferentiated melanocyte stem cells, differentiating melanoblasts and 
fully differentiated melanocytes. All of these three subpopulations might display 
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differential expression profiles and in this case would be pooled together. Another subject 
of concern is that the induction of the GFP system is under the control of the Dct 
promoter, which itself is controlled by Mitf activity. Cell sorting based on an MITF target 
driven reporter on a Mitf mutant genetic background might skew the threshold of 
detection and therefore bias the population sampling between mutants.  
The in vitro alternative does not come without a cost either, as it has the major 
disadvantage that the in vitro culture conditions only partially reflect the in vivo situation. 
As I explain in more detail in the second part of the discussion, in specific cases, culture 
conditions might strongly influence the expression profile of the cell population. In 
addition, when placed in culture, the vast majority of the cells do not survive. Only the 
cells that are in the appropriate proliferation state or able to adapt will be able to survive 
in culture, thereby potentially introducing a cell population-specific selection. In vitro 
modeling implies that the cells are able to divide indefinitely, or at least for several 
passages. In a non-inducible system of differentiation versus proliferation, the cell 
population that is in the process of differentiation might be lost after only a few passages.  
Nevertheless, using melanocyte cell lines we performed preliminary experiments in order 
to decipher Mitf exon 2B regulations. In unpublished results, Wang et al. demonstrate 
that exon 2B incorporation in Mitf mRNA is regulated through the cell cycle with a 
preferential exclusion of exon 2B during S phase. While the level of significance of this 
fluctuation with respect to the pool of MITF protein has not yet been tested, the temporal 
synchronization between the decrease of a S-phase inhibiting isoform and the S-phase is 
indeed intriguing.  
 
Discussion 
 56 
2) The discrepancies between in vitro and in vivo experiments 
 
One of the most important points of this thesis centers on the demonstration that 
in vitro and in vivo results can lead to different conclusions. The original experiments 
testing the role of MITF S73 phosphorylation suggested that phosphorylation leads to an 
increase of MITF transcriptional activity and a reduction of its stability, and that the 
S73A mutation prevents these changes. The in vivo results show, however, that the 
prevention of S73 phosphorylation by the introduction of an alanine at this position 
produces a net gain-of-function, perhaps because an increased stability of the MITF 
protein might compensate its possible reduction in activity. In this context, then, we 
demonstrate that under normal circumstances, S73 phosphorylation-mediated 
transcriptional activation does not play any significant role in the development of 
melanocytes. Nevertheless, once Mitf levels are reduced in a sensitized background, S73 
phosphorylation becomes important as it increases white spotting.  
The Mitfmi-S73A mouse model is a perfect example supporting these discrepancies between 
in vivo and in vitro results. In the NCC experiment performed in vitro from in vivo tissue, 
cells clearly show an increased proliferative rate, while in the animal, absolutely no 
difference in cell numbers can be observed. A likely hypothesis to explain this difference 
is based on the consideration that in vitro and in vivo conditions are vastly different with 
respect to availability of growth factors. It is known that in order to maintain in vitro 
melanocyte cultures, one has to add excess amounts of growth factors to compensate for 
the lack of cellular matrix provided by the in vivo environment. Unlike normal 
melanocytes in vivo, in vitro cultures of pigmented cells are perpetually in a growth state, 
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perhaps similar to what is observed in the cancers. In order to sustain this level of growth, 
it is very likely that the dose of growth factors or their response to them, would be above 
the in vivo threshold of signaling activity.  
How is this related to the MITF phosphorylation and activity topic? As I mentioned 
earlier, one of the major factors involved in melanocyte proliferation is KIT Ligand, 
which activates the MAPK pathway. The same signaling pathway is involved in MITF 
phosphorylation. Hemesath et al. show that they can induce complete phosphorylation of 
MITF within 8 minutes of incubation with MAPK activators in vitro. Wu et al. show that 
MITF expression disappears within 4 hours of MAPK activation due to ubiquitin-
mediated degradation. It is therefore puzzling to link the disappearance of MITF 
expression within 4h and the upregulation of target genes 8h after induction, especially 
when no MITF protein levels were shown in the luciferase activation test (Hemesath et 
al., 1998; Wu et al., 2000). Without MAPK induction, the 50% of phosphorylated MITF 
protein do not show a higher activation of the reporter gene. An upregulation of MITF 
activity is therefore only observed subsequently to the replenishment of newly 
synthesized MITF protein after ubiquitination-mediated depletion of the MITF protein 
pool. Hence, the upregulation of Mitf target gene activation can be seen as a 
compensatory mechanism following prior depletion of MITF as newly synthesized 
protein might be transcriptionally more active than older protein. Considering the in vivo 
situation, it is conceivable, therefore, that this extent of MITF phosphorylation in vitro 
would not reflect the state of phosphorylation in vivo. 
With respect to proliferation, the same remarks regarding the association of an over 
activation of the MAPK and MITF are valid. The differential effects on proliferation 
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between MITF 2B+ and MITF 2B- are only seen in vitro, where the MAPK activation 
threshold is likely higher than in vivo. We know from several publications that 
constitutive activation of the MAPK pathway in melanocytes leads to senenscence-
mediated cell cycle arrest. Intriguingly, similar phenomenons happen in melanoma.  
 
 
 
3) Mitf gain-of-function and melanoma. 
 
In early stages of melanoma, constitutively active BRAF or NRAS lead to 
senescence. The association of the MITF 2B- isoform in this context would then correlate 
with the in vitro NCC experiments, because MITF 2B- expressing cells would continue to 
proliferate despite MAPK-signaling. This could be tested by introducing an MITF S73A 
mutant, for instance, on a melanocyte-specific BRAF V600E background and by 
studying tumor formation in such mice. 
In contrast, in vivo reductions of endogenous Kit signaling leads to a slightly more severe 
pigmentation defect in absence of a phosphorylatable serine. This might demonstrate the 
role of MITF phosphorylation in the survival/proliferation balance. Mitf phosphorylation 
would promote cell differentiation and survival and inhibit cell proliferation, whereas 
Mitf 2B- and Mitf 2B+ S73A might promote differentiation and proliferation. 
The large majority of previously identified Mitf mutant alleles are loss-of-
function mutations, ultimately resulting in a loss, or reduced number, of the neural crest-
derived pigment cells. Here, we presented new Mitf alleles that show apparent gain-of-
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function compared to wild type. As described earlier, melanoma is often associated with 
an increased copy number of the Mitf gene, and a likely associated gain of activity. While 
none of our Mitf alleles in mice displayed spontaneous formations of melanoma tumors 
on their own, it may be interesting to investigate their potential interaction with other 
known tumor promoting factors besides constitutively active MAPK, such as PTEN 
knock-outs. The alleles described here are very particular because, unlike wild-type, they 
lead to MITF proteins that lose critical regulation sites that may be important for cancer 
progression. The study of the specific interaction of these MITF regulation mutants with 
oncogenic pathways may reveal potential therapeutic targets or at least help understand 
how MITF activity is involved in the tumor formation process. 
 
 
In conclusion, we have identified several key mechanisms of Mitf post-
transcriptional and post-translational regulations, which seem to play major roles with 
respect to net MITF activity. Although we identified several alleles with hypermorphic 
functions, they did not produce striking phenotypes by themselves in vivo. These results 
combined with recent findings from other groups, however, prompt a series of new 
questions that would be interesting to answer: 
 
 
♦ Exon 2B alternative splicing: Is exon 2B alternative splicing linked to the MAPK 
signaling pathway as it is for exon 6A alternative splicing? And is exon 2B 
splicing or MITF phosphorylation regulated during the cell cycle? 
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♦ Protein interaction: What are the factors binding specifically to MITF S73-P, 
potentially explaining the difference in cell proliferation inhibition? 
 
♦ Transcriptional activation: Are the expression profiles of these mice similar or do 
they present major differences that could explain their distinct phenotypes? 
 
♦ Melanoma: Would Mitf gain of function alleles result in a higher melanoma 
progression on a mouse cancer model, or would it prevent cell proliferation? 
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Synthèse du travail de thèse 
 
 
 
 
L’épissage alternatif et les modifications post-traductionnelles font partie des 
mécanismes biologiques grâce auxquels un seul et unique gène peut générer plusieurs 
protéines de fonction diverse. Grâce à l’analyse de résultats issus de techniques récentes 
telles que le séquençage de nouvelle génération aussi appelé « RNA-seq » et la 
protéomique, on a pu mettre en évidence que la grande majorité des ARN pré-messagers 
comportant plusieurs exons sont sujets à des modifications post-trancriptionnelles 
d’épissage alternatif, et que de telles modifications post-traductionnelles modulent 
l’activité de bon nombre de protéines de cellules eucaryotes. Dans ce travail de thèse, 
nous nous sommes intéressés à un modèle génétique murin grâce auquel nous avons pu 
tester in vivo l’effet de mutations ponctuelles de sites de phosphorylation connus pour 
affecter la fonction d’un facteur de transcription crucial pour la lignée mélanocytaire : 
MITF.  
La lignée mélanocytaire et son utilisation dans l’étude d’interactions génétiques et de 
modulations de l’activité de ces constituants, présente plusieurs avantages. Premièrement, 
la fonctionnalité de ce type cellulaire n’est pas requise pour la survie de l’animal, 
deuxièmement, les phénotypes de pigmentation sont aisément identifiables et 
quantifiables sans intervention nécessaire sur l’animal et enfin le processus de 
pigmentation de la peau met en jeu la majorité des processus de régulation cellulaires tels 
que la prolifération, la différentiation, la maintenance de l’état différencié et la survie 
cellulaire. Jusqu'à maintenant, 179 gènes ont été identifiés comme ayant un impact sur la 
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biologie des mélanocytes et la pigmentation. Au centre de cette vaste liste se trouve le 
facteur de transcription Microphthalmia, qui est le régulateur principal de ce type 
cellulaire. Il régule à la fois la prolifération, la différentiation et la survie des 
mélanocytes. Ainsi l’étude des processus de régulation de l’activité de ce facteur de 
transcription permet de comprendre comment des fonctions si diverses et parfois 
opposées comme l’activation de la prolifération et de la différentiation peuvent être 
régulées par un seul gène. 
Chez la souris, l’importance du gène Mitf est d’autant plus soulignée par une pléthore de 
plus de 30 allèles différents, qui ont été identifiés depuis son clonage (Hodgkinson et al., 
1993). Le domaine basique de MITF permet la fixation à l’ADN tandis que les domaines 
HLH et LZ jouent un rôle important dans l’homo et l’hétérodimérisation avec ses 
partenaires. La grande majorité des allèles identifiés de Mitf par le passé, tels que Mitfmi, 
Mitfmi-wh, Mitfmi-ce, Mitfmi-ew, Mitfmi-or, Mitfmi-vit, sont des mutations qui altèrent l’un ou 
l’autre de ces deux domaines, ce qui provoque une perte partielle ou totale de l’activité de 
la protéine. 
Chez l’homme les mutations du gène MITF provoquent des défauts de pigmentation de la 
peau et du développement de l’œil ainsi que, dans certains cas, une surdité congénitale. 
L’ensemble des symptômes présentés par ces sujets est généralement regroupé sous un 
sous type du syndrome de Waardenburg, lequel rassemble des mutations d’autres gènes 
tels que SOX10 ou PAX3, tous deux situés dans la voie d’activation de la transcription de 
MITF dans les mélanocytes. 
 
Synthèse 
 63 
Le gène Mitf appartient à la superfamille de facteurs de transcription de type bHLH-LZ 
(basic Helix-Loop-Helix Leucine-Zipper), tels que Myc, Mad ou Max, et a une structure 
génétique relativement complexe, constituée de 9 promoteurs alternatifs. L’activation 
transcriptionnelle de certaines isoformes est hautement spécifique du type cellulaire. Les 
isoformes A-Mitf ou H-Mitf sont exprimées de façon ubiquitaire contrairement à 
l’isoforme M-Mitf qui est spécifique aux Melanocytes. Outre la régulation du niveau 
d’expression, chacun de ces transcrits est régulé par des mécanismes d’épissage alternatif 
sur deux sous-exons : 6A et 2B. Le rôle du premier a été associé à une augmentation de la 
stabilité de fixation à l’ADN lorsqu’il est présent dans la protéine et également à 
l’inhibition de la prolifération médiée par Mitf. L’exon 2B, quant à lui, contient un site de 
phosphorylation lié à la voie des MAPK, la Serine 73, qui a été associé in vitro comme 
jouant un rôle important dans la régulation de l’activité de MITF ainsi que sa stabilité 
(Bismuth et al., 2005; Hemesath et al., 1998; Wu et al., 2000). Au total, Mitf peut donc 
donner naissance à 36 transcrits différents. 
 
Du fait de cette complexité moléculaire, un premier travail de recherche a été dédié à 
l’élaboration de méthodes quantitative et qualitatives par RT-PCR afin d’identifier et de 
mesurer l’expression de ces isoformes multiples dans divers tissus. Nous avons ainsi 
présenté une méthode simple de quantification de transcrits complexes, applicable à 
d’autres gènes sujets aux mêmes types de régulations transcriptionnelles et d’épissages 
alternatifs. 
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Intrigué par la dualité fonctionnelle apparente du rôle de la phosphorylation de la Serine 
73 in vitro, notre groupe de recherche avait préalablement tenté de déterminer le rôle de 
celle-ci in vivo en mutant S73 en une alanine non phosphorylable, de façon endogène. 
Bien que cette mutation ait été effective sur le plan génomique par une substitution du 
codon S73 en codon A73, elle a également provoque un effet inattendu sur la régulation 
de l’épissage de l’exon 2B sur lequel se situe le site de phosphorylation. L’altération du 
codon S73 entraine une forte augmentation de l’exclusion de l’exon 2B quelque soit le 
contexte génétique. Une seconde tentative par insertion de transgènes codant pour MITF 
S73A a eu le même effet sur le profile d’épissage de l’exon 2B. Cette étude réalisée par le 
laboratoire du Dr Steingrimsson a cependant apporté des éléments nouveaux concernant 
le rôle de la phosphorylation de la S409 ainsi que l’absence totale de l’exon 2B. Ce 
travail a démontré que ni la phosphorylation de la serine S73 ni la présence de l’exon 2B 
ni la phosphorylation de la S409 ne sont requises pour conserver l’activité 
transcriptionnelle de MITF in vivo.  
 
Parallèlement, dans le but de comprendre les raisons de l’association entre la mutation du 
codon de la S73 et de l’exclusion préférentielle de l’exon 2B des transcrits Mitf, notre 
laboratoire a donc étudié de façon approfondie les mécanismes moléculaires impliqués 
dans cette observation. Nous avons ainsi identifié que le codon de la S73 fait partie d’un 
site de fixation d’un facteur de régulation de l’épissage de la famille des 
« Serine/Arginine rich proteins » SRp40. La mutation du codon S73 entraine une 
diminution de la fixation de ce facteur et favorise ainsi le choix de la jonction exon2A-2B 
comme site d’épissage préférentiel. De ce fait, l’inclusion de l’exon 2B est 
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intrinsèquement liée au statut du codon S73. Afin d’étudier le rôle de la phosphorylation 
de cette serine indépendamment de l’exclusion de l’exon 2B qui la comporte, nous avons 
entrepris de re-cibler le gène Mitf endogène en apportant des altérations de séquences 
supplémentaires qui permettent l’inclusion de l’exon 2B dans 100% des transcrits 
quelque soit la séquence du codon 73. La jonction entre l’exon 2A et 2B correspond à la 
séquence consensus qui définit la limite entre l’extrémité 3’ d’un exon et le début d’un 
intron. Ainsi, notre stratégie a été de modifier cette séquence afin qu’elle ne soit plus 
reconnue par le complexe d’épissage, en conjonction avec l’altération du codon S73. 
Les résultats décrits dans ce travail démontrent que l’absence de phosphorylation de 
MITF sur la Serine 73 non seulement n’est pas indispensable à l’activité transcriptionelle, 
mais provoque aussi un gain de stabilité suffisant de la protéine qui a pour conséquence 
un gain de fonction au niveau phénotypique. Nous avons également pu lier l’absence de 
phosphorylation à la perte totale ou partielle d’inhibition de la progression dans le cycle 
cellulaire. 
Du fait de son rôle central sur la survie, la différentiation et la prolifération des 
melanocytes, il n’est pas surprenant de retrouver Mitf associé au mélanome. Le 
dérèglement pathologique de ce type cellulaire est dans la très forte majorité associé à 
une activation constitutive de la voix des MAPK et à un gain de l’activité de MITF. Nous 
suggérons donc que la perte de phosphorylabilité de MITF par une augmentation de 
l’exclusion de l’exon 2B (déjà rapportée dans des métastases de mélanome (Cronin et al., 
2009)) ou par l’altération de la réaction de phosphorylation (augmentation de l’activité 
des phosphatases ou mutation du site de phosphorylation) peuvent être des éléments 
déterminant dans le développement du processus tumoral du mélanome. 
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En outre, en collaboration avec le laboratoire du Dr Steingrimsson, nous avons participé à 
la caractérisation d’un nouvel allèle du gène Mitf de type suppresseur. Au cours de ce 
travail basé sur un crible de mutations aléatoires sur un fond génétique sensibilisé de 
souris homozygotes pour l’allèle Mitfmi-sp, nous avons identifié une mutation intragénique 
de Mitfmi-sp produisant un nouvel allèle nommé Mitfmi-sl. Mitfmi-sl possède, en plus de la 
mutation Mitfmi-sp, qui provoque la dégradation par « Non-sense mediated decay » des 
transcrits MITF 6A+, un codon stop prématuré qui tronque la protéine à l’acide amine 
315. MITF perd ainsi plusieurs sites de modifications post traductionnelles, tels que la 
Lysine 316 impliquée dans la réduction de l’activité de MITF par SUMOylation. Cette 
modification post-traductionnelle a d’ailleurs été récemment liée à un risque accru de 
contracter un mélanome lorsqu’elle est perdue ou altérée (Bertolotto et al., 2011). Ainsi 
nous avons démontré que ce nouvel allèle possédait un gain d’activité transcriptionnelle 
in vitro ainsi qu’un gain phénotypique associé à une augmentation du niveau 
d’expression transcriptionnelle de Mitf in vivo. 
 
En conclusion, nous avons identifié certains mécanismes de régulations post 
transcriptionnelles et post traductionnelles jouant des rôles importants dans le contrôle de 
la biologie des mélanocytes par MITF. Bien que les nouveaux allèles de Mitf, décrits 
dans cette thèse, présentent des gains de fonction sans qu’aucun mélanome spontané ne 
soit apparu, certaines des données obtenues in vitro suggèrent qu’il est probable que ces 
allèles puissent avoir un potentiel oncogénique supérieur à l’allèle témoin en présence de 
mutations de type BRAF V600E ou PTEN-/-.  
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RESUME 
 
 
 
 
 
 
Le facteur de transcription Microphthalmia (Mitf) et la voie de signalisation des « Mitotic 
Activated Protein Kinase » (MAPK) sont des éléments déterminants pour la 
différentiation, la prolifération et la survie des melanocytes. L’altération des fonctions de 
l’un ou l’autre se manifeste par une perte totale ou partielle de ce type cellulaire. A 
l’inverse, le mélanome est associé très majoritairement à une activation constitutive des 
MAPK, et parfois, à un gain d’activité de MITF. Afin d’étudier les interactions entre les 
MAPK et l’activité de MITF, nous nous sommes intéressés aux modifications post 
transcriptionnelles qui permettent la génération d’isoformes multiples dotées d’activité 
différentes. MITF contient un site de phosphorylation, la serine 73 (S73), qui a été 
démontré par le passé comme jouant un rôle à la fois dans l’augmentation de l’activité et 
dans la réduction de la stabilité de MITF in vitro. Pour comprendre le rôle de cette serine 
in vivo, une tentative de mutation S73A de Mitf a été réalisée. Ce codon fait parti d’un 
« Exon splicing Enhancer » et sa mutation réduit l’affinité de fixation de la protéine 
SRp40 et l’exclusion de l’exon 2B dans lequel est situé ce site de phosphorylation. Pour 
dissocier l’exclusion de l’exon 2B de sa phosphorylation, nous avons donc altéré la 
jonction de l’exon 2A-2B afin qu’elle ne soit plus reconnue par le spliceosome. En 
conséquence, l’exon 2B ne peut plus être exclu des transcrits Mitf quelque soit le statut 
du codon 73. La comparaison de 3 nouveaux allèles Mitf S-S73A S-S73D et S-S73S, où 
l’inclusion de l’exon 2B est forcée, nous a permis d’associer l’absence de 
phosphorylation à un gain d’activité de MITF. 
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